U.S. patent application number 14/739676 was filed with the patent office on 2015-10-01 for novel human genes relating to respiratory diseases and obesity.
The applicant listed for this patent is OSCIENT PHARMACEUTICALS CORPORATION. Invention is credited to Kristina Allen, Richard Del Mastro, Josee Dupuis, Tim Keith, Randall Little, Sunil Pandit, Jason Simon, Paul Van Eerdewegh.
Application Number | 20150274816 14/739676 |
Document ID | / |
Family ID | 32303414 |
Filed Date | 2015-10-01 |
United States Patent
Application |
20150274816 |
Kind Code |
A1 |
Keith; Tim ; et al. |
October 1, 2015 |
NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY
Abstract
This invention relates to isolated nucleic acids comprising
genes of human chromosome 12q23-qter and the proteins encoded by
these genes. Expression vectors and host cells containing such
genes or fragments thereof, as well as antibodies to the proteins
encoded by these nucleic acids are also included herein.
Inventors: |
Keith; Tim; (Bedford,
MA) ; Little; Randall; (Newtonville, MA) ; Van
Eerdewegh; Paul; (Weston, MA) ; Dupuis; Josee;
(Newton, MA) ; Del Mastro; Richard; (Norfolk,
MA) ; Simon; Jason; (Westfield, NJ) ; Allen;
Kristina; (Hopkinton, MA) ; Pandit; Sunil;
(Gaithersburg, MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
OSCIENT PHARMACEUTICALS CORPORATION |
Waltham |
MA |
US |
|
|
Family ID: |
32303414 |
Appl. No.: |
14/739676 |
Filed: |
June 15, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14174444 |
Feb 6, 2014 |
|
|
|
14739676 |
|
|
|
|
13405525 |
Feb 27, 2012 |
|
|
|
14174444 |
|
|
|
|
13087480 |
Apr 15, 2011 |
8124734 |
|
|
13405525 |
|
|
|
|
12180184 |
Jul 25, 2008 |
7928200 |
|
|
13087480 |
|
|
|
|
10743704 |
Dec 22, 2003 |
7407804 |
|
|
12180184 |
|
|
|
|
09627465 |
Jul 28, 2000 |
6737519 |
|
|
10743704 |
|
|
|
|
60211749 |
Jun 14, 2000 |
|
|
|
60146336 |
Jul 30, 1999 |
|
|
|
Current U.S.
Class: |
424/139.1 ;
530/387.3; 530/387.9; 530/391.1 |
Current CPC
Class: |
C07K 16/18 20130101;
C07K 14/47 20130101; C07K 2317/24 20130101; A61P 11/06
20180101 |
International
Class: |
C07K 16/18 20060101
C07K016/18 |
Claims
1. An isolated antibody or epitope-binding fragment thereof which
binds to a polypeptide comparing the amino acid sequence of SEQ ID
NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9, wherein the
antibody or epitope-binding fragment binding is to the SEQ ID NO:3,
SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9 portion of the
polypeptide.
2. The isolated antibody or epitope-binding fragment of claim 1,
which binds to an immunogenic component comprising at least 30
amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or
SEQ ID NO:9.
3. The isolated antibody or epitope-binding fragment of claim 1,
which binds to an immunogenic component comprising at least 50
amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or
SEQ ID NO:9.
4. The isolated antibody or epitope-binding fragment of claim 1,
which binds to an immunogenic component comprising at least 100
amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or
SEQ ID NO:9.
5. The isolated antibody or epitope-binding fragment of claim 1
which binds to a polypeptide having an amino acid sequence of at
least 200 consecutive residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID
NO:7, or SEQ ID NO:9 or an immunogenic component thereof.
6. The isolated antibody or epitope-binding fragment of claim 1,
which is immobilized on a solid support.
7. The isolated antibody or epitope-binding fragment of claim 1,
which binds to a polypeptide having an amino acid sequence of SEQ
ID NO: 3.
8. The isolated antibody or epitope-binding fragment of claim 1,
which binds to a polypeptide having an amino acid sequence of SEQ
ID NO: 5.
9. The isolated antibody or epitope-binding fragment of claim 1,
which binds to a polypeptide having an amino acid sequence of SEQ
ID NO: 7.
10. The isolated antibody or epitope-binding fragment of claim 1,
which binds to a polypeptide having an amino acid sequence of SEQ
ID NO: 9.
11. The isolated antibody or epitope-binding fragment of claim 1
which is a monoclonal antibody.
12. The isolated antibody or epitope-binding fragment of claim 1
which is a polyclonal antibody.
13. The isolated antibody or epitope-binding fragment of claim 1
which is a recombinant antibody.
14. The isolated antibody or epitope-binding fragment of claim 1
which is a chimeric antibody.
15. The isolated antibody or epitope-binding fragment of claim 1
which is a humanized antibody.
16. The isolated antibody or epitope-binding fragment of claim 1
bound to said polypeptide.
17. A pharmaceutical composition comprising the isolated antibody
or epitope-binding fragment of claim 1 and a pharmaceutically
acceptable carrier.
18. An isolated antibody or epitope-binding fragment thereof which
binds to a polypeptide having an amino acid sequence encoded by 50
or more consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6, or SEQ ID NO:8 wherein the antibody or epitope-binding
fragment binding is to the amino acid sequence encoded by 50 or
more consecutive nucleotides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6, or SEQ ID NO:8 portion of the polypeptide.
19. The isolated antibody or epitope-binding fragment of claim 18,
which binds to an immunogenic component comprising at least 30
amino acid residues encoded by consecutive nucleotides of SEQ ID
NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.
20. The isolated antibody or epitope-binding fragment of claim 18,
which binds to an immunogenic component comprising at least 50
amino acid residues encoded by consecutive nucleotides of SEQ ID
NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.
21. The isolated antibody or epitope-binding fragment of claim 18,
which binds to an immunogenic component comprising at least 100
amino acid residues encoded by consecutive nucleotides of SEQ ID
NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.
22. The isolated antibody or epitope-binding fragment of claim 18,
which is immobilized on a solid support.
23. The isolated antibody or epitope-binding fragment of claim 18
which is a monoclonal antibody.
24. The isolated antibody or epitope-binding fragment of claim 18
which is a polyclonal antibody.
25. The isolated antibody or epitope-binding fragment of claim 18
which is a recombinant antibody.
26. The isolated antibody or epitope-binding fragment of claim 18
which is a chimeric antibody.
27. The isolated antibody or epitope-binding fragment of claim 18
which is a humanized antibody.
28. The isolated antibody or epitope-binding fragment of claim 18
bound to said polypeptide.
29. A pharmaceutical composition comprising the isolated antibody
or epitope-binding fragment of claim 18 and a pharmaceutically
acceptable carrier.
Description
RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
patent application Ser. No. 14/174,444, filed Feb. 6, 2014; which
is a continuation application of U.S. patent application Ser. No.
13/405,525 (now abandoned), filed Feb. 27, 2012; which is a
divisional application of U.S. patent application Ser. No.
13/087,480 (now U.S. Pat. No. 8,124,734), filed on Apr. 15, 2011;
which is a divisional application of U.S. patent application Ser.
No. 12/180,184 (now U.S. Pat. No. 7,928,200) filed on Jul. 25,
2008; which is a divisional of U.S. patent application Ser. No.
10/743,704 (now U.S. Pat. No. 7,407,804), filed on Dec. 22, 2003,
which is a divisional application of U.S. patent application Ser.
No. 09/627,465 (now U.S. Pat. No. 6,737,519), filed on Jul. 28,
2000, which claims the benefit of U.S. Provisional Application Ser.
No. 60/146,336 filed Jul. 30, 1999 and U.S. Provisional Application
Ser. No. 60/211,749 filed Jun. 14, 2000, the entire teachings of
all are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates generally to isolated nucleic
acids and the classification of the same. The invention more
particularly relates to a novel gene and novel nucleic acids
related to asthma and other respiratory diseases and the
classification and therapeutic and diagnostic uses of this
gene.
BACKGROUND
[0003] Wilkinson et al. showed linkage of asthma to markers on
human chromosome 12 (Genomics, 53: 251-259 (1998)). In addition,
Wilson et al. has shown that obesity may be linked to asthma (Arch.
Intern. Med. 159: 2513-14 (1999)). In particular chromosomal region
12q23-qter has been linked to a variety of genetic disorders
including male germ cell tumors, histidinemia, growth retardation
with deafness and mental retardation, deficiency of Acyl-CoA
dehydrogenase, spinal muscular atrophy, Darier disease,
cardiomyopathy, Spinocerebellar ataxia-2, brachydactyly,
Mevalonicaciduria, Hyperimmunoglobulinemia D, Noonan syndrome-1,
Cardiofaciocutaneous syndrome, spinal muscular atrophy-4,
tyrosinemia, phenylketonuria, B-cell non-Hodgkin lymphoma,
Ulnar-mammary syndrome, Holt-Oram syndrome, Scapuloperoneal spinal
muscular atrophy, alcohol intolerance, MODY, Diabetes mellitus,
noninsulin-dependent,2 and diabetes mellitus insulin-dependent (See
National Center for Biotechnology Information: at the website of:
(hypertext transfer protocol, (i.e., http), world wide web (i.e.,
www), National Center for Biotechnology Information (ncbi).National
Library of Medicine (nlm).National Institutes of Health
(NIH).Goveurnent (gov)/omim.). Although this region appears to
contain genes affecting these disorders few genes have been
discovered. There is a need in the art for identifying specific
genes for such disorders because they are also associated with
obesity and lung disease, particularly inflammatory lung disease
phenotypes such as Chronic Obstructive Lung Disease (COPD), Adult
Respiratory Distress Syndrome (ARDS), and asthma. Identification
and characterization of such genetic compositions will make
possible the development of effective diagnostics and therapeutic
means to treat lung related disorders as well as the other diseases
described herein.
SUMMARY OF THE INVENTION
[0004] This invention relates to Gene 214 located on chromosome
12q23-qter. Nucleic acids comprising all or a part of, or
complementary fragments of Gene 214 and cDNA are described in
various embodiments. Vectors and host cells containing the nucleic
acids herein described are also included in this invention. These
nucleic acids can be used in therapeutic applications for a
multitude of diseases either through the overexpression of a
recombinant nucleic acid comprising all or a portion of a Gene 214
gene, or by the use of these oligonucleotides and genes to modulate
the expression of an endogenous gene or the activity of an
endogenous gene product. Examples of therapeutic approaches include
anti-sense inhibition of gene expression, gene therapy, monoclonal
antibodies that specifically bind to the gene products, and the
like. In vitro expression of the recombinant gene products can also
be obtained.
[0005] Diagnostic methods are also described which utilize all or
part of the nucleic acids of this invention. Such nucleic acids can
be used, for example, as part of diagnostic methods to identify
Gene 214 nucleic acids to screen for a predisposition to various
genetic diseases. In addition, nucleic acids described herein can
be used to identify chromosomal abnormalities within the
chromosomal region 12q23-qter.
[0006] Further, this invention identifies various single nucleotide
polymorphisms (SNPs) within several of the nucleic acids described
herein. Some of these polymorphisms also comprise changes to the
polypeptides of the present invention. The SNPs, together with the
wild-type alleles can be used to prepare specific probes for
detection of various disease states in an individual. Thus, in one
embodiment, this invention provides a method of detecting
chromosome abnormalities on chromosome 12q23-qter.
[0007] Proteins, polypeptides, and peptides encoded by all or a
part of the nucleic acids comprising Gene 214 are included in this
invention. Such amino acid sequences are useful for diagnostic and
therapeutic purposes. Further, antibodies can be raised against all
or a part of these amino acid sequences for specific diagnostic and
therapeutic methods requiring such antibodies. These antibodies can
be polyclonal, monoclonal, or antibody fragments.
[0008] In a further embodiment, vectors and host cells containing
vectors which comprise all or a portion of the nucleic acid
sequences of this invention can be constructed for nucleic acid
preparations, including anti-sense, and/or for expression of
encoded proteins and polypeptides. Such host cells can be
prokaryotic or eukaryotic cells.
[0009] Still another embodiment of the invention comprises a method
of identifying a protein which is a candidate for being involved in
asthma (a "candidate protein"). Candidate proteins are identified
by a process comprising (i) identifying a protein in a first
individual having the asthma phenotype; (ii) identifying a protein
in a second individual not having the asthma phenotype; comparing
the protein of the first individual to the protein of the second
individual, wherein (a) the protein that is present in the second
individual but not the first individual is the candidate protein or
(b) the protein that is present in a higher amount in the second
individual than in the first individual is the candidate protein or
(c) the protein that is present in a lower amount in the second
individual than in the first individual is the candidate
protein.
[0010] This invention also includes nonhuman transgenic animals
containing one or more of the nucleic acids of this invention for
screening and other purposes. Further, knockout nonhuman transgenic
animals can be produced wherein one or more endogenous genes or
portions of such genes corresponding to the nucleic acids of this
invention are replaced by marker genes or are deleted.
BRIEF DESCRIPTION OF THE FIGURES
[0011] FIG. 1 shows the plot of multipoint LOD score against the
map location of the markers along chromosome 12.
[0012] FIG. 2 depicts the STS content of the 12q23-qter BAC
RP11-0702C13 containing Gene 214
[0013] FIGS. 3A-3C depict the nucleotide (SEQ ID NO: 2) and amino
acid sequence (SEQ ID NO: 3) of Gene 214a.
[0014] FIGS. 4A-4C depict the nucleotide (SEQ ID NO: 4) and amino
acid sequence (SEQ ID NO: 5) of Gene 214b.
[0015] FIGS. 5A-5C depict the nucleotide (SEQ ID NO: 6) and amino
acid sequence (SEQ ID NO: 7) of Gene 214c.
[0016] FIGS. 6A-6D depict the nucleotide (SEQ ID NO: 8) and amino
acid sequence (SEQ ID NO: 9) of Gene 214d.
[0017] FIGS. 7A-7D depict the nucleotide (SEQ ID NO: 10) and amino
acid sequence (SEQ ID NO: 11) of Gene 214e.
[0018] FIGS. 8A-8B show a schematic view of the exons of Gene 214a,
214b, 214c, 214d, and 214e and the corresponding single nucleotide
polymorphisms.
[0019] FIG. 9 shows a Northern Analysis of Gene 214.
[0020] FIG. 10A-10B depict the nucleic acid sequence of the exons
of Gene 214: Exon A--SEQ ID NO: 38; Exon B--SEQ ID NO: 39; Exon
C--SEQ ID NO: 40; Exon C.2--SEQ ID NO: 41; Exon E.1--SEQ ID NO: 42;
Exon E.2--SEQ ID NO: 43; Exon E.3--SEQ ID NO: 44; Exon F--SEQ ID
NO: 45.
DETAILED DESCRIPTION OF THE INVENTION
[0021] The present invention relates to Gene 214 nucleic acids
comprising genomic DNA within BAC RP11-0702C13, the corresponding
cDNA sequences, RNA, fragments of the genomic, cDNA, or RNA nucleic
acids comprising 20, 40, 60, 100, 200, 500 or more contiguous
nucleotides, and the complements thereof. Closely related variants
are also included as part of this invention, as well as recombinant
nucleic acids comprising at least 50, 60, 70, 80, or 90% of the
nucleic acids described above which would be identical to a Gene
214 nucleic acids except for one or a few substitutions, deletions,
or additions.
[0022] Further, the nucleic acids of this invention include the
adjacent chromosomal regions of Gene 214 required for accurate
expression of the respective gene. In a preferred embodiment, the
present invention is directed to at least 15 contiguous nucleotides
of the nucleic acid sequence of any of SEQ ID NO:2 (FIGS. 3A-3C),
SEQ ID NO:4 (FIGS. 4A-4C), SEQ ID NO:6 (FIGS. 5A-5C), SEQ ID NO: 8
(FIGS. 6A-6D), and SEQ ID NO:10 (FIGS. 7A-7D). More particularly,
embodiments of this invention include the BAC clone containing
segments of Gene 214 including RP11-0702C13. A preferred embodiment
is the nucleotide sequence of the BAC clones consisting of SEQ ID
NO:1.
[0023] This invention further relates to methods using isolated
and/or recombinant nucleic acids (DNA or RNA) that are
characterized by their ability to hybridize to (a) a nucleic acid
encoding a protein or polypeptide, such as a nucleic acid having
any of the sequences of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ
ID NO: 8, and SEQ ID NO:10 or (b) a portion of the foregoing (e.g.,
a portion comprising the minimum nucleotides of the Gene 214
nucleic acid code a functional Gene 214 protein or the minimum
number to inhibit an endogenous Gene 214; or by their ability to
encode a polypeptide having the amino acid sequence of SEQ ID NO:3,
SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9 and SEQ ID NO: 11 or to
encode functional equivalents thereof; e.g., a polypeptide which
when incorporated into a cell, has all or part of the activity of a
Gene 214 protein, or by both characteristics. A functional
equivalent of a Gene 214 protein, therefore, would have a similar
amino acid sequence (at least 65% sequence identity) and similar
characteristics to, or perform in substantially the same way as
Gene 214 protein. A nucleic acid which hybridizes to a nucleic acid
encoding a Gene 214 protein or polypeptide, such as SEQ ID NO:2,
SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, and SEQ ID NO:10 can be
double- or single-stranded. Hybridization to DNA such as DNA having
the sequence SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8,
and SEQ ID NO:10 includes hybridization to the strand shown or its
complementary strand.
[0024] In one embodiment, the percent amino acid sequence
similarity between a Gene 214 polypeptide such as SEQ ID NO:3, SEQ
ID NO:5, SEQ ID NO:7, SEQ ID NO: 9 and SEQ ID NO: 11, and
functional equivalents thereof is at least about 50%. In a
preferred embodiment, the percent amino acid sequence similarity
between such a Gene 214 polypeptide and its functional equivalents
is at least about 65%. More preferably, the percent amino acid
sequence similarity between a Gene 214 polypeptide and its
functional equivalents is at least about 75%, and still more
preferably, at least about 80%. To determine percent nucleotide or
amino acid sequence similarity, sequences can be compared to
publicly available sequence databases (National Center for
Biotechnology Information, National Library of Medicine, 38A,
8N905, 8600 Rockville Pike, Bethesda, MD 20894;
www.ncbi.nlm.nih.gov) using the blastn2 algorithm (Altsch, Nucl.
Acids Res., 25:3389-3402 (1997)). The parameters for a typical
search are: E=0.05, v=50, B=50 (where E is the expected probability
score cutoff, V is the number of database entries returned in the
reporting of the results, and B is the number of sequence
alignments returned in the reporting of the results (Altsch et al,
J. Mol. Biol., 215:403-410 (1990)).
[0025] Isolated and/or recombinant nucleic acids meeting these
criteria comprise nucleic acids having sequences identical to
sequences of naturally occurring Gene 214 genes such as Gene 214a,
Gene 214b, Gene 214c, Gene 214d, Gene 214e, and portions thereof,
or variants of the naturally occurring genes. Such variants include
mutants differing by the addition, deletion or substitution of one
or more nucleotides, modified nucleic acids in which one or more
nucleotides are modified (e.g., DNA or RNA analogs), and mutants
comprising one or more modified nucleotides including repeated
fragments.
[0026] Such nucleic acids, including DNA or RNA, can be detected
and isolated by hybridization under high stringency conditions or
moderate stringency conditions, for example, which are chosen so as
to not permit the hybridization of nucleic acids having
non-complementary sequences. "Stringency conditions" for
hybridizations is a term of art which refers to the conditions of
temperature and buffer concentration which permit hybridization of
a particular nucleic acid to another nucleic acid in which the
first nucleic acid may be perfectly complementary to the second, or
the first and second may share some degree of complementarity which
is less than perfect. For example, certain high stringency
conditions can be used which distinguish perfectly complementary
nucleic acids from those of less complementarity. "High stringency
conditions" and "moderate stringency conditions" for nucleic acid
hybridizations are explained on pages 2.10.1-2.10.16 (see
particularly 2.10.8-11) and pages 6.3.1-6 in Current Protocols in
Molecular Biology (Ausubel, F. M. et al., eds., Vol. 1, containing
supplements up through Supplement 29, 1995), the teachings of which
are hereby incorporated by reference. The exact conditions which
determine the stringency of hybridization depend not only on ionic
strength, temperature and the concentration of destabilizing agents
such as formamide, but also on factors such as the length of the
nucleic acid sequence, base composition, percent mismatch between
hybridizing sequences and the frequency of occurrence of subsets of
that sequence within other non-identical sequences. Thus, high or
moderate stringency conditions can be determined empirically.
[0027] High stringency hybridization procedures (1) employ low
ionic strength and high temperature for washing, such as 0.015 M
NaCl/0.0015 M sodium citrate, pH 7.0 (0.1.times.SSC) with 0.1%
sodium dodecyl sulfate (SDS) at 50.degree. C.; (2) employ during
hybridization 50% (vol/vol) formamide with 5.times.Denhardt's
solution (0.1% weight/volume highly purified bovine serum
albumin/0.1% wt/vol Ficoll/0.1% wt/vol polyvinylpyrrolidone), 50 mM
sodium phosphate buffer at pH 6.5 and 5.times.SSC at 42.degree. C.;
or (3) employ hybridization with 50% formamide, 5.times.SSC, 50 mM
sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate,
5.times.Denhardt's solution, sonicated salmon sperm DNA (50
.mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42.degree. C., with
washes at 42.degree. C. in 0.2.times.SSC and 0.1% SDS.
[0028] By varying hybridization conditions from a level of
stringency at which no hybridization occurs to a level at which
hybridization is first observed, conditions which will allow a
given sequence to hybridize with the most similar sequences in the
sample can be determined. Preferably the hybridizing sequences will
have 60-70% sequence identity, more preferably 70-85% sequence
identity, and even more preferably 90-100% sequence identity.
[0029] Exemplary conditions are described in Krause, M. H. and S.
A. Aaronson (1991) Methods in Enzymology, 200:546-556. Also, see
especially page 2.10.11 in Current Protocols in Molecular Biology
(supra), which describes how to determine washing conditions for
moderate or low stringency conditions. Washing is the step in which
conditions are usually set so as to determine a minimum level of
complementarity of the hybrids. Generally, from the lowest
temperature at which only homologous hybridization occurs, a 1%
mismatch between hybridizing nucleic acids results in a 1.degree.
C. decrease in the melting temperature T.sub.m, for any chosen SSC
concentration. Generally, doubling the concentration of SSC results
in an increase in T.sub.m of .about.17.degree. C. Using these
guidelines, the washing temperature can be determined empirically
for moderate or low stringency, depending on the level of mismatch
sought.
[0030] Isolated and/or recombinant nucleic acids that are
characterized by their ability to hybridize to (a) a nucleic acid
encoding a Gene 214 polypeptide, such as the nucleic acids depicted
as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, and SEQ ID
NO:10, b) the complement, (c) or a portion of (a) or (b) (e.g.
under high or moderate stringency conditions), may further encode a
protein or polypeptide having at least one function characteristic
of a Gene 214 polypeptide, such as protective barrier of the
respiratory epithelium activity, or binding of antibodies that also
bind to non-recombinant Gene 214 protein or polypeptide. The
catalytic or binding function of a protein or polypeptide encoded
by the hybridizing nucleic acid may be detected by standard
enzymatic assays for activity or binding (e.g., assays which
measure the binding of a transit peptide or a precursor, or other
components of the translocation machinery). Enzymatic assays,
complementation tests, or other suitable methods can also be used
in procedures for the identification and/or isolation of nucleic
acids which encode a polypeptide such as a polypeptide of the amino
acid sequences SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9
and SEQ ID NO: 11, or a functional equivalent of these
polypeptides. The antigenic properties of proteins or polypeptides
encoded by hybridizing nucleic acids can be determined by
immunological methods employing antibodies that bind to a Gene 214
polypeptide such as immunoblot, immunoprecipitation and
radioimmunoassay. PCR methodology, including RAGE (Rapid
Amplification of Genomic DNA Ends), can also be used to screen for
and detect the presence of nucleic acids which encode Gene 214-like
proteins and polypeptides, and to assist in cloning such nucleic
acids from genomic DNA. PCR methods for these purposes can be found
in Innis, M. A., et al. (1990) PCR Protocols: A Guide to Methods
and Applications, Academic Press, Inc., San Diego, Calif.,
incorporated herein by reference.
[0031] It is understood that, as a result of the degeneracy of the
genetic code, many nucleic acid sequences are possible which encode
a Gene 214-like protein or polypeptide. Some of these will have
little homology to the nucleotide sequences of any known or
naturally-occurring Gene 214-like gene but can be used to produce
the proteins and polypeptides of this invention by selection of
combinations of nucleotide triplets based on codon choices. Such
variants, while not hybridizable to a naturally-occurring Gene 214
gene, are contemplated within this invention.
[0032] The nucleic acids described herein are used in the methods
of the present invention for production of proteins or
polypeptides, through incorporation into cells, tissues, or
organisms. In one embodiment, DNA containing all or part of the
coding sequence for a Gene 214 polypeptide, or DNA which hybridizes
to DNA having the sequence SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6,
SEQ ID NO: 8, and SEQ ID NO:10, is incorporated into a vector for
expression of the encoded polypeptide in suitable host cells. The
encoded polypeptide consisting of Gene 214, or its functional
equivalent is capable of normal activity, such as protecting the
respiratory epithelium. The term "vector" as used herein refers to
a nucleic acid molecule capable of replicating another nucleic acid
to which it has been linked. A vector, for example, can be a
plasmid.
[0033] Nucleic acids referred to herein as "isolated" are nucleic
acids separated away from the nucleic acids of the genomic DNA or
cellular RNA of their source of origin (e.g., as it exists in cells
or in a mixture of nucleic acids such as a library), and may have
undergone further processing. "Isolated", as used herein, refers to
nucleic or amino acid sequences that are at least 60% free,
preferably 75% free, and most preferably 90% free from other
components with which they are naturally associated. "Isolated"
nucleic acids (polynucleotides) include nucleic acids obtained by
methods described herein, similar methods or other suitable
methods, including essentially pure nucleic acids, nucleic acids
produced by chemical synthesis, by combinations of biological and
chemical methods, and recombinant nucleic acids which are isolated.
Nucleic acids referred to herein as "recombinant" are nucleic acids
which have been produced by recombinant DNA methodology, including
those nucleic acids that are generated by procedures which rely
upon a method of artificial replication, such as the polymerase
chain reaction (PCR) and/or cloning into a vector using restriction
enzymes. "Recombinant" nucleic acids are also those that result
from recombination events that occur through the natural mechanisms
of cells, but are selected for after the introduction to the cells
of nucleic acids designed to allow or make probable a desired
recombination event. Portions of the isolated nucleic acids which
code for polypeptides having a certain function can be identified
and isolated by, for example, the method of Jasin, M., et al., U.S.
Pat. No. 4,952,501.
[0034] A further embodiment of the invention is antisense nucleic
acids or oligonucleotides which are complementary, in whole or in
part, to a target molecule comprising a sense strand, and can
hybridize with the target molecule. The target can be DNA, or its
RNA counterpart (i.e., wherein T residues of the DNA are U residues
in the RNA counterpart). When introduced into a cell, antisense
nucleic acids or oligonucleotides can inhibit the expression of the
gene encoded by the sense strand or the mRNA transcribed from the
sense strand. Antisense nucleic acids can be produced by standard
techniques. See, for example, Shewmaker, et al., U.S. Pat. No.
5,107,065.
[0035] In a particular embodiment, an antisense nucleic acid or
oligonucleotide is wholly or partially complementary to and can
hybridize with a target nucleic acid (either DNA or RNA), wherein
the target nucleic acid can hybridize to a nucleic acid having the
sequence of the complement of the strand in SEQ ID NO:2, SEQ ID
NO:4, SEQ ID NO:6, SEQ ID NO: 8, and SEQ ID NO:10. For example, an
antisense nucleic acid or oligonucleotide can be complementary to a
target nucleic acid having the sequence shown as the strand of the
open reading frame of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID
NO: 8, and SEQ ID NO:10 or nucleic acid encoding a functional
equivalent of Gene 214, or to a portion of these nucleic acids
sufficient to allow hybridization. A portion, for example a
sequence of 16 nucleotides, could be sufficient to inhibit
expression of the protein. Or, an antisense nucleic acid or
oligonucleotide, complementary to 5' or 3' untranslated regions, or
overlapping the translation initiation codon (5' untranslated and
translated regions), of the Gene 214 gene, or a gene encoding a
functional equivalent can also be effective. In another embodiment,
the antisense nucleic acid is wholly or partially complementary to
and can hybridize with a target nucleic acid which encodes a Gene
214 polypeptide.
[0036] In addition to the antisense nucleic acids of the invention,
oligonucleotides can be constructed which will bind to duplex
nucleic acid either in the gene or the DNA:RNA complex of
transcription, to form a stable triple helix-containing or triplex
nucleic acid to inhibit transcription and/or expression of a gene
encoding Gene 214, or its functional equivalent (Frank-Kamenetskii,
M. D. and Mirkin, S. M. (1995) Ann. Rev. Biochem. 64:65-95.) Such
oligonucleotides of the invention are constructed using the
base-pairing rules of triple helix formation and the nucleotide
sequence of the gene or mRNA for Gene 214. These oligonucleotides
can block Gene 214-type activity in a number of ways, including
prevention of transcription of the Gene 214 gene or by binding to
mRNA as it is transcribed by the gene.
[0037] The invention also relates to proteins or polypeptides
encoded by the novel nucleic acids described herein. The proteins
and polypeptides of this invention can be isolated and/or
recombinant. Proteins or polypeptides referred to herein as
"isolated" are proteins or polypeptides purified to a state beyond
that in which they exist in cells. In a preferred embodiment, they
are at least 10% pure; i.e., most preferably they are substantially
purified to 80 or 90% purity. "Isolated" proteins or polypeptides
include proteins or polypeptides obtained by methods described
infra, similar methods or other suitable methods, and include
essentially pure proteins or polypeptides, proteins or polypeptides
produced by chemical synthesis or by combinations of biological and
chemical methods, and recombinant proteins or polypeptides which
are isolated. Proteins or polypeptides referred to herein as
"recombinant" are proteins or polypeptides produced by the
expression of recombinant nucleic acids.
[0038] In a preferred embodiment, the protein or portion thereof
has at least one function characteristic of a Gene 214 protein or
polypeptide, for example, protective barrier to the respiratory
epithelium activity in the case of Gene 214 analogs, and/or
antigenic function (e.g., binding of antibodies that also bind to
naturally occurring Gene 214 polypeptide). As such, these proteins
are referred to as analogs, and include, for example, naturally
occurring Gene 214, variants (e.g. mutants) of those proteins
and/or portions thereof. Such variants include mutants differing by
the addition, deletion or substitution of one or more amino acid
residues, or modified polypeptides in which one or more residues
are modified, and mutants comprising one or more modified residues.
The variant can have "conservative" changes, wherein a substituted
amino acid has similar structural or chemical properties, e.g.,
replacement of leucine with isoleucine. More infrequently, a
variant can have "nonconservative" changes, e.g., replacement of a
glycine with a tryptophan. Guidance in determining which amino acid
residues can be substituted, inserted, or deleted without
abolishing biological or immunological activity can be found using
computer programs well known in the art, for example, DNASTAR
software (DNASTAR, Inc., Madison, Wis. 53715 U.S.A.).
[0039] A "portion" as used herein with regard to a protein or
polypeptide, refers to fragments of that protein or polypeptide.
The fragments can range in size from 5 amino acid residues to all
but one residue of the entire protein sequence. Thus, a portion or
fragment can be at least 5, 5-50, 50-100, 100-200, 200-400,
400-800, or more consecutive amino acid residues of a Gene 214
protein or polypeptide, for example, SEQ ID NO:3, SEQ ID NO:5, SEQ
ID NO:7, SEQ ID NO: 9 and SEQ ID NO: 11, or a variant thereof.
[0040] The invention also relates to isolated, synthesized and/or
recombinant portions or fragments of a Gene 214 protein or
polypeptide as described above. Polypeptide fragments of the enzyme
can be made which have full or partial function on their own, or
which when mixed together (though fully, partially, or
nonfunctional alone), spontaneously assemble with one or more other
polypeptides to reconstitute a functional protein having at least
one functional characteristic of a Gene 214 proteinof this
invention.
[0041] The invention also concerns the use of the nucleotide
sequence of the nucleic acids of this invention to identify DNA
probes for Gene 214 genes, PCR primers to amplify Gene 214 genes,
nucleotide polymorphisms in Gene 214 genes, and regulatory elements
of the Gene 214 genes.
[0042] Gene 214 was isolated by narrowly defining the region of
chromosome 12q23-qter 12q23-qter which was associated with airway
hyperresponsiveness and asthma. Gene 214 is also important in other
diseases such as obesity and thus, there was a need to identify and
isolate the gene.
[0043] To aid in the understanding of the specification and claims,
the following definitions are provided.
[0044] "Disorder region" refers to a portion of the human
chromosome 12 bounded by the markers D12S2070 to the 12q telomere.
A "disorder-associated" nucleic acid or "disorder-associated"
polypeptide sequence refers to a nucleic acid sequence that maps to
region 12q23-qter and polypeptides encoded therein. For nucleic
acid sequences, this encompasses sequences that are homologous or
complementary to the sequence, as well as "sequence-conservative
variants" and "function-conservative variants." For polypeptide
sequences, this encompasses "function-conservative variants."
Included are naturally-occurring mutations causative of respiratory
diseases or obesity, such as but not limited to mutations which
cause inappropriate expression (e.g., lack of expression,
over-expression, expression in an inappropriate tissue type).
"Sequence-conservative" variants are those in which a change of one
or more nucleotides in a given codon position results in no
alteration in the amino acid encoded at that position.
"Function-conservative" variants are those in which a change in one
or more nucleotides in a given codon position results in a
polypeptide sequence in which a given amino acid residue in a
polypeptide has been changed without substantially altering the
overall conformation and function of the native polypeptide,
including, but not limited to, replacement of an amino acid with
one having similar physico-chemical properties (such as, for
example, acidic, basic, hydrophobic, and the like).
"Function-conservative" variants also include analogs of a given
polypeptide and any polypeptides that have the ability to elicit
antibodies specific to a designated polypeptide.
[0045] "Nucleic acid or "polynucleotide" as used herein refers to
purine- and pyrimidine-containing polymers of any length, either
polyribonucleotides or polydeoxyribonucleotide or mixed
polyribo-polydeoxyribo nucleotides. This includes single- and
double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA
hybrids, as well as "protein nucleic acids" (PNA) formed by
conjugating bases to an amino acid backbone. This also includes
nucleic acids containing modified bases.
[0046] A "coding sequence" or a "protein-coding sequence" is a
polynucleotide sequence capable of being transcribed into mRNA
and/or capable of being translated into a polypeptide. The
boundaries of the coding sequence are typically determined by a
translation start codon at the 5'-terminus and a translation stop
codon at the 3'-terminus.
[0047] A "complement" of a nucleic acid sequence as used herein
refers to the "antisense" sequence that participates in
Watson-Crick base-pairing with the original sequence.
[0048] A "probe" refers to a nucleic acid or oligonucleotide that
forms a hybrid structure with a sequence in a target region due to
complementarily of at least one sequence in the probe with a
sequence in the target region.
[0049] Nucleic acids are "hybridizable" to each other when at least
one strand of nucleic acid can anneal to another nucleic acid
strand under defined stringency conditions. As is well known in the
art, stringency of hybridization is determined, e.g., by (a) the
temperature at which hybridization and/or washing is performed, and
(b) the ionic strength and polarity (e.g., formamide) of the
hybridization and washing solutions, as well as other parameters.
Hybridization requires that the two nucleic acids contain
substantially complementary sequences; depending on the stringency
of hybridization, however, mismatches may be tolerated. The
appropriate stringency for hybridizing nucleic acids depends on the
length of the nucleic acids and the degree of complementarily,
variables well known in the art.
[0050] An "immunogenic component", is a moiety that is capable of
eliciting a humoral and/or cellular immune response in a host
animal.
[0051] An "antigenic component" is a moiety that binds to its
specific antibody with sufficiently high affinity to form a
detectable antigen-antibody complex.
[0052] A "sample" as used herein refers to a biological sample,
such as, for example, tissue or fluid isolated from an individual
(including without limitation plasma, serum, cerebrospinal fluid,
lymph, tears, saliva, milk, pus, and tissue exudates and
secretions) or from in vitro cell culture constituents, as well as
samples obtained from e.g., a laboratory procedure.
[0053] "Gene" refers to a DNA sequence that encodes through its
template or messenger RNA a sequence of amino acids characteristic
of a specific peptide, polypeptide or protein. The term "gene" as
used herein with reference to genomic DNA includes intervening,
non-coding regions, as well as regulatory regions, and can include
5' and 3' ends.
[0054] "Gene sequence" refers to a DNA molecule, including both a
DNA molecule which contains a non-transcribed or non-translated
sequence. The term is also intended to include any combination of
gene(s), gene fragment(s), non-transcribed sequence(s) or
non-translated sequence(s) which are present on the same DNA
molecule.
[0055] A gene sequence is "wild-type" if such sequence is usually
found in individuals unaffected by the disease or condition of
interest. However, environmental factors and other genes can also
play an important role in the ultimate determination of the
disease. In the context of complex diseases involving multiple
genes ("oligogenic disease"), the "wild type" or normal sequence
can also be associated with a measurable risk or susceptibility,
receiving its reference status based on its frequency in the
general population.
[0056] A gene sequence is a "mutant" sequence if it differs from
the wild-type sequence. In some cases, the individual carrying such
gene has increased susceptibility toward the disease or condition
of interest. In other cases, the "mutant" sequence might also refer
to a sequence that decreases the susceptibilty toward a disease or
condition of interest, and thus acting in a protective manner. Also
a gene is a "mutant" gene if too much ("overexpressed") or too
little ("underexpressed") of such gene is expressed in the tissues
in which such gene is normally expressed, thereby causing the
disease or condition of interest.
[0057] A gene sequence is a "variant" sequence if it is
substantially similar in structure to either the entire gene or to
a fragment of the gene. Both wild-type genes and mutant genes have
variant sequences.
[0058] The sequences of the present invention may be derived from a
variety of sources including DNA, cDNA, synthetic DNA, synthetic
RNA or combinations thereof. Such sequences may comprise genomic
DNA which may or may not include naturally occurring introns.
Moreover, such genomic DNA may be obtained in association with
promoter regions or poly (A) sequences. The sequences, genomic DNA
or cDNA may be obtained in any of several ways. Genomic DNA can be
extracted and purified from suitable cells by means well known in
the art. Alternatively, mRNA can be isolated from a cell and used
to produce cDNA by reverse transcription or other means.
[0059] "cDNA" refers to complementary or copy DNA produced from an
RNA template by the action of RNA-dependent DNA polymerase (reverse
transcriptase). Thus, a "cDNA clone" means a duplex DNA sequence
complementary to an RNA molecule of interest, carried in a cloning
vector or PCR amplified. This term includes genes from which the
intervening sequences have been removed.
[0060] "Recombinant DNA" means a molecule that has been recombined
by in vitro splicing/and includes cDNA or a genomic DNA
sequence.
[0061] "Cloning" refers to the use of in vitro recombination
techniques to insert a particular gene or other DNA sequence into a
vector molecule. In order to successfully clone a desired gene, it
is necessary to use methods for generating DNA fragments, for
joining the fragments to vector molecules, for introducing the
composite DNA molecule into a host cell in which it can replicate,
and for selecting the clone having the target gene from amongst the
recipient host cells.
[0062] "cDNA library" refers to a collection of recombinant DNA
molecules containing cDNA inserts which together comprise the
entire genome of an organism. Such a cDNA library can be prepared
by methods known to one skilled in the art and described by, for
example, Cowell and Austin, "cDNA Library Protocols," Methods in
Molecular Biology (1997). Generally, RNA is first isolated from the
cells of an organism from whose genome it is desired to clone a
particular gene.
[0063] "Cloning vehicle" refers to a plasmid or phage DNA or other
DNA sequence which is able to replicate in a host cell. The cloning
vehicle is characterized by one or more endonuclease recognition
sites at which such DNA sequences may be cut in a determinable
fashion without loss of an essential biological function of the
DNA, which may contain a marker suitable for use in the
identification of transformed cells.
[0064] "Expression control sequence" refers to a sequence of
nucleotides that control or regulate expression of structural genes
when operably linked to those genes. These include, for example,
the lac systems, the trp system, major operator and promoter
regions of the phage lambda, the control region of fd coat protein
and other sequences known to control the expression of genes in
prokaryotic or eukaryotic cells. Expression control sequences will
vary depending on whether the vector is designed to express the
operably linked gene in a prokaryotic or eukaryotic host, and may
contain transcriptional elements such as enhancer elements,
termination sequences, tissue-specificity elements and/or
translational initiation and termination sites.
[0065] "Expression vehicle" refers to a vehicle or vector similar
to a cloning vehicle but which is capable of expressing a gene
which has been cloned into it, after transformation into a host.
The cloned gene is usually placed under the control of (i.e.,
operably linked to) an expression control sequence.
[0066] "Operably linked" means that the promoter controls the
initiation of expression of the gene. A promoter is operably linked
to a sequence of proximal DNA if upon introduction into a host cell
the promoter determines the transcription of the proximal DNA
sequence(s) into one or more species of RNA. A promoter is operably
linked to a DNA sequence if the promoter is capable of initiating
transcription of that DNA sequence.
[0067] "Host" includes prokaryotes and eukaryotes. The term
includes an organism or cell that is the recipient of a replicable
expression vehicle.
[0068] "Amplification of nucleic acids" refers to methods such as
polymerase chain reaction (PCR), ligation amplification (or ligase
chain reaction, LCR) and amplification methods based on the use of
Q-beta replicase. These methods are well known in the art and
described, for example, in U.S. Pat. Nos. 4,683,195 and 4,683,202.
Reagents and hardware for conducting PCR are commercially
available. Primers useful for amplifying sequences from the
disorder region are preferably complementary to, and preferably
hybridize specifically to, sequences in the 12q23-qter region or in
regions that flank a target region therein. Gene 214 generated by
amplification may be sequenced directly. Alternatively, the
amplified sequence(s) may be cloned prior to sequence analysis.
[0069] "Antibodies" refer to polyclonal and/or monoclonal
antibodies and fragments thereof, and immunologic binding
equivalents thereof, that can bind to asthma proteins and fragments
thereof or to nucleic acid sequences from the 12q23-qter region,
particularly from the asthma locus or a portion thereof. The term
antibody is used both to refer to a homogeneous molecular entity,
or a mixture such as a serum product made up of a plurality of
different molecular entities. Proteins may be prepared
synthetically in a protein synthesizer and coupled to a carrier
molecule and injected over several months into rabbits. Rabbit sera
is tested for immunoreactivity to the protein or fragment.
Monoclonal antibodies may be made by injecting mice with the
proteins, or fragments thereof. Monoclonal antibodies will be
screened by ELISA and tested for specific immunoreactivity with
protein or fragments thereof. (Harlow et al, Antibodies: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y. (1988.) These antibodies will be useful assays as well
as pharmaceuticals.
[0070] A nucleic acid or fragment thereof is "substantially
homologous" or "substantially similar" to another if, when
optimally aligned (with appropriate nucleotide insertions and/or
deletions) with the other nucleic acid (or its complementary
strand), there is nucleotide sequence identity in at least about
60% of the nucleotide bases, usually at least about 70%, more
usually at least about 80%, preferably at least about 90%, and more
preferably at least about 95-98% of the nucleotide bases.
[0071] Alternatively, substantial homology or similarity exists
when a nucleic acid or fragment thereof will hybridize, under
selective hybridization conditions, to another nucleic acid (or a
complementary strand thereof). Selectivity of hybridization exists
when hybridization which is substantially more selective than total
lack of specificity occurs. Typically, selective hybridization will
occur when there is at least about 55% homology over a stretch of
at least about nine or more nucleotides, preferably at least about
65%, more preferably at least about 75%, and most preferably at
least about 90%. (See, M. Kanehisa, 1984, Nucleic Acids Res., 12(1
Pt 1):203-13; M. Kanehisa et al., 1984, Nucleic Acids Res., 12(1 Pt
1):149-58; M. Kanehisa et al., 1984, Nucleic Acids Res. 12(1 Pt
1):417-28). The length of homology comparison, as described, may be
over longer stretches, and in certain embodiments will often be
over a stretch of at least about 14 nucleotides, usually at least
about 20 nucleotides, more usually at least about 24 nucleotides,
typically at least about 28 nucleotides, more typically at least
about 32 nucleotides, and preferably at least about 36 or more
nucleotides.
[0072] Technical and scientific terms used herein have the meanings
commonly understood by one of ordinary skill in the art to which
the present invention pertains, unless otherwise defined. Reference
is made herein to various methodologies known to those of skill in
the art. Publications and other materials setting forth such known
methodologies to which reference is made are incorporated herein by
reference in their entireties as though set forth in full. Standard
reference works setting forth the general principles of recombinant
DNA technology include Sambrook, J., et al., Molecular Cloning: A
Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press,
Planview, N.Y. (1989); Kaufman, P. B., et al., Eds., Handbook of
Molecular and Cellular Methods in Biology and Medicine, CRC Press,
Boca Raton (1995); McPherson, M. J., Ed., Directed Mutagenesis: A
Practical Approach, IRL Press, Oxford (1991); Jones, J., Amino Acid
and Peptide Synthesis, Oxford Science Publications, Oxford (1992);
Austen, B. M. and Westwood, O. M. R., Protein Targeting and
Secretion, IRL Press, Oxford (1991); DNA Cloning, Volumes I and II
(D. N Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed,
1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins
eds. 1984); the series, Methods in Enzymology (Academic Press,
Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, eds.);
PCR-A Practical Approach (McPherson, Quirke, and Taylor, eds.,
1991); Transcription and Translation, 1984 (Hames and Higgins
eds.); Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized
Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical
Guide to Molecular Cloning; Gene Transfer Vectors for Mammalian
Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor
Laboratory); Martin J. Bishop, ed., Guide to Human Genome
Computing, 2d Edition, Academic Press, San Diego, Calif. (1998);
and Leonard F. Peruski, Jr., and Anne Harwood Peruski, The Internet
and the New Biology: Tools for Genomic and Molecular Research,
American Society for Microbiology, Washington, D.C. (1997).
Standard reference works setting forth the general principles of
immunology include Sell, S., Immunology, Immunopathology &
Immunity, 5th Ed., Appleton & Lange, Publ., Stamford, Conn.
(1996); Male, D., et al., Advanced Immunology, 3d Ed., Times Mirror
Int'l Publishers Ltd., Publ., London (1996); Stites, D. P., and
Ten, A. I., Basic and Clinical Immunology, 7th Ed., Appleton &
Lange, Publ., Norwalk, Conn. (1991); and Abbas, A. K., et al.,
Cellular and Molecular Immunology, W. B. Saunders Co., Publ.,
Philadelphia, Pa. (1991). Any suitable materials and/or methods
known to those of skill can be utilized in carrying out the present
invention; however, preferred materials and/or methods are
described. Materials, reagents and the like to which reference is
made in the following description and examples are obtainable from
commercial sources, unless otherwise noted.
[0073] The nucleic acids of the invention may be isolated directly
from cells. Alternatively, the polymerase chain reaction (PCR)
method can be used to produce the nucleic acids of the invention,
using either chemically synthesized strands or genomic material as
templates. Primers used for PCR can be synthesized using the
sequence information provided herein and can further be designed to
introduce appropriate new restriction sites, if desirable, to
facilitate incorporation into a given vector for recombinant
expression.
[0074] The invention also provides vectors comprising the
disorder-associated sequences or derivatives or fragments thereof
and host cells for the production of purified proteins. A large
number of vectors, including plasmid and fungal vectors, have been
described for replication and/or expression in a variety of
eukaryotic and prokaryotic hosts, and may be used for gene therapy
as well as for simple cloning or protein expression.
[0075] Using the information provided in SEQ ID NO:2, SEQ ID NO:4,
SEQ ID NO:6, SEQ ID NO: 8, and SEQ ID NO:10, one skilled in the art
will be able to clone and sequence all representative nucleic acids
of interest, including nucleic acids encoding complete
protein-coding sequences. It is to be understood that
non-protein-coding sequences contained within SEQ ID NO:2, SEQ ID
NO:4, SEQ ID NO:6, SEQ ID NO: 8, and SEQ ID NO:10 and the genomic
sequence of SEQ ID NO:1 are also within the scope of the invention.
Such sequences include, without limitation, sequences important for
replication, recombination, transcription and translation.
Non-limiting examples include promoters and regulatory binding
sites involved in regulation of gene expression, and 5'- and
3'-untranslated sequences (e.g., ribosome-binding sites) that form
part of mRNA molecules.
[0076] The nucleic acids of the present invention find use as
primers and templates for the recombinant production of
disorder-associated peptides or polypeptides, for chromosome and
gene mapping, to provide antisense sequences, for tissue
distribution studies, to locate and obtain full length genes, to
identify and obtain homologous sequences (wild-type and mutants),
and in diagnostic applications.
[0077] Polypeptides according to the invention are at least five or
more residues in length. Preferably, the polypeptides comprise at
least about 12, more preferably at least about 20 and most
preferably at least about 30 such residues. Nucleic acids
comprising protein-coding sequences can be used to direct the
expression of asthma-associated polypeptides in intact cells or in
cell-free translation systems. The known genetic code, tailored if
desired for more efficient expression in a given host organism, can
be used to synthesize oligonucleotides encoding the desired amino
acid sequences. The resulting oligonucleotides can be inserted into
an appropriate vector and expressed in a compatible host
organism.
[0078] The polypeptides of the present invention, including
function-conservative variants, may be isolated from wild-type or
mutant cells, or from heterologous organisms or cells (e.g.,
bacteria, fungi, yeast, insect, plant, and mammalian cells) in
which a disorder-associated protein-coding sequence has been
introduced and expressed. Furthermore, the polypeptides may be part
of recombinant fusion proteins. The polypeptides can also,
advantageously, be made using cell-free protein synthesis systems
or by synthetic chemistry. Polypeptides may be chemically
synthesized by commercially available automated procedures,
including, without limitation, exclusive solid phase synthesis,
partial solid phase methods, fragment condensation or classical
solution synthesis.
[0079] Methods for polypeptide purification are well-known in the
art, including, without limitation, preparative disc-gel
electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC,
gel filtration, ion exchange and partition chromatography, and
countercurrent distribution. For some purposes, it is preferable to
produce the polypeptide in a recombinant system in which the
disorder-associated protein contains an additional sequence tag
that facilitates purification. Alternatively, antibodies produced
against an disorder-associated protein or against peptides derived
therefrom can be used as purification reagents. Other purification
methods are possible.
[0080] The present invention also encompasses derivatives and
homologies of disorder-associated polypeptides. For some purposes,
nucleic acid sequences encoding the peptides may be altered by
substitutions, additions, or deletions that provide for
functionally equivalent molecules, i.e., function-conservative
variants.
[0081] The isolated polypeptides may be modified by, for example,
phosphorylation, sulfation, acylation, or other protein
modifications. They may also be modified with a label capable of
providing a detectable signal, either directly or indirectly,
including, but not limited to, radioisotopes and fluorescent
compounds.
[0082] Both the naturally occurring and recombinant forms of the
polypeptides of the invention can advantageously be used to screen
compounds for binding activity. Many methods of screening for
binding activity are known by those skilled in the art and may be
used to practice the invention. Several methods of automated assays
have been developed in recent years so as to permit screening of
tens of thousands of compounds in a short period of time. Such
high-throughput screening methods are particularly preferred. The
use of high-throughput screening assays to test for inhibitors is
greatly facilitated by the availability of large amounts of
purified polypeptides, as provided by the invention. The
polypeptides of the invention also find use as therapeutic agents
as well as antigenic components to prepare antibodies.
[0083] The polypeptides of this invention find use as immunogenic
components useful as antigens for preparing antibodies by standard
methods. It is well known in the art that immunogenic epitopes
generally contain at least about five amino acid residues, Ohno et
al., 1985, Proc. Nati. Acad. Sci. USA 82:2945. Therefore, the
immunogenic components of this invention will typically comprise at
least five amino acid residues of the sequence of the complete
polypeptide chains. Preferably, they will contain at least 7, and
most preferably at least about 10 amino acid residues or more to
ensure that they will be immunogenic. Whether a given component is
immunogenic can readily be determined by routine experimentation
Such immunogenic components can be produced by proteolytic cleavage
of larger polypeptides or by chemical synthesis or recombinant
technology and are thus not limited by proteolytic cleavage sites.
The present invention thus encompasses antibodies that specifically
recognize asthma--associated immunogenic components.
[0084] Antibodies according to the present invention include
polyclonal and monoclonal antibodies. The antibodies may be
elicited in an animal host by immunization with disorder-associated
immunogenic components or may be formed by in vitro immunization
(sensitization) of immune cells. The immunogenic components used to
elicit the production of antibodies may be isolated from cells or
chemically synthesized. The antibodies may also be produced in
recombinant systems programmed with appropriate antibody-encoding
DNA. Alternatively, the antibodies may be constructed by
biochemical reconstitution of purified heavy and light chains. The
antibodies include hybrid antibodies, chimeric antibodies, and
univalent antibodies. Also included are Fab fragments, including
Fab.sup.1 and Fab(ab).sup.2 fragments of antibodies.
[0085] These antibodies, whether polyclonal or monoclonal, can be
used, e.g., in an immobilized form bound to a solid support by well
known methods, to purify the immunogenic components and
disorder-associated polypeptides by immunoaffinity chromatography.
Antibodies against the immunogenic components can also be used,
unlabeled or labeled by standard methods, as the basis for
immunoassays, i.e., as diagnostic reagents.
[0086] Hybridomas of the invention used to make monoclonal
antibodies against the immunogenic components of the invention are
produced by well-known techniques. Usually, the process involves
the fusion of an immortalizing cell line with a B-lymphocyte that
produces the desired antibody. Alternatively, non-fusion techniques
for generating immortal antibody-producing cell lines are possible,
and come within the purview of the present invention, e.g.,
virally-induced transformation, Casali et al., 1986, Science
234:476. Immortalizing cell lines are usually transformed mammalian
cells, particularly myeloma cells of rodent, bovine, and human
origin. Most frequently, rat or mouse myeloma cell lines are
employed as a matter of convenience and availability.
[0087] Hybridomas are selected by standard procedures, such as HAT
(hypoxanthine-aminopterin-thymidine) selection. From among these
hybridomas, those secreting the desired antibody are selected by
assaying their culture medium by standard immunoassays, such as
Western blotting, ELISA (enzyme-linked immunosorbent assay), RtA
(radioimmunoassay), or the like. Antibodies are recovered from the
medium using standard protein purification techniques, Tijssen,
1985, Practice and Theory of Enzyme Immunoassays, Elsevier,
Amsterdam.
I. Localization of an Asthma Locus on Chromosome 12q23-qter and the
Characterization of a Candidate Gene within the Region
[0088] To identify genes in the region on 12q23-qter, a set of
bacterial artificial chromosome (BAC) clones containing this
chromosomal region was identified. The BAC clones served as a
template for genomic DNA sequencing and serve as reagents for
identifying coding sequences by direct cDNA selection. Genomic
sequencing and direct cDNA selection were used to characterize DNA
from 12q23-qter.
[0089] When a gene has been genetically localized to a specific
chromosomal region, the genes in this region can be characterized
at the molecular level by a series of steps that include: cloning
of the entire region of DNA in a set of overlapping clones
(physical mapping), characterization of genes encoded by these
clones by a combination of direct cDNA selection, exon trapping and
DNA sequencing (gene identification), and identification of
mutations in these genes by comparative DNA sequencing of affected
and unaffected members of the kindred and/or in unrelated affected
individuals and unrelated unaffected controls(mutation
analysis).
[0090] Physical mapping is accomplished by screening libraries of
human DNA cloned in vectors that are propagated in a host such as
E. coli, using hybridization or PCR assays from unique molecular
landmarks in the chromosomal region of interest. To generate a
physical map of the disorder region, a library of human DNA cloned
in BACs was screened with a set of overgo markers that had been
previously mapped to chromosome 12q23-qter by the efforts of the
Human Genome Project. Overgos are unique molecular landmarks in the
human genome that can be assayed by hybridization. Through the
combined efforts of the Human Genome Project, the location of
thousands of overgos on the twenty-two autosomes and two sex
chromosomes has been determined. For a positional cloning effort,
the physical map is tied to the genetic map because the markers
used for genetic mapping can also be used as overgos for physical
mapping. By screening a BAC library with a combination of overgos
derived from genetic markers, genes, and random DNA fragments, a
physical map comprised of overlapping clones representing all of
the DNA in a chromosomal region of interest can be assembled.
[0091] BACs are cloning vectors for large (80 kilobase to 200
kilobase) segments of human or other DNA that are propagated in E.
coli. To construct a physical map using BACs, a library of BAC
clones is screened so that individual clones harboring the DNA
sequence corresponding to a given overgo or set of overgos are
identified. Throughout most of the human genome, the overgo markers
are spaced approximately 20 to 50 kilobases apart, so that an
individual BAC clone typically contains at least two overgo
markers. In addition, the BAC libraries that were screened contain
enough cloned DNA to cover the human genome twelve times over.
Therefore, an individual overgo typically identifies more than one
BAC clone. By screening a twelve-fold coverage BAC library with a
series of overgo markers spaced approximately 50 kilobases apart, a
physical map consisting of a series of overlapping contiguous BAC
clones, i.e., BAC "contigs," can be assembled for any region of the
human genome. This map is closely tied to the genetic map because
many of the overgo markers used to prepare the physical map are
also genetic markers.
[0092] When constructing a physical map, it often happens that
there are gaps in the overgo map of the genome that result in the
inability to identify BAC clones that are overlapping in a given
location. Typically, the physical map is first constructed from a
set of overgos identified through the publicly available literature
and World Wide Web resources. The initial map consists of several
separate BAC contigs that are separated by gaps of unknown
molecular distance. To identify BAC clones that fill these gaps, it
is necessary to develop new overgo markers from the ends of the
clones on either side of the gap. This is done by sequencing the
terminal 200 to 300 base pairs of the BACs flanking the gap, and
developing a PCR or hybridization based assay. If the terminal
sequences are demonstrated to be unique within the human genome,
then the new overgo can be used to screen the BAC library to
identify additional BACs that contain the DNA from the gap in the
physical map. To assemble a BAC contig that covers a region the
size of the disorder region (6,000,000 or more base pairs), it is
necessary to develop new overgo markers from the ends of a number
of clones.
[0093] After building a BAC contig, this set of overlapping clones
serves as a template for identifying the genes encoded in the
chromosomal region. Gene identification can be accomplished by many
methods. Three methods are commonly used: (1) a set of BACs
selected from the BAC contig to represent the entire chromosomal
region can be sequenced, and computational methods can be used to
identify all of the genes, (2) the BACs from the BAC contig can be
used as a reagent to clone cDNAs corresponding to the genes encoded
in the region by a method termed direct cDNA selection, or (3) the
BACs from the BAC contig can be used to identify coding sequences
by selecting for specific DNA sequence motifs in a procedure called
exon trapping. The present invention includes Gene 214 identified
by the first two methods.
[0094] To sequence the entire BAC contig representing the disorder
region, a set of BACs can be chosen for subcloning into plasmid
vectors and subsequent DNA sequencing of these subclones. Since the
DNA cloned in the BACs represents genomic DNA, this sequencing is
referred to as genomic sequencing to distinguish it from cDNA
sequencing. To initiate the genomic sequencing for a chromosomal
region of interest, several non-overlapping BAC clones are chosen.
DNA for each BAC clone is prepared, and the clones are sheared into
random small fragments which are subsequently cloned into standard
plasmid vectors such as pUC 18. The plasmid clones are then grown
to propagate the smaller fragments, and these are the templates for
sequencing. To ensure adequate coverage and sequence quality for
the BAC DNA sequence, sufficient plasmid clones are sequenced to
yield three-fold coverage of the BAC clone. For example, if the BAC
is 100 kilobases long, then phagemids are sequenced to yield 300
kilobases of sequence. Since the BAC DNA was randomly sheared prior
to cloning in the phagemid vector, the 300 kilobases of raw DNA
sequence can be assembled by computational methods into overlapping
DNA sequences termed sequence contigs. For the purposes of initial
gene identification by computational methods, three-fold coverage
of each BAC is sufficient to yield twenty to forty sequence contigs
of 1000 base pairs to 20,000 base pairs.
[0095] The sequencing strategy employed in this invention was to
initially sequence "seed" BACs from the BAC contig in the disorder
region. The sequence of the "seed" BACs was then used to identify
minimally overlapping BACs from the contig, and these were
subsequently sequenced. In this manner, the entire candidate region
can be sequenced, with several small sequence gaps left in each
BAC. This sequence serves as the template for computational gene
identification. One method for computational gene identification is
to compare the sequence of BAC contig to publicly available
databases of cDNA and genomic sequences, e.g. unigene, dbEST,
genbank. These comparisons are typically done using the BLAST
family of computer algorithms and programs (Altschul et al, J. Mol.
Biol., 215:403-410 (1990)). The BAC sequence can also be translated
into protein sequence, and the protein sequence can be used to
search publicly available protein databases, using a version of
BLAST designed to analyze protein sequences (Altshul et al, Nucl.
Acids Res., 25:3389-3402 (1997)). Another method is to use computer
algorithms such as MZEF (Zhang, Proc. Natl. Acad. Sci., 94:565-568
(1997)), GRAIL (Uberbacher et al, Methods Enzymol., 266:259-281
(1996)), and Genscan (Burge and Karlin, J. Mol. Biol., 268:78-94)
which predicts the location of exons in the sequence based on the
presence of specific DNA sequence motifs that are common to all
exons, as well as the presence of codon usage typical of human
protein encoding sequences.
[0096] In addition to identifying genes by computational methods,
genes were also identified by direct cDNA selection (Del Mastro and
Lovett, Methods in Molecular Biology, Humana Press Inc., NJ
(1996)). In direct cDNA selection, cDNA pools from tissues of
interest are prepared, and BACs from the candidate region are used
in a liquid hybridization assay to capture the cDNAs which base
pair to coding regions in the BAC. In the methods described herein,
the cDNA pools were created from several different tissues by
random priming and oligo dT priming the first strand cDNA from
polyA RNA, synthesizing the second strand cDNA by standard methods,
and adding linkers to the ends of the cDNA fragments. The linkers
are used to amplify the cDNA pools. BAC clones from the disorder
region identified by screening the RPCI-11 BAC library (P. deJong,
Russell Park Cancer Institute) were used as a template for
initiating DNA synthesis to create a biotin labeled copy of BAC
DNA. The biotin labelled copy of the BAC DNA is then denatured and
incubated with an excess of the PCR amplified, linkered cDNA pools
which have also been denatured. The BAC DNA and cDNA are allowed to
anneal in solution, and heteroduplexes between the BAC and the cDNA
are isolated using streptavidin coated magnetic beads. The cDNAs
that are captured by the BAC are then amplified using primers
complimentary to the linker sequences, and the
hybridization/selection process is repeated for a second round.
After two rounds of direct cDNA selection, the cDNA fragments are
cloned, and a library of these direct selected fragments is
created.
[0097] The cDNA clones isolated by direct selection are analyzed by
two methods. Since a pool of BACs from the disorder region is used
to provide the genomic target DNA sequence, the cDNAs must be
mapped to BAC genomic clones to verify their chromosomal location.
This is accomplished by arraying the cDNAs in microtiter dishes,
and replicating their DNA in high density grids. Individual genomic
clones known to map to the region are then hybridized to the grid
to identify direct selected cDNAs mapping to that region. cDNA
clones that are confirmed to correspond to individual BACs are
sequenced. To determine whether the cDNA clones isolated by direct
selection share sequence identity or similarity to previously
identified genes, the DNA and protein coding sequences are compared
to publicly available databases using the BLAST family of
programs.
[0098] The combination of genomic DNA sequence and cDNA sequence
provided by BAC sequencing and by direct cDNA selection yields an
initial list of putative genes in the region. The genes in the
region were all candidates for the asthma locus. To further
characterize each gene, Northern blots were performed to determine
the size of the transcript corresponding to each gene, and to
determine which putative exons were transcribed together to make an
individual gene. For Northern blot analysis of each gene, probes
were prepared from direct selected cDNA clones or by PCR amplifying
specific fragments from genomic DNA, cDNA or from the BAC encoding
the putative gene of interest. The Northern blots gave information
on the size of the transcript and the tissues in which it was
expressed. For transcripts which were not highly expressed, it was
sometimes necessary to perform a reverse transcription PCR assay
using RNA from the tissues of interest as a template for the
reaction.
[0099] Gene identification by computational methods and by direct
cDNA selection provides unique information about the genes in a
region of a chromosome. When genes are identified, then it is
possible to examine different individuals for mutations in each
gene. Variants in gene sequences between individuals can be
inherited allelic differences or can arise from mutations in the
individuals. Gene sequence variants are clinically important in
that they can affect drug action on such gene. Most drugs elicit a
safe response in only a fraction of individuals, and drugs are
commonly administered to patients with no certainty that they will
be safe and effective. Many important drugs are effective in only
30-40% of patients for whom the drug is prescribed, and virtually
all drugs cause adverse events in some individuals. Identification
of mutations in disorder genes in different individuals will enable
a correlation between the safety and efficacy of drug therapies
used to treat lung diseases and the genotypes of the treated
individuals. This correlation enables health care providers to
prescribe a drug regimen which is most appropriate for the
individual patient rather than trying different drug regimens in
turn until a successful drug is identified. Identification of
variants in disorder genes will also have a benefit during the
development of new drugs for the treatment of lung diseases, as the
ability to correlate genetic variation with the efficacy of new
candidate drugs will enhance lead optimization and increase the
efficiency and success rate of new drug approvals.
A. Family Collection
[0100] A critical component of any disease gene search is the
careful selection and phenotyping of family resources. The family
collection utilized in this study consists of 421 Caucasian
affected sibling ("sib") pairs families collected in the United
States and the United Kingdom, as well as an additional 63
Caucasian families from the United Kingdom collected under
different ascertainment criteria.
[0101] The affected sibling (or "sib") pair families in the United
States collection were Caucasian families with two affected
siblings that were identified through both private practice and
community physicians. Advertising was also used to identify
candidates. A total of 98 families were collected in Kansas,
Nebraska, and Southern California. In the United Kingdom
collection, 323 families were identified through physicians'
registers in a region surrounding Southampton and including the
Isle of Wight.
[0102] Families were included in the study if they met all of the
following criteria: (1) the biological mother and biological father
were Caucasian and agreed to participate in the study, (2) at least
two biological siblings were alive, each with a current physician
diagnosis of asthma, and 5 to 21 years of age, and (3) the two
siblings were currently taking asthma medications on a regular
basis. This included regular, intermittent use of inhaled or oral
bronchodilators and regular use of cromolyn, theophylline, or
steroids.
[0103] Families were excluded from the study if they met any one of
the following criteria: (1) both parents were affected (i.e., with
a current diagnosis of asthma, having asthma symptoms, or on asthma
medications at the time of the study), or (2) any of the siblings
to be included in the study was less than 5 years of age, or (3)
any asthmatic family member to be included in the study was taking
beta-blockers at the time of the study or (4) any family member had
congenital or acquired pulmonary disease at birth (e.g. cystic
fibrosis) history of serious cardiac disease (myocardial
infarction) or any history of serious pulmonary disease (e.g.
emphysema) or (5) pregnant.
[0104] An additional 63 families from the United Kingdom were
utilized from an earlier collection effort with different
ascertainment criteria. These families were recruited either: 1)
without reference to asthma and atopy or 2) by having at least one
family member or at least two family members affected with asthma.
The randomly ascertained samples were identified from general
practitioner registers in the Southampton area. For the families
with affected members, the probands were recruited from hospital
based clinics in Southampton. The phenotypic and genotypic data
information for 17 markers for 21 of these 63 families was obtained
from the website:
http://cedar.genetics.soton.ac.uk/pub/PROGRAMS/BETA/data/bet12.ped.
B. Genome Scan
[0105] In order to identify chromosomal regions linked to asthma,
the inheritance pattern of alleles from genetic markers spanning
the genome was assessed on the collected family resources. As
described above, combining these results with the segregation of
the asthma phenotype in these families allows the identification of
genetic markers that are tightly linked to asthma, thus providing
an indication of the location of genes predisposing affected
individuals to asthma. The following discussion describes the
protocol used to assess the genotypes of the collected population
using genetic markers spanning the entire genome.
[0106] Genotypes of PCR amplified simple sequence microsatellite
genetic linkage markers were determined using ABI model 377
Automated Sequencers. Microsatellite markers comprising a variation
of a human linkage mapping panel as released from the Cooperative
Human Linkage Center (CHLC), also known as the Weber lab screening
set version 8, were obtained from Research Genetics Inc.
(Huntsville, Al) in the fluorescent dye-conjugated form (Dubovsky
et al., Hum. Mol. Genet. March; 4(3):449-452 (1995)).
[0107] Our variation of the Weber 8 screening set consists of 529
markers with an average spacing of 6.87 cM (autosomes only) and
6.98 cM (all chromosomes). Eighty-nine percent of the markers
consist of either tri- or tetra-nucleotide microsatellites. In
addition, there exist no gaps in chromosomal coverage greater than
17.5 cM.
[0108] Study subject genomic DNA (5 .mu.l; 4.5 ng/.mu.l) was
amplified in a 10 .mu.l PCR reaction using AmpliTaq Gold DNA
polymerase (0.225 U) and containing the final reaction components:
1.times.PCR buffer (80 mM (NH.sub.4).sub.2SO.sub.4, 30 mM Tris-HCl
(pH 8.8), 0.5% Tween-20), 200 .mu.M each dATP, dCTP, dGTP and dTTP,
1.5-3.5 .mu.M MgCl.sub.2 and 250 .mu.M forward and reverse PCR
primers. PCR reactions were set up in 192 well plates (Costar)
using a Tecan Genesis 150 robotic workstation equipped with a
refrigerated deck. PCR reactions were overlaid with 20 .mu.l
mineral oil, and thermocycled on an MJ Research Tetrad DNA Engine
equipped with four 192 well heads under the following conditions:
92.degree. C. for 3 min, 6 cycles of 92.degree. C. 30 sec,
56.degree. C. 1 min, 72.degree. C. 45 sec, followed by 20 cycles of
92.degree. C. 30 sec, 55.degree. C. 1 min, 72.degree. C. 45 sec and
a 6 min incubation at 72.degree. C. PCR products of 8-12
microsatellite markers were subsequently pooled using a Tecan
Genesis 200 robotic workstation into two 96 well microtitre plates
(2.0 .mu.l PCR product from TET and FAM labeled markers, 3.01 HEX
labeled markers) and brought to a final volume of 25 .mu.l with
H.sub.2O. 1.9 .mu.l of pooled PCR product was transferred to a
loading plate and combined with 3.0 .mu.l loading buffer (loading
buffer is 2.5 l formamide/blue dextran (9.0 mg/ml), 0.5 .mu.l
GS-500 TAMRA labeled size standard, Perkin-Elmer/ABI division).
Samples were denatured in the loading plate for 4 min at 95.degree.
C., placed on ice for 2 min, and electrophoresed in a 5% denaturing
polyacrylamide gel (FMC on the ABI 377XL). Samples (0.8 .mu.l) were
loaded using an 8 channel Hamilton Syringe pipettor.
[0109] Each gel consisted of 62 study subjects and 2 control
subjects (CEPH parents ID #1331-01 and 1331-02, Coriell Cell
Repository, Camden, N.J.). Genotyping gels were scored in duplicate
by investigators blind to patient identity and affection status
using GENOTYPER analysis software V 1.1.12 (ABI Division, Perkin
Elmer Corporation). Nuclear families were loaded onto the gel with
the parents flanking the siblings to facilitate error detection.
Data with allele peak amplitude less than 100, as detected by
GENESCAN analysis software V 2.0.2 (ABI Division, Perkin Elmer
Corporation), were either left unscored or rerun.
[0110] The final tables obtained from the Genotyper output for each
gel analysed were imported into a Sybase Database. Allele calling
(binning) was performed using the SYBASE version of the ABAS
software (Ghosh et al, Genome Research 7:165-178 (1997)). Offsize
bins were checked manually and incorrect calls were corrected or
blanked. The binned alleles were then imported into the program
MENDEL (Lange et al., Genetic Epidemiology, 5, 471(1988)) for
inheritance checking using the USERM13 subroutine (Boehnke et al,
AM J. Hum. Genet. 48:22-25 (1991)). Non-inheritance was
investigated by examining the genotyping traces and once all
discrepancies were resolved, the subroutine USERM13 was used to
estimate allele frequencies.
C. Linkage Analysis
[0111] Linkage analysis is possible because of the nature of
inheritance of chromosomes from parents to offspring. During
meiosis, the two parental homologues pair to guide their proper
separation to daughter cells. While they are lined up and paired,
the two homologues exchange pieces of the chromosomes, in an event
called "crossing over" or "recombination." The resulting
chromosomes contain parts that originate from both parental
homologues. The closer together two sequences are on the
chromosome, the less likely that a recombination event will occur
between them, and the more closely linked they are. Data obtained
from the different families are combined and analyzed together by a
computer using statistical methods. The result is information
indicating the evidence for linkage between the genetic markers
used and a disease susceptibility locus. A recombination frequency
of 1% is equivalent to approximately 1 map unit, a relationship
that holds up to frequencies of about 20% or 20 cM. Furthermore, 1
centiMorgan (cM) is roughly equivalent to 1,000 kb of DNA.
[0112] The entire human genome is 3,300 cM long. In order to find
an unknown disease gene within 5-10 cM of a marker locus, the whole
human genome can be searched with roughly 330 informative marker
loci spaced at approximately 10 cM intervals (Botstein et al, Am.
J. Hum. Genet., 32:314-331 (1980)). The reliability of linkage
results is established by using a number of statistical methods.
The methods most commonly used for the detection by linkage
analysis of oligogenes involved in the etiology of a complex trait
are non-parametric or model-free methods which have been
implemented into the computer programs MAPMAKER/SIBS (Kruglyak L
& Lander E S, Am J Hum Genet 57:439-454, 1995) and GENEHUNTER
(Kruglyak L et al., Am J Hum Genet 58:1347-1363, 1996). Linkage
analysis is performed by typing members of families with multiple
affected individuals at a given marker locus and evaluating if the
affected members (excluding parent-offspring pairs) share alleles
at the marker locus that are identical by descent (IBD) more often
than expected by chance alone. As a result of the rapid advances in
mapping the human genome over the last few years, and concomitant
improvements in computer methodology, it has become feasible to
carry out linkage analyses using multi-point data. Multi-point
analysis provides a simultaneous analysis of linkage between the
trait and several linked genetic markers, when the recombination
distance among the markers is known. A LOD score statistic is
computed at multiple locations along a chromosome to measure the
evidence that a susceptibility locus is located nearby. A LOD score
is the logarithm base 10 of the ratio of the likelihood that a
susceptibility locus exists at a given location to the likelihood
that no susceptibility locus is located there. By convention, when
testing a single marker, a total LOD score greater than +3.0 (that
is, odds of linkage being 1,000 times greater than odds of no
linkage) is considered to be significant evidence for linkage.
[0113] Multi-point analysis is advantageous for two reasons. First,
the informativeness of the pedigrees is usually increased. Each
pedigree has a certain amount of potential information, dependent
on the number of parents heterozygous for the marker loci and the
number of affected individuals in the family. However, few markers
are sufficiently polymorphic as to be informative in all those
individuals. If multiple markers are considered simultaneously,
then the probability of an individual being heterozygous for at
least one of the markers is greatly increased. Second, an
indication of the position of the disease gene among the markers
may be determined. This allows identification of flanking markers,
and thus eventually allows identification of a small region in
which the disease gene resides.
[0114] For the initial linkage analysis, the phenotype and asthma
affection status were defined by a patient described above who
answered the following questions in the affirmative: (i) have you
ever had asthma, (ii) do you have a current physician's diagnosis
of asthma, and (iii) are you currently taking asthma medications?
Medications include inhaled or oral bronchodilators, cromolyn,
theophylline or steroids.
[0115] The distribution of the number of genotyped affected
siblings was as follows: 88.7% of the families had 2 siblings,
10.9% had 3 siblings and 0.5% had 4 siblings. Ninety eight families
were ascertained in the US and 386 in the UK.
[0116] Allele sharing methods, implemented in the MAPMAKER/SIBS
(Kruglyak L & Lander E S, Am J Hum Genet 57:439-454, 1995),
were used on our sample of affected sibling pairs. Multipoint
linkage analyses were performed using 54 polymorphic markers
spanning a 162 cM region on both arms of chromosome 12. The map
location and distances between markers were obtained from the
genetic maps published by the Marshfield medical research
foundation (http://www.marshmed.org/genetics/). Ambiguous order in
the Marshfield map was resolved using the program MULTIMAP (Matise
T C et al., Nature Genet 6:384-390, 1994) on the 46.
[0117] FIG. 1 displays the multipoint LOD score against the map
location of markers along chromosome 12. A Maximum LOD Score (MLS)
of 2.9 was obtained at location 161.7 cM, 1.0 cM distal to markers
D12597 and D1251045. An excess sharing by descent (Identity By
Descent, IBD=2) of 0.31 was observed at the maximum LOD score.
Table 1 lists the single and multipoint LOD scores at each
marker.
[0118] These data suggest that chromosome 12 is a location that may
contain a gene or genes involved in asthma and diseases
thereof.
TABLE-US-00001 TABLE 1 Chromosome 12 Linkage Analysis Marker
Distance Two-point Multipoint D12S372 6.4 0.0 0.0 GATA49D12 17.7
0.0 0.0 D12S77 20.3 0.0 0.0 D12S391 26.2 0.0 0.0 D12S358 26.2 0.0
0.0 D12S364 30.6 0.2 0.0 D12S373 36.1 0.0 0.0 D12S1042 48.7 0.0 0.0
GATA91H06 56.3 0.0 0.0 D12S368 66.0 0.2 0.3 D12S398 68.2 0.2 0.4
D12S83 75.2 1.1 0.0 D12S1294 78.1 0.0 0.0 IFNgama 80.4 0.0 0.0
D12S375 80.5 0.3 0.0 D12S43 80.5 0.3 0.0 D12S1052 83.2 0.0 0.0
D12S92 83.2 1.0 0.0 D12S326 86.4 0.1 0.1 D12S64 89.4 0.0 0.2
D12S379 93.7 0.0 0.1 D12S311 94.5 0.1 0.0 D12S82 95.0 0.1 0.1
D12S819 95.0 0.0 0.1 D12S1064 95.0 0.0 0.0 D12S95 96.1 0.2 0.2
D12S829 97.2 0.1 0.6 D12S1706 104.1 0.6 0.4 D12S1300 104.1 0.2 0.3
D12S1727 107.2 0.0 0.1 D12S1607 107.9 0.0 0.1 IGF1 109.5 0.0 0.0
PAH 109.5 0.0 0.0 D12S360 111.3 0.0 0.0 D12S338 111.9 0.0 0.0
D12S78 111.9 0.0 0.0 D12S811 120.7 0.1 0.3 D12S1341 123.0 0.0 0.5
NOS1 123.1 0.1 0.4 D12S2070 125.3 0.2 0.7 D12S366 133.3 1.2 1.7
D12S1619 134.5 0.8 1.8 D12S385 135.1 2.0 1.6 PLA2G1B 136.8 0.9 1.4
D12S395 136.8 2.1 1.5 D12S300 140.2 0.9 1.7 D12S342 144.8 1.6 2.2
D12S324 147.2 1.3 1.4 D12S2078 149.6 0.9 1.9 D12S1659 155.9 0.3 1.6
D12S97 160.7 0.9 2.7 D12S1045 160.7 3.0 2.8 D12S392 165.7 1.1 2.3
D12S357 168.8 0.8 1.1
D. Linkage Results
[0119] The linkage results for chromosome 12 described above were
used to delineate a candidate region for disorder-associated
gene(s) located on chromosome 12. Gene discovery efforts were
initiated in a .about.43 cM interval from marker D12S2070 to the
12q telomere, representing a 99% confidence interval. All genes
known to map to this interval were considered as candidates. The
discovery of novel genes using direct cDNA selection focused on a
.about.15 cM region approximately between markers D12S1609 and
D12S357.
[0120] The following section describes details of the efforts to
generate cloned coverage of the disorder gene region on chromosome
12, i.e., construction of a BAC contig spanning the region. There
are two primary reasons for this: 1) to provide genomic clones for
DNA sequencing; analysis of this sequence provides information
about the gene content of the region, and 2) to provide reagents
for direct cDNA selection; this provides additional information
about novel genes mapping to the interval. The physical map
consists of an ordered set of molecular landmarks, and a set of
bacterial artificial chromosome (BAC, Kim, U.-J., et al., (1996),
Genomics 34, 213-218 and Shizuya, H., et al., (1992). Proc. Natl.
Acad. Sci. USA 89, 8794-8797) clones that contain the disorder gene
region from chromosome 12q23-qter.
[0121] FIG. 2 depicts the STS content of BAC RP11-0702113 in
12q23-qter. Gene 214 is located within this BAC as indicated at the
top of the figure. Markers used to screen the RPCI-11 BAC library
(P. deJong--Roswell Park Cancer Institute) are shown vertically
above the solid black horizontal line. The following steps were
performed:
[0122] 1. Map Integration. Various publicly available mapping
resources were utilized to identify existing STS markers (Olson et
al, (1989), Science, 245:1434-1435) in the 12q23-qter region.
Resources included the Genome Database (GDB) at the website of:
(hypertext transfer protocol, genomedatabase, world wide
web.gdb.org/); Genethon at the website of: (hypertext transfer
protocol, world wide web. genethon-en.html); Marshfield Center for
Medical Genetics at the website of: (hypertext transfer protocol,
world wide web. marshmed.org/genetics/); the Whitehead Institute
Genome Center at the website of: (hypertext transfer protocol,
world wide web-genome.wi.mit.edu/); GeneMap98, dbSTS and dbEST at
the website of: NCBI, (hypertext transfer protocol, world wide web,
ncbi.nlm.nih.gov/); the Sanger Centre at the website of: (hypertext
transfer protocol, world wide web.sanger.ac.uk/); and the Stanford
Human Genome Center at the website of: (hypertext transfer
protocol, world wide web-shgc.stanford.edu/). Maps were integrated
manually to identify markers mapping to the disorder region. A list
of the markers is provided in Table 2.
[0123] 2. Marker Development. Sequences for existing STSs were
obtained from the GDB, RHDB at the website of the Genome Database,
RHDB, (hypertext transfer protocol, world wide web.
ebi.ac.uk/RHdb/), or NCBI and were used to pick primer pairs
(overgos, See Table 2) for BAC library screening. Novel markers
were developed either from publicly available genomic sequences,
proprietary cDNA sequences or from sequences derived from BAC
insert ends (described below). Primers were chosen using a script
that automatically performs vector and repetitive sequence masking
using Crossmatch (P. Green, U. of Washington); subsequent primer
picking was performed using a customized Filemaker Pro database.
Primers for use in PCR-based clone confirmation or radiation hybrid
mapping (described below) were chosen using the program Primer3
(Steve Rozen, Helen J. Skaletsky (1996, 1997); Primer3 is available
at the website of (hypertext transfer protocol, world wide web,
-genome.wi.mit.edu/genomesoftware;other/primer3.htm/).
TABLE-US-00002 TABLE 2 Lo- DNA Forward Reverse Overgo cus Type Gene
Primer Primer B0702C13A1x BACend GTAGTAA AGAGAGG CAGAATG AACAGCA
GACTTTG TCAAAGT A C (SEQ ID (SEQ ID NO: 12) NO: 13) A005Q05 EST
CAAACAG GTGTTTC GGTCCAC AGCCACA CGTGGAA TTTCCAC A G (SEQ ID (SEQ ID
NO: 14) NO: 15) Th Gene Mucin ATCCACC GACCATC 8 GCTAGAA AACTGAT
(MUC8) ACCCACT GAGTGGG C T (SEQ ID (SEQ ID NO: 16) NO: 17)
B0702C13A1y BACend TCATGGG TGGCCTC GGTGCTT AAAGGCT TGACCTT CAAGGTC
G A (SEQ ID (SEQ ID NO: 18) NO: 19)
[0124] 3. Radiation Hybrid (RH) Mapping. Radiation hybrid mapping
was performed against the Genebridge4 panel (Gyapay, et al.,
(1996), Hum. Mol. Genet. 5:339-46) purchased from Research
Genetics, in order to refine the chromosomal localization of
genetic markers used in genotyping as well as to identify, confirm
and refine localizations of markers from proprietary sequences.
Standard PCR procedures were used for typing the RH panel with
markers of interest. Briefly, 10 .mu.l PCR reactions contained 25
ng DNA of each of the 93 Genebridge4 RH samples. PCR products were
electrophoresed in 2% agarose gels (Sigma) containing 0.5 .mu.g/ml
ethidium bromide in 1.times.TBE at 150 volts for 45 min. The
electrophoresis units used were the Model A3-1 systems from Owl
Scientific Products. Typically, gels contained 10 tiers of lanes
with 50 wells/tier. Molecular weight markers (100 bp ladder,
GIBCO/BRL) were loaded at both ends of the gel. Images of the gels
were captured with a Kodak DC40 CCD camera and processed with Kodak
1D software. The gel data were exported as tab delimited text
files; names of the files included information about the panel
screened, the gel image files and the marker screened. These data
were automatically imported using a customized Perl script into
Filemaker databases for data storage and analysis. The data were
then automatically formatted and submitted to an internal server
for linkage analysis to create a radiation hybrid map using
RHMAPPER (Stein, L., Kruglyak, L., Slonim, D., and El Lander
(1995); available from the Whitehead Institute/MIT Center for
Genome Research, at
http://www.genome.wi.mit.edu/ftp/pub/software/rhmapper/, and via
anonymous ftp to ftp.genome.wi.mit.edu, in the directory
/pub/software/rhmapper.) The RH mapping results obtained for Gene
214 indicate that it is present in the 12Q 12-qter region at 507.12
cRays on the 684 coordinate system.
[0125] 4. BAC Library Screening. The protocol used for BAC library
screening was based on the "overgo" method, originally developed by
John McPherson at Washington University in St. Louis
(http://www.tree.caltech.edu/protocols/overgo.html, and Cai, W-W.,
et al., (1998), Genomics 54:387-397). This method involves filling
in the overhangs generated after annealing two primers, each 22
nucleotides in length, that overlap by 8 nucleotides. The resulting
labeled 36 by product is then used in hybridization-based screening
of high density grids derived from the RPCI-11 BAC library (Pieter
deJong, Roswell Park Cancer Institute,
http://bacpac.med.buffalo.edu). Typically, 15 probes were pooled
together in one hybridization of 12 filters (13.5 genome
equivalents).
[0126] Stock solutions (2 .mu.M) of combined complementary oligos
were heated at 80.degree. C. for 5 min, then placed at 37.degree.
C. for 10 min followed by storage on ice. Labeling reactions were
set up as follows: 1.0 .mu.l H.sub.2O, 5 .mu.l mixed oligos-2 .mu.M
each, 0.5 .mu.l BSA (2 mg/ml), 2 .mu.l OLB (-A, -C, -N6) Solution
(see below), 0.5 .mu.l .sup.32P-dATP (3000 Ci/mmol), 0.5 .mu.l
.sup.32P-dCTP (3000 Ci/mmol), 0.5 .mu.l Klenow fragment (5
U/.mu.l). The reaction was incubated at room temperature for 1 hr
followed by removal of unincorporated nucleotides with Sephadex G50
spin columns.
OLB (-A, -C, -N6) Solution
[0127] Solution O--1.25 M Tris-HCL, pH 8, 125 M MgCl.sub.2
[0128] Solution A--1 ml Solution O, 18 .mu.l 2-mercaptoethanol, 5
.mu.l 0.1M dTTP, 5 .mu.l 0.1M dGTP
[0129] Solution B--2M HEPES-NaOH, pH 6.6
[0130] Solution C--3 mM Tris-HCl, pH 7.4, 0.2 mM EDTA
[0131] Solutions A, B, and C were combined to a final ratio of
1:2.5:1.5, aliquots were stored at -20.degree. C.
[0132] High density BAC library membranes were pre-wetted in
2.times.SSC at 58.degree. C. Filters were then drained slightly and
placed in hybridization solution (1% Bovine serum albumin, 1 mM
EDTA-pH 8.0, 7% SDS, and 0.5 M sodium phosphate) pre-warmed to
58.degree. C. and incubated at 58.degree. C. for 2-4 hr. Typically,
6 filters were hybridized per container. Ten ml of
pre-hybridization solution were removed, combined with the
denatured overgo probes, and added back to the filters.
Hybridization was performed overnight at 58.degree. C. The
hybridization solution was removed and filters were washed once in
2.times.SSC, 0.1% SDS, followed by a 30 minute wash in the same
solution but at 58.degree. C. Filters were then washed in
1.5.times.SSC, 01.% SDS at 58.degree. C. for 30 min. 0.5.times.SSC,
0.1% SDS at 58.degree. C. for 30 min and finally in 0.1.times.SSC,
0.1% SDS at 58.degree. C. for 30 min. Filters were then wrapped in
Saran Wrap and exposed to film overnight. To remove bound probe,
filters were treated in 0.1.times.SSC, 0.1% SDS pre-warmed to
95.degree. C. and allowed to return to room temperature. Clone
addresses were determined as described by instructions supplied by
RPCI.
[0133] Recovery of clonal BAC cultures from the library involved
streaking out a sample from the appropriate library well onto LB
agar (Maniatis, T., Fritsch, E. F., and J. Sambrook, (1982)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y.) containing 12.5 .mu.g/ml
chloramphenicol (Sigma) and incubating overnight. A single colony
and a portion of the initial streak quadrant were inoculated into
400 .mu.l LB plus chloramphenicol in wells of a 96 well plate.
Cultures were grown overnight at 37.degree. C. For storage, 100
.mu.l of 80% glycerol was added and the plates placed at
-80.degree. C. To determine the marker content of clones, aliquots
of the 96 well plate cultures were transferred to the surface of
nylon filters (GeneScreen Plus, NEN) placed on LB/chloramphenicol
Petri plates. Colonies were grown overnight at 37.degree. C. and
colony lysis was performed as follows: Filters were placed on pools
of 10% SDS for 3 min, 0.5 N NaOH, 1.5 M NaCl for 5 min, and 0.5 M
Tris-HCl, pH 7.5, 1 M NaCl for 5 min. Filters were then air dried
and washed free of debris in 2.times.SSC for 1 hr. The filters were
air dried for at least 1 hr and DNA crosslinked linked to the
membrane using standard conditions. Probe hybridization and filter
washing were performed as described above for the primary library
screening. Confirmed clones were stored in LB containing 15%
glycerol.
[0134] In some cases polymerase chain reaction (PCR) was used to
confirm the marker content of clones. PCR conditions for each
primer pair were initially optimized with respect to MgCl.sub.2
concentration. The standard buffer was 10 mM Tris-HCl (pH 8.3), 50
mM KCl, MgCl.sub.2, 0.2 mM each dNTP, 0.2 .mu.M each primer, 2.7
ng/gl human DNA, 0.25 units of AmpliTaq (Perkin Elmer) and
MgCl.sub.2 concentrations of 1.0 mM, 1.5 mM, 2.0 mM or 2.4 mM.
Cycling conditions included an initial denaturation at 94.degree.
C. for 2 minutes followed by 40 cycles at 94.degree. C. for 15
seconds, 55.degree. C. for 25 seconds, and 72.degree. C. for 25
seconds followed by a final extension at 72.degree. C. for 3
minutes. Depending on the results from the initial round of
optimization the conditions were further optimized if necessary.
Variables included increasing the annealing temperature to
58.degree. C. or 60.degree. C., increasing the cycle number to 42
and the annealing and extension times to 30 seconds, and using
AmpliTaqGold (Perkin Elmer).
[0135] 5. BAC DNA Preparation. Several different types of DNA
preparation methods were used for isolation of BAC DNA. The manual
alkaline lysis miniprep protocol listed below (Maniatis, T.,
Fritsch, E. F., and J. Sambrook, (1982) Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y.) was successfully used for most applications, i.e.,
restriction mapping, CHEF gel analysis and FISH mapping, but was
not reproducibly successful in endsequencing. The Autogen protocol
described below was used specifically for BAC DNA preparation for
endsequencing purposes.
[0136] For manual alkaline lysis BAC minipreps, bacteria were grown
in 15 ml Terrific Broth containing 12.5 .mu.g/ml chloramphenicol in
a 50 ml conical tube at 37.degree. C. for 20 hrs with shaking at
300 rpm. The cultures were centrifuged in a Sorvall RT 6000 D at
3000 rpm (1800.times.g) at 4.degree. C. for 15 min. The supernatant
was then aspirated as completely as possible. In some cases cell
pellets were frozen at -20.degree. C. at this step for up to 2
weeks. The pellet was then vortexed to homogenize the cells and
minimize clumping. 250 .mu.l of P1 solution (50 mM glucose, 15 mM
Tris-HCl, pH 8, 10 mM EDTA, and 100 .mu.g/ml RNase A) was added and
the mixture pipeted up and down to mix. The mixture was then
transferred to a 2 ml Eppendorf tube. 350 .mu.l of P2 solution (0.2
N NaOH, 1% SDS) was then added, and the mixture mixed gently and
incubated for 5 min at room temperature. 350 .mu.l of P3 solution
(3M KOAc, pH 5.5) was added and the mixture mixed gently until a
white precipitate formed. The solution was incubated on ice for 5
min and then centrifuged at 4.degree. C. in a microfuge for 10 min.
The supernatant was transferred carefully (avoiding the white
precipitate) to a fresh 2 ml Eppendorf tube, and 0.9 ml of
isopropanol was added; the solution was mixed and left on ice for 5
min. The samples were centrifuged for 10 min, and the supernatant
removed carefully. Pellets were washed in 70% ethanol and air dried
for 5 min. Pellets were resuspended in 200 .mu.l of TE8 (10 mM
Tris-HCl, pH 8.0, 1.0 mM EDTA, pH 8.0), and RNase (Boehringer
Mannheim) added to 100 .mu.g/ml. Samples were incubated at
37.degree. C. for 30 min, then precipitated by addition of
NH.sub.4OAc to 0.5 M and 2 volumes of ethanol. Samples were
centrifuged for 10 min, and the pellets washed with 70% ethanol
followed by air drying and dissolving in 50 .mu.l TE8. Typical
yields for this DNA prep were 3-5 .mu.g/15 ml bacterial culture.
Ten to 15 .mu.l were used for EcoRI restriction analysis; 5 .mu.l
was used for NotI digestion and clone insert sizing by CHEF gel
electrophoresis.
[0137] Autogen 740 BAC DNA preparations for endsequencing were
prepared by dispensing 3 ml of LB media containing 12.5 .mu.g/ml of
chloramphenicol into autoclaved Autogen tubes. A single tube was
used for each clone. For inoculation, glycerol stocks were removed
from -70.degree. C. storage and placed on dry ice. A small portion
of the glycerol stock was removed from the original tube with a
sterile toothpick and transferred into the Autogen tube; the
toothpick was left in the Autogen tube for at least two minutes
before discarding. After inoculation the tubes were covered with
tape making sure the seal was tight. When all samples were
inoculated, the tube units were transferred into an Autogen rack
holder and placed into a rotary shaker at 37.degree. C. for 16-17
hours at 250 rpm. Following growth, standard conditions for BAC DNA
preparation, as defined by the manufacturer, were used to program
the Autogen. Samples were not dissolved in TE8 as part of the
program--DNA pellets were left dry. When the program was complete
the tubes were removed from the output tray and 30 .mu.l of sterile
distilled and deionized H2O was added directly to the bottom of the
tube. The tubes were then gently shaken for 2-5 seconds and then
covered with parafilm and incubated at room temperature for 1-3
hours. DNA samples were then transferred to an Eppendorf tube and
used either directly for sequencing or stored at 4.degree. C. for
later use.
[0138] 6. BAC Clone Characterization. DNA samples prepared either
by manual alkaline lysis or the Autogen protocol were digested with
EcoRI for analysis of restriction fragment sizes. These data were
used to compare the extent of overlap among clones. Typically 1-2
.mu.g were used for each reaction. Reaction mixtures included:
1.times.Buffer 2 (New England Biolabs), 0.1 mg/ml bovine serum
albumin (New England Biolabs), 50 .mu.g/ml RNase A (Boehringer
Mannheim), and 20 units of EcoRI (New England Biolabs) in a final
volume of 25 .mu.l. Digestions were incubated at 37.degree. C. for
4-6 hours. BAC DNA was also digested with NotI for estimation of
insert size by CHEF gel analysis (see below). Reaction conditions
were identical to those for EcoRI except that 20 units of NotI were
used. Six pi of 6.times.Ficoll loading buffer containing bromphenol
blue and xylene cyanol was added prior to electrophoresis.
[0139] EcoRI digests were analyzed on 0.6% agarose (Seakem, FMC
Bioproducts) in 1.times.TBE containing 0.5 .mu.g/ml ethidium
bromide. Gels (20 cm.times.25 cm) were electrophoresed in a Model
A4 electrophoresis unit (Owl Scientific) at 50 volts for 20-24 hrs.
Molecular weight size markers included undigested lambda DNA,
HindIII digested lambda DNA, and HaeIII digested .X174 DNA.
Molecular weight markers were heated at 65.degree. C. for 2 min
prior to loading the gel. Images were captured with a Kodak DC40
CCD camera and analyzed with Kodak 1D software.
[0140] NotI digests were analyzed on a CHEF DRII (BioRad)
electrophoresis unit according to the manufacturer's
recommendations. Briefly, 1% agarose gels (BioRad pulsed field
grade) were prepared in 0.5.times.TBE, equilibrated for 30 min in
the electrophoresis unit at 14.degree. C., and electrophoresed at 6
volts/cm for 14 hrs with circulation. Switching times were ramped
from 10 sec to 20 sec. Gels were stained after electrophoresis in
0.5 .mu.g/ml ethidium bromide. Molecular weight markers included
undigested lambda DNA, HindIII digested lambda DNA, lambda ladder
PFG ladder, and low range PFG marker (all from New England
Biolabs).
[0141] 7. BAC Endsequencing. The sequence of BAC insert ends
utilized DNA prepared by either of the two methods described above.
The ends of BAC clones were sequenced for the purpose of filling
gaps in the physical map and for gene discovery information. The
following vector primers specific to the BAC vector pBACe3.6 were
used to generate endsequence from BAC clones:
TABLE-US-00003 pBAC (SEQ ID NO: 20) 5'-2 TGT AGG ACT ATA TTG CTC
and pBAC (SEQ ID NO: 21) 3'-1 CGA CAT TTA GGT GAC ACT.
[0142] The following sequencing protocol using ABI dye-terminator
chemistry was used to set up sequencing reactions for 96 clones.
The BigDye (Mix: Perkin Elmer/ABI BigDye) Terminator Ready Reaction
Mix with AmpliTaq'' FS, Part number 4303151, was used for
sequencing with fluorescently labelled dideoxy nucleotides. A
master sequencing mix was prepared for each primer reaction set
including:
1600 .mu.l of BigDye terminator mix (ABI) 800 .mu.l of 5.times.CSA
buffer (ABI) 800 .mu.l of primer (either pBAC 5'-2 or pBAC 3'-1 at
3.2 .mu.M)
[0143] The sequencing cocktail was vortexed to ensure it was
well-mixed and 32 .mu.l was aliquoted into each PCR tube. Eight
.mu.l of the Autogen DNA for each clone was transferred from the
DNA source plate to a corresponding well of the PCR plate. The PCR
plates were sealed tightly and centrifuged briefly to collect all
the reagents. Cycling conditions were as follows:
95.degree. C. for 5 minutes
[0144] 95.degree. C. for 30 seconds
[0145] 50.degree. C. for 20 seconds
[0146] 65.degree. C. for 4 minutes
[0147] Go to steps 2 through 4 above for an additional 74 times
[0148] 4.degree. C. forever
[0149] At the end of the sequencing reaction, the plates were
removed from the thermocycler and centrifuged briefly.
Centri.cndot.Sep 96 plates were then used according to
manufacturer's recommendation to remove unincorporated nucleotides,
salts and excess primers. Each sample was resuspended in 1.5 .mu.l
of loading dye of which 1.3 .mu.l was loaded on ABI 377 Fluorescent
Sequencers. The resulting endsequences were then used to develop
markers to rescreen the BAC library for filling gaps and were also
analyzed by BLAST searching for EST or gene content.
E. Sub-Cloning and Sequencing of BACS from 12q23-qter
[0150] The physical map of the chromosome 12 region provides the
BAC clone and location for use as sequencing templates (see FIG.
2). DNA sequencing of the BAC RPCI-11.sub.--0702C13 from the region
is contained within (SEQ ID NO: 1).
[0151] DNA for BAC RPCI-11.sub.--0702C13 (the "BAC DNA") was
isolated according to one of two protocols: either a Qiagen
purification of BAC DNA (Qiagen, Inc., Chatsworth, Calif., per
manufacturer's instructions) or a manual purification using a
method which is a modification of the standard alkaline
lysis/Cesium Chloride preparation of plasmid DNA (see e.g., Ausubel
et al, (1997), Current Protocols in Molecular Biology, John Wiley
& Sons). Briefly, for the manual protocol, cells were pelleted,
resuspended in GTE (50 mM glucose, 25 mM Tris-Cl (pH 8), 10 mM
EDTA) and lysozyme (50 mg/ml solution), followed by NaOH/SDS (1%
SDS/.2N NaOH) and then an ice-cold solution of 3M KOAc (pH
4.5-4.8). RNaseA was added to the filtered supernatant, followed by
treatment with Proteinase K and 20% SDS. The DNA was then
precipitated with isopropanol, dried and resuspended in TE (10 mM
Tris, 1 mM EDTA (pH 8.0)). The BAC DNA was further purified by
Cesium Chloride density gradient centrifugation (Ausubel et al,
(1997), Current Protocols in Molecular Biology, John Wiley &
Sons).
[0152] Following isolation, the BAC DNA was hydrodynamically
sheared using HPLC (Hengen, et al., (1997), Trends in Biochem.
Sci., 22:273-274) to an insert size of 2000-3000 bp. After
shearing, the DNA was concentrated and separated on a standard 1%
agarose gel. A single fraction, corresponding to the approximate
size, was excised from the gel and purified by electroelution
(Sambrook et al, (1989), Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor Laboratory, Cold Spring, NY).
[0153] The purified DNA fragments were then blunt-ended using T4
DNA polymerase. The healed DNA was then ligated to unique
BstXI-linker adapters (5' GTCTTCACCACGGGG (SEQ ID NO: 22) and 5'
GTGGTGAAGAC (SEQ ID NO: 23) in 100-1000 fold molar excess). These
linkers are complimentary to the BstXI-cut pMPX vectors, while the
overhang is not self-complimentary. Therefore, the linkers will not
concatemerize nor will the cut-vector re-ligate to itself easily.
The linker-adapted inserts were separated from unincorporated
linkers on a 1% agarose gel and purified using GeneClean (BIO 101,
Inc.). The linker-adapted insert was then ligated to a modified
pBlueScript vector to construct a "shotgun" subclone library. The
vector contains an out-of-frame lacZ gene at the cloning site which
becomes in-frame in the event that an adapter-dimer is cloned,
allowing these to be avoided by their blue color.
[0154] All subsequent steps were based on sequencing by ABI377
automated DNA sequencing methods. Only major modifications to the
protocols are highlighted. Briefly, the library was then
transformed into DH5-competent cells (Gibco/BRL, DH5-transformation
protocol). Quality was assessed by plating onto antibiotic plates
containing ampicillin and IPTG/XgaI. The plates were incubated
overnight at 37.degree. C. Successful transformants were then used
for plating of clones and picking for sequencing. The cultures were
grown overnight at 37.degree. C. DNA was purified using a silica
bead DNA preparation (Ng et al, Nucl. Acids Res., 24:5045-5047
(1996)) method. In this manner, 25 .mu.g of DNA was obtained per
clone.
[0155] These purified DNA samples were then sequenced using ABI
dye-terminator chemistry. The ABI dye terminator sequence reads
were run on ABI377 machines and the data were directly transferred
to UNIX machines following lane tracking of the gels. All reads
were assembled using PHRAP (P. Green, Abstracts of DOE Human Genome
Program Contractor-Grantee Workshop V, January 1996, p. 157) with
default parameters and quality scores. SEQ ID NO:1 comprises a
portion of the BAC which includes the genomic sequence of Gene
214
F. Gene Identification
[0156] Any gene or EST mapping to the interval based on public map
data or proprietary map data was considered a candidate disorder
gene.
[0157] 1. Gene Identification from clustered DNA fragments. DNA
sequences corresponding to gene fragments in public databases
(Genbank and human dbEST) and proprietary cDNA sequences (IMAGE
consortium and direct selected cDNAs) were masked for repetitive
sequences and clustered using the PANGEA Systems (Oakland, Calif.)
EST clustering tool. The clustered sequences were then subjected to
computational analysis to identify regions bearing similarity to
known genes. This protocol included the following steps:
[0158] i. The clustered sequences were compared to the publicly
available Unigene database (National Center for Biotechnology
Information, National Library of Medicine, 38A, 8N905, 8600
Rockville Pike, Bethesda, Md. 20894; www.ncbi.nlm.nih.gov) using
the blastn2 algorithm (Altschul et al, Nucl. Acids Res.,
25:3389-3402 (1997)). The parameters for this search were: E=0.05,
v=50, B=50 (where E is the expected probability score cutoff, V is
the number of database entries returned in the reporting of the
results, and B is the number of sequence alignments returned in the
reporting of the results (Altschul et al, J. Mol. Biol.,
215:403-410 (1990)).
[0159] ii. The clustered sequences were compared to the Genbank
database (National Center for Biotechnology Information, National
Library of Medicine, 38A, 8N905, 8600 Rockville Pike, Bethesda, Md.
20894; www.ncbi.nlm.nih.gov) using blastn2 (Altschul et al, Nucl.
Acids. Res., 25:3389-3402 (1997)). The parameters for this search
were E=0.05, V=50, B=50, where E, V, and B are defined as
above.
[0160] iii. The clustered sequences were translated into protein
for all six reading frames, and the protein sequences were compared
to a non-redundant protein database compiled from Genpept Swissprot
PIR (National Center for Biotchnology Information, National Library
of Medicine, 38A, 8N905, 8600 Rockville Pike, Bethesda, Md. 20894;
www.ncbi.nlm.nih.gov). The parameters for this search were E=0.05,
V=50, B=50, where E, V, and B are defined as above.
[0161] iv. The clustered sequences were compared to BAC sequences
(see below) using blastn2 (Altschul et al, Nucl. Acids. Res.,
25:3389-3402 (1997)). The parameters for this search were E=0.05,
V=50, B=50, where E, V, and B are defined as above.
[0162] 2. Gene Identification from BAC Genomic Sequence. Following
assembly of the BAC sequences into contigs, the contigs were
subjected to computational analyses to identify coding regions and
regions bearing DNA sequence similarity to known genes. This
protocol included the following steps:
[0163] i. Contigs were degapped. The sequence contigs often contain
symbols (denoted by a period symbol) that represent locations where
the individual ABI sequence reads have insertions or deletions.
Prior to automated computational analysis of the contigs, the
periods were removed. The original data were maintained for future
reference.
[0164] ii. BAC vector sequences were "masked" within the sequence
by using the program crossmatch (Phil Green,
http:\\chimera.biotech.washington.edu\UWGC). Since the shotgun
library construction detailed above left some BAC vector in the
shotgun libraries, this program was used to compare the sequence of
the BAC contigs to the BAC vector and to mask any vector sequence
prior to subsequent steps. Masked sequence was marked by an "X" in
the sequence files, and remained inert during subsequent
analyses.
[0165] iii. E. coli sequences contaminating the BAC sequences were
masked by comparing the BAC contigs to the entire E. coli DNA
sequence.
[0166] iv. Repetitive elements known to be common in the human
genome were masked using crossmatch. In this implementation of
crossmatch, the BAC sequence is compared to a database of human
repetitive elements (Jerzy Jerka, Genetic Information Research
Institute, Palo Alto, Calif.). The masked repeats were marked by X
and remained inert during subsequent analyses.
[0167] v. The location of exons within the sequence was predicted
using the MZEF computer program (Zhang, Proc. Natl. Acad. Sci.,
94:565-568 (1997); GenScan (Burge and Karlin, J. Mol. Biol.,
268:78-94)).
[0168] vi. The sequence was compared to the publicly available
unigene database (National Center for Biotechnology Information,
National Library of Medicine, 38A, 8N905, 8600 Rockville Pike,
Bethesda, Md. 20894; www.ncbi.nlm.nih.gov) using the blastn2
algorithm (Altschul et al, Nucl. Acids Res., 25:3389-3402 (1997)).
The parameters for this search were: E=0.05, v=50, B=50 (where E is
the expected probability score cutoff, V is the number of database
entries returned in the reporting of the results, and B is the
number of sequence alignments returned in the reporting of the
results (Altschul et al, J. Mol. Biol., 215:403-410 (1990)).
[0169] vii. The sequence was translated into protein for all six
reading frames, and the protein sequences were compared to a
non-redundant protein database compiled from Genpept Swissprot PIR
(National Center for Biotchnology Information, National Library of
Medicine, 38A, 8N905, 8600 Rockville Pike, Bethesda, Md. 20894;
www.ncbi.nlm.nih.gov). The parameters for this search were E=0.05,
V=50, B=50, where E, V, and B are defined as above.
[0170] viii. The BAC DNA sequence was compared to a database of
clustered sequences using blastn2 (Altschul et al, Nucl. Acids.
Res., 25:3389-3402 (1997)). The parameters for this search were
E=0.05, V=50, B=50, where E, V, and B are defined as above. The
database of clustered sequences was prepared utilizing a
proprietary clustering technology (Pangea Systems, Inc.) using cDNA
clones derived from direct selection experiments (described below),
human dbEST mapping to the 12q23-qter region, proprietary cDNAs,
Genbank genes and IMAGE consortium cDNA clones.
[0171] ix. The BAC sequence was compared to the sequences derived
from the ends of BACs from the region on chromosome 12 using
blastn2 (Altschul et al, Nucl. Acids. Res., 25:3389-3402 (1997)).
The parameters for this search were E=0.05, V=50, B=50, where E, V,
and B are defined as above.
[0172] x. The BAC sequence was compared to the Genbank database
(National Center for Biotechnology Information, National Library of
Medicine, 38A, 8N905, 8600 Rockville Pike, Bethesda, Md. 20894;
www.ncbi.nlm.nih.gov) using blastn2 (Altschul et al, Nucl. Acids.
Res., 25:3389-3402 (1997)). The parameters for this search were
E=0.05, V=50, B=50, where E, V, and B are defined as above.
[0173] xi. The BAC sequence was compared to the STS division of
Genbank database (National Center for Biotechnology Information,
National Library of Medicine, 38A, 8N905, 8600 Rockville Pike,
Bethesda, Md. 20894; www.ncbi.nlm.nih.gov) using blastn2 (Altschul
et al., 1997). The parameters for this search were E=0.05, V=50,
B=50, where E, V, and B are defined as above.
[0174] xii. The BAC sequence was compared to the Expressed Sequence
Tag (EST) Genbank database (National Center for Biotchnology
Information, National Library of Medicine, 38A, 8N905, 8600
Rockville Pike, Bethesda, Md. 20894; www.ncbi.nlm.nih.gov) using
blastn2 (Altschul et al., Nucl. Acids. Res., 25:3389-3402 (1997)).
The parameters for this search were E=0.05, V=50, B=50, where E, V,
and B are defined as above.
[0175] xiii. The BAC sequence was compared to the Expressed
Sequence Tag (EST) Genbank database (National Center for
Biotchnology Information, National Library of Medicine, 38A, 8N905,
8600 Rockville Pike, Bethesda, Md. 20894; www.ncbi.nlm.nih.gov)
using blastn2 (Altschul et al., Nucl. Acids. Res., 25:3389-3402
(1997)). The parameters for this search were E=0.05, V=50, B=50,
where E, V, and B are defined as above.
G. cDNA Cloning and Expression Analysis
[0176] 1. Construction of cDNA libraries. Directionally cloned cDNA
libraries from normal lung and bronchial epithelium were
constructed using standard methods described previously (Soares et.
al., 1994, Automated DNA Sequencing and Analysis, Adams, Fields and
Venter, Eds., Academic Press, NY, pages 110-114). Total and
cytoplasmic RNAs were extracted from tissue or cells by
homogenizing the sample in the presence of Guanidinium
Thiocyanate-Phenol-Chloroform extraction buffer (e.g. Chomczynski
and Sacchi, Anal. Biochem., 162:156-159 (1987)) using a polytron
homogenizer (Brinkman Instruments). PolyA+ RNA was isolated from
total/cytoplasmic RNA using dynabeads-dT according to the
manufacturer's recommendations (Dynal, Inc.). The ds cDNA
synthesized was then ligated into the plasmid vector pBluescript II
KS+ (Stratagene, La Jolla, Calif.), and the ligation mixture was
transformed into E. coli host DH10B or DH12S by electroporation
(Soares, 1994). Following overnight growth at 37.degree. C., DNA
was recovered from the E. coli colonies after scraping the plates
by processing as directed for the Mega-prep kit (Qiagen,
Chatsworth, Calif.). The quality of the cDNA libraries was
estimated by counting a portion of the total number of primary
transformants, determining the average insert size and the
percentage of plasmids with no cDNA insert. Additional cDNA
libraries (human total brain, heart, kidney, leukocyte, and fetal
brain) were purchased from Life Technologies, Bethesda, Md.
[0177] cDNA libraries, both oligo (dT) and random hexamer-primed
were used for isolating cDNA clones mapping within the disorder
critical region. Four 10.times.10 arrays of each of the cDNA
libraries were prepared as follows: the cDNA libraries were titered
to 2.5.times.10.sup.6 using primary transformants. The appropriate
volume of frozen stock was used to inoculate 2 L of LB/ampicillin
(100 .mu.g/.mu.l). 400 aliquots containing 4 ml of the inoculated
liquid culture were generated. Each tube contained about 5000 cfu.
The tubes were incubated at 30.degree. C. overnight with shaking
until an OD of 0.7-0.9 was obtained. Frozen stocks were prepared
for each of the cultures by aliquotting 300 .mu.l of culture and
100 .mu.l of 80% glycerol. Stocks were frozen in a dry ice/ethanol
bath and stored at -70.degree. C. DNA was isolated from the
remaining culture using the Qiagen (Chatsworth, Calif.) spin
mini-prep it according to the manufacturer's instructions. The DNAs
from the 400 cultures were pooled to make 80 column and row pools.
Markers were designed to amplify putative exons from candidate
genes. Once a standard PCR condition was identified and specific
cDNA libraries were determined to contain cDNA clones of interest,
the markers were used to screen the arrayed library. Positive
addresses indicating the presence of cDNA clones were confirmed by
a second PCR using the same markers.
[0178] Once a cDNA library was identified as likely to contain cDNA
clones corresponding to a specific transcript of Gene 214, it was
used to isolate a clone or clones containing cDNA inserts. This was
accomplished by a modification of the standard "colony screening"
method (Sambrook et al, Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y. (1989)).
Specifically, twenty 150 mm LB+ampicillin agar plates were spread
with 20,000 colony forming units (cfu) of cDNA library and the
colonies allowed to grow overnight at 37.degree. C. Colonies were
transferred to nylon filters (Hybond from Amersham, or equivalent)
and duplicates prepared by pressing two filters together
essentially as described (Sambrook et al, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor N.Y. (1989)). The "master" plate was then incubated an
additional 6-8 hrs to allow the colonies additional growth. The DNA
from the bacterial colonies was then bound onto the nylon filters
by treating the filters sequentially with denaturing solution (0.5
N NaOH, 1.5 M NaCl) for two minutes, neutralization solution (0.5 M
Tris-Cl pH 8.0, 1.5 M NaCl) for two minutes (twice). The bacterial
colonies were removed from the filters by washing in a solution of
2.times.SSC/2% SDS for one minute while rubbing with tissue paper.
The filters were air dried and baked under vacuum at 80.degree. C.
for 1-2 hrs to cross link the DNA to the filters.
[0179] cDNA hybridization probes were prepared by random hexamer
labelling (Fineberg and Vogelstein, Anal. Biochem., 132:6-13
(1983)) or by including gene-specific primers and no random
hexamers in the reaction (for small fragments). The colony
membranes were then pre-washed in 10 mM Tris-Cl pH 8.0, 1 M NaCl, 1
mM EDTA, 0.1% SDS for 30 minutes at 55.degree. C. Following the
pre-wash, the filters were pre-hybridized in >2 ml/filter of
6.times.SSC, 50% deionized formamide, 2% SDS, 5.times.Denhardt's
solution, and 100 mg/ml denatured salmon sperm DNA, at 42.degree.
C. for 30 minutes. The filters were then transferred to
hybridization solution (6.times.SSC, 2% SDS, 5.times.Denhardt's,
100 mg/ml denatured salmon sperm DNA) containing denatured
a-32P-dCTP-labelled cDNA probe and incubated overnight at
42.degree. C.
[0180] The following morning, the filters were washed under
constant agitation in 2.times.SSC, 2% SDS at room temperature for
20 minutes, followed by two washes at 65.degree. C. for 15 minutes
each. A second wash was performed in 0.5.times.SSC, 0.5% SDS for 15
minutes at 65.degree. C. Filters were then wrapped in plastic wrap
and exposed to radiographic film. Individual colonies on plates
were aligned with the autoradiograph and positive clones picked
into a 1 ml solution of LB Broth containing ampicillin. After
shaking at 37.degree. C. for 1-2 hours, aliquots of the solution
were plated on 150 mm plates for secondary screening. Secondary
screening was identical to primary screening (above) except that it
was performed on plates containing .about.250 colonies so that
individual colonies could be clearly identified. Positive cDNA
clones were characterized by restriction endonuclease cleavage,
PCR, and direct sequencing to confirm the sequence identity between
the original probe and the isolated clone.
[0181] To obtain the full-length cDNA, novel sequence from the
5'-end of the clone was used to reprobe the library. This process
is repeated until the length of the cDNA cloned matched that of the
mRNA, estimated by Northern analysis.
[0182] Rapid Amplification of cDNA ends (RACE) was performed
following the manufacturer's instructions using a Marathon cDNA
Amplification Kit (Clontech, Palo Alto, Calif.) as a method for
cloning the 5' and 3' ends of candidate genes. cDNA pools were
prepared from total RNA by performing first strand synthesis, where
a sample of total RNA sample was mixed with a modified oligo (dT)
primer, heated to 70.degree. C., cooled on ice and followed by the
addition of: 5.times. first strand buffer, 10 mM dNTP mix, and AMV
Reverse Transcriptase (20 U/.mu.l). The reaction mixture was
incubated at 42.degree. C. for an hour and placed on ice. For
second strand synthesis, the following components were added
directly to the reaction tube: 5.times. second strand buffer, 10 mM
dNTP mix, sterile water, 20.times. second strand enzyme cocktail
and the reaction tube was incubated at 16.degree. C. for 1.5 hours.
T4 DNA Polymerase was added to the reaction tube and incubated at
16.degree. C. for 45 minutes. The second-strand synthesis was
terminated with the addition of an EDTA/Glycogen mix. The sample
was subjected to a phenol/chloroform extraction and an ammonium
acetate precipitation. The cDNA pools were checked for quality by
analyzing on an agarose gel for size distribution. Marathon cDNA
adapters were then ligated onto the cDNA ends. The specific
adapters contained priming sites that allowed for amplification of
either 5' or 3' ends, and varied depending on the orientation of
the gene specific primer (GSP) that was chosen. An aliquot of the
double stranded cDNA was added to the following reagents: 10 .mu.M
Marathon cDNA adapter, 5.times.DNA ligation buffer, T4 DNA ligase.
The reaction was incubated at 16.degree. C. overnight and heat
inactivated to terminate the reaction. PCR was performed by the
addition of the following to the diluted double stranded cDNA pool:
10.times.cDNA PCR reaction buffer, 10 .mu.M dNTP mix, 10 .mu.M GSP,
10 .mu.M AP1 primer (kit), 50.times. Advantage cDNA Polymerase Mix.
Thermal Cycling conditions were 94.degree. C. for 30 seconds, 5
cycles of 94.degree. C. for 5 seconds, 72.degree. C. for 4 minutes,
5 cycles of 94.degree. C. for 5 seconds, 70.degree. C. for 4
minutes, 23 cycles of 94.degree. C. for 5 seconds, 68.degree. C.
for 4 minutes. After the first round of PCR was performed using the
GSP to extend to the end of the adapter to create the adapter
primer binding site, exponential amplification of the specific cDNA
of interest was performed. Usually, a second, nested PCR was
performed to provide specificity. The RACE product was analyzed on
an agarose gel. Following excision from the gel and purification
(GeneClean, BIO 101), the RACE product was then cloned into pCTNR
(General Contractor DNA Cloning System, 5'-3', Inc.) and sequenced
to verify that the clone was specific to Gene 214.
[0183] 2. Expression Analysis. To characterize the expression of
Gene 214, a series of experiments were performed. First,
oligonucleotide primers were designed for use in the polymerase
chain reaction (PCR) so that portions of a cDNA, EST, or genomic
DNA could be amplified from a pool of DNA molecules or RNA
population (RT-PCR). The PCR primers were used in a reaction
containing genomic DNA to verify that they generated a product of
the predicted size (based on the genomic sequence). A critical
piece of data that is required when characterizing novel genes is
the length, in nucleotides, of the processed transcript or
messenger RNA (mRNA). Those skilled in the art primarily determine
the length of an mRNA by Northern analysis (Sambrook et al,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory, Cold Spring Harbor NY (1989)). Probes were generated
using one of the methods described below. Briefly, sequence
verified IMAGE consortium cDNA clones were digested with
appropriate restriction endonucleases to release the insert. The
restriction digest was electrophoresed on an agarose gel and the
bands containing the insert were excised. The gel piece containing
the DNA insert was placed in a Spin-X (Corning Costar Corporation,
Cambridge, Mass.) or Supelco spin column (Supelco Park, Pa.) and
spun at high speed for 15 mins. The DNA was ethanol precipitated
and resuspended in TE. Alternatively, PCR products obtained from
genomic DNA or RT-PCR were also purified as described above.
Inserts purified from IMAGE clones were random primer labelled
(Feinberg and Vogelstein) to generate probes for hybridization.
Probes from purified PCR products were generated by incorporation
of a-.sup.32P-dCTP in second round of PCR. FIG. 9 is the Northern
blot for Gene 214 which includes PolyA+selected RNA from 1) a
lymphoblast cell line from as asthmatic individual, 2) lung and 3)
trachea. Expression of Gene 214 was detected in lung at moderate
levels, with a weak signal in trachea. Expression was not found in
any other tissues examined. The lung-specific expression of Gene
214 implicates it as a gene involved in lung biology and further
valicates as a candidate asthma gene.
[0184] 3. RT-PCR. RT-PCR was used as an alternate method to
Northern blotting to detect mRNAs with low levels of expression.
Total RNA from multiple human tissues was purchased from Clontech
(Palo Alto, Calif.) and genomic DNA was removed from the total RNA
by DNaseI digestion. The "Superscript' Preamplification System for
First strand cDNA synthesis" (Life Technologies, Gaithersburg, Md.)
was used according to manufacturer's specifications with oligo(dT)
or random hexamers to synthesize cDNA from the DNaseI treated total
RNA. Gene specific primers were used to amplify the target cDNAs in
a 30 .mu.l PCR reaction containing 0.5 .mu.l of first strand cDNA,
1 .mu.l sense primer (10 uM), 1 .mu.l antisense primer (10 uM), 3
.mu.l dNTPs (2 mM), 1.2 .mu.l MgCl.sub.2 (25 mM), 3 .mu.l
10.times.PCR buffer and 1 unit of Taq Polymerase (Perkin Elmer).
The PCR reaction was initially denatured at 94.degree. C. for 4
min, then 30 cycles of denaturation at 94.degree. C. for 30 sec,
annealing at 58.degree. C. for 1 min and extension at 72.degree. C.
for 1 min, followed by a final extension at 72.degree. C. for 7
min. PCR products were analyzed on agarose gels.
H. Characteristics and Function of Gene 214
[0185] BAC RP11-702C13 (196 Kb) maps to chromosome 12q24 and
contains the STS marker A005Q05 located approximately 165 cM from
the telomere of the p-arm of chromosome 12. Gene 214 maps within a
10,318 kb sequenced contig of the BAC RP11-702C13 (FIG. 2). BLAST
analysis against DNA and protein databases indicated that a portion
of Gene 214 was 100% homologous to a nucleic acid sequence known as
mucin 8 (MUC8). Northern blot analysis of Gene 214 detected a 4.4
Kb transcript in lung (FIG. 9). The MUC8 fragment is 1.4 Kb in
length (Shanker et. al., Am J. Respir. Cell Mol. Biol., 16:232-241
(1997)). Enclosed herein are an additional four alternatively
transcribed variants. (SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ
ID NO: 8, and SEQ ID NO:10). The five variants of Gene 214/MUC8
contain a putative open reading frames that vary in size, from 1167
bp to 1350 bp, and thus encode proteins from 388 to 449 amino acids
(SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9, and SEQ ID
NO:11).
[0186] Mucin 8 belongs to a growing family of genes that encode
mucins. Currently, there are 9 members of this family, MUC1, MUC2,
MUC3, MUC4, MUC5, MUC5B, MUC6 and MUC7, and the fragment MUC8. All
but MUC3 and MUC6 are expressed in the upper and/or lower
respiratory tract (Zuhdi Alimam et al., Am. J. Respir. Cell Mol.
Biol., 22:253-260 [2000]). All the mucins share a common
characteristic: tandem repeated amino acid sequences within the
protein core. These repeats are rich in serine, threonine and
proline and are heavily glycosylated via O-glycosidic bonds. The
tandem repeat units vary in length from as few as 8 to as many as
169 amino acids and are always flanked by non-repeat regions. The
MUC8 core protein is unique among the mucins, in that it possesses
a degenerate 41 bp tandem repeat that encodes 2 types of consensus
peptide repeats; three 41 bp repeats encode one peptide sequence
while a 2 bp deletion in the perfect 41 bp repeat disrupts the
tandem and generates a second smaller repetitive portion of the
protein (Shanker et. al., Biochem. J., 300:295-298 (1994).
[0187] The respiratory epithelium is protected by a viscoelastic
gel, mucus, that is normally produced at low levels. In a healthy
individual, 10 mls of sputum are transported to the larynx and
swallowed. In asthmatic individuals, mucus production is increased.
This causes airway obstruction due to the sputum being very
tenacious, and hence forming viscid plugs that can be difficult to
expectorate. The overproduction of mucus in asthmatics has been
attributed to the increased numbers of goblets cells, goblet cell
hyperplasia (GCH), and enlargement of the sub-mucosal glands. GCH
is presumed to be due to a combination of mucus gland stimulation
by neural stimuli and inflammatory mediators. In situ hybridization
revealed that multiple airway mucin genes account for the total
mucin secretion derived from the airway epithelia. Further,
immunohistochemical staining of tracheobronchial epithelium with
polyclonal antibodies raised to MUC8, indicated that the protein
was primarily localized to sub-mucosal glands (Shanker et. al., Am
J. Respir. Cell Mol. Biol., 16:232-241 [1997]). Therefore it is
likely that the relationship and functional role of Gene 214/MUC8
are involved in the pathophysiology of asthma and other respiratory
diseases.
I. Mutation Analysis
[0188] In order to conduct mutation analysis, the genomic structure
for Gene 214 was identified. The precise intron-exon junctions were
determined based on the consensus sequences at splice junctions.
The exon prediction programs MZEF (Zhang, Proc. Natl. Acad. Sci.,
94:565-568 (1997); and GenScan (Burge and Karlin, J. Mol. Biol.,
268:78-94) were also utilized to help identify the exons.
[0189] A combination of fluorescent single stranded confirmation
(SSCP) analysis (ABI) and DNA sequencing was utilized to precisely
identify and determine the nature of the variant at the nucleotide
level. SSCP analysis was used to screen individual DNA for
variants. Briefly, polymerase chain reaction (PCR) was used to
generate templates from unrealted asthmatic individuals that showed
increased sharing for the 12q23-qter chromosomal region and
contributed towards linkage. Non-asthmatic individuals were used as
controls. Enzymatic amplification of genes within the asthma region
on 12q23-qter was accomplished using PCR with oligonucleotides
flanking each exon as well as the putative 5' regulatory elements
of each gene. The primers were chosen to amplify each exon as well
as 15 or more base pairs within each intron on either side of the
splice site. The forward and the reverse primers had two different
dye colors to allow analysis of each strand and confirm variants
independently. Standard PCR assay was utilized for each exon primer
pair following optimization. Buffer and cycling conditions were
specific to each primer set. The products were denatured using a
formamide dye and electrophoresed on non-denaturing acrylamide gels
with varying concentrations of glycerol (at least two different
glycerol concentrations).
[0190] Primers utilized in fluorescent SSCP experiments to screen
coding and non-coding regions of Gene 214 for polymorphisms are
provided in Table 3. Column one lists the gene targeted for
mutation analysis. Column two lists the specific exon analyzed.
Column three provides the GTC assigned primer name. Columns four
and five list the forward primer sequence and reverse primer
sequence, respectively.
TABLE-US-00004 TABLE 3 Forward Reverse Gene Exon SSCP Assay Primer
Primer 214 A 196_214_A_F_ GCCCTTAGGG CCACATCGTG 197_214_A_R
AGAGCAGC CCTTTGTGTA (SEQ ID (SEQ ID NO: 24) NO: 25) 214 B
192_214_B_F_ CACTGTGTTA GTTGGGATTA 193_214_B_R AAACGCCTGG
CAGGCACGAG (SEQ ID (SEQ ID NO: 26) NO: 27) 214 B 194_214_B_F_
CAGAAGCAAC ACTACAGGTT 195_214_B_R CCACATGACC TGCACCACCA (SEQ ID
(SEQ ID NO: 28) NO: 29) 214 C 626_214_C_F_ ATGCTCTCCT AGGGAATGCA
627_214_C_R GATGGCTCCT GGTGCAAAG (SEQ ID (SEQ ID NO: 30) NO: 31)
214 C 628_214_C_F_ ACTCGGGAAA CATACCTTGA 629_214_C_R GGAAGGCTCT
GTGCACACCG (SEQ ID (SEQ ID NO: 32) NO: 33)
[0191] Primers utilized in DNA sequencing for purposes of
confirming polymorphisms detected using fluorescent SSCP are
provided in Table 4. Column one lists the specific exon sequenced.
Column two provides the GTC assigned forward primer name and column
three lists the forward primer sequence. Columns four and five
lists the GTC assigned reverse primer name and the corresponding
reverse primer sequence, respectively.
TABLE-US-00005 TABLE 4 Forward Forward Reverse Reverse Gene Exon
Primer Sequence Primer Sequence 214 B MDSeq_ GACAGTCT MDSeq_
TGGAGATG 15_214_ GCTCCACA 15_214_ AAGTCTTG B_F TCCA B_R CTCTTG (SEQ
ID (SEQ ID NO: 34) NO: 35) 214 C MDSeq_ ATATGTTT MDSeq_ CCCAGGCT
110_214_ GCTGGCTT 110_214_ GTGTGTCC C_F TGGG C_R TCTA (SEQ ID (SEQ
ID NO: 36) NO: 37)
[0192] Single nucleotide polymorphisms (SNPs) that were identified
in Gene 214 are provided in Table 5. Column one contains the exon
or intron in which the SNP was detected. Column two provides a
reference sequence in which the SNP appears underlined. Column
three lists the base change of the SNP. Column four details the
location of the SNP as intronic or exonic. Column five describes
the SNP location of the genomic BAC sequence of SEQ ID NO:1. The
SNPs are also described in FIGS. 8A-8B).
TABLE-US-00006 TABLE 5 Reference Intron/ Exon Sequence PMP Exon
Location B ACTACAGGTTTGCAC A > G Intron 6674 CACCATGTCCTGCTA
(SEQ ID ATTTTTTTTT NO: 47) (SEQ ID NO: 46) B TGTGCACTCTTGGGC C >
T 3'UTR 6976 ATACGCCTAGGAGTG (SEQ ID GAACTGCTG NO: 49) (SEQ ID NO:
48) C GGGCTCTGCGCCACC C > T Intron 3161 TCAACCCAGGCGTTT (SEQ ID
GTTCCGCAG NO: 51) (SEQ ID NO: 50)
[0193] FIGS. 8A-8B illustrate the five different transcripts of
Gene 214 and show the genomic structure of the gene. The exons are
shown to scale and the SNPs are identified by their location along
the genomic BAC DNA (SEQ ID NO:1).
J. Restriction Fragment Length Polymorphism (RFLP Assay) and Allele
Specific Oligonucleotide Analysis (ASO Assay)
[0194] To identify other individuals with the polymorphisms listed
in Table 5, RFLP assay and ASA were performed.
[0195] 1. RFLP Assay. The amplicon, containing the polymorphism,
was PCR amplified using primers that were used to generate a
fragment for sequencing (sequencing primers) or SSCP (SSCP
primers). The appropriate population of individuals was PCR
amplified in 96 well microtitre plates.
[0196] Enzymes were purchased from New England Biolabs (NEB). The
restriction cocktail containing the appropriate enzyme for the
particular polymorphism is added to the PCR product. The reaction
is incubated at the appropriate temperature according to the
manufacturer's recommendations (NEB) for two to three hours,
followed by a 4.degree. C. incubation. After digestion, the
reactions were size fractionated using the appropriate agarose gel
depending on the assay specifications (2.5%, 3%, or metaphor). Gels
are electrophoresed in 1.times.TBE Buffer at 170 Volts for
approximately two hours.
[0197] The gel is illuminated using ultraviolet light and the image
is saved as a Kodak 1D file. Using the Kodak 1D image analysis
software, the images are scored and the data is exported to
EXCEL.
[0198] 2. ASO assay. The amplicon, containing the polymorphism, was
PCR amplified using primers that were used to generate a fragment
for sequencing (sequencing primers) or SSCP (SSCP primers). The
appropriate population of individuals was PCR amplified in 96 well
microtitre plates and re-arrayed into 384 well microtitre plates
using a Tecan Genesis RSP200. The amplified products were loaded
onto 2% agarose gels and size fractionated at 150V for 5 minutes.
The DNA was transferred from the gel to Hybond N+ nylon membrane
(Amersham-Pharmacia) using a Vacuum blotter (Bio-Rad). The filter
containing the blotted PCR products was transferred to a dish
containing 300 mls of pre-hybridization solution (5.times.SSPE
{pH7.4}, 2% SDS, 5.times.Denhardts). The filter was left in the
pre-hybridization solution at 40.degree. C. for >1 hour. After
pre-hybridization, 10 mls of the pre-hybridization solution and the
filter were transferred to a washed glass bottle. The allele
specific oligonucleotides (ASO) were designed with the polymorphism
in the middle. The size of the oligonucleotide was dependent upon
the GC content of the sequence around the polymorphism. Those ASOs
that had a G or C polymorphism were designed so that the Tm was
between 54-56.degree. C. and those that had an A or T variance were
designed so that the Tm was between 60-64.degree. C. All
oligonucleotides were phosphate free at the 5'end and purchased
from Gibco BRL. For each polymorphism 2 ASOs were designed: one for
each variant.
[0199] The two ASOs that represented the polymorphism were
resuspended at a concentration of 1 .mu.g/.mu.l and separately
end-labeled with .gamma.-ATP.sup.32 (6000 Ci/mmol) (NEN) using T4
polynucleotide kinase according to manufacturer recommendations
(NEB). The end-labeled products were removed from the
unincorporated .gamma.-ATP.sup.32 by passing the reactions through
Sephadex G-25 columns according to manufacturers recommendation
(Amersham-Pharmacia). The entire end-labeled product of one ASO was
added to the bottle containing the appropriate filter and 10 mls of
hybridization solution. The hybridization reaction was placed in a
rotisserie oven (Hybaid) and left at 40.degree. C. for a minimum of
4 hours. The other ASO was stored at -20.degree. C.
[0200] After the prerequisite hybridization time had elapsed, the
filter was removed from the bottle and transferred to 1 liter of
wash solution (0.1.times.SSPE {pH7.4}, 0.1% SDS) pre-warmed to
45.degree. C. After 15 minutes the filter was transferred to
another liter of wash solution (0.1.times.SSPE {pH7.4}, 0.1% SDS)
pre-warmed to 50.degree. C. After 15 minutes the filter was wrapped
in Saran, placed in an autoradiograph cassette and an X-ray film
(Kodak) placed on top of the filter. Depending on the efficiency of
the end-labeling reaction of the ASO and its hybridization to the
filter an image would be observed on the film within an hour. After
an image had been captured on film for the 50.degree. C. wash, the
process was repeated for wash steps at 55.degree. C., 60.degree. C.
and 65.degree. C. The image that captured the best result was
used.
[0201] The ASO was removed from the filter by adding 1 liter of
boiling strip solution (0.1.times.SSPE {pH7.4}, 0.1% SDS). This was
repeated two more times. After removing the ASO the filter was
pre-hybridized in 300 mls of pre-hybridization solution
(5.times.SSPE {pH7.4}, 2% SDS, 5.times.Denhardts) at 40.degree. C.
for >1 hour. The second end-labeled ASO corresponding to the
other variant was removed from storage at -20.degree. C. and thawed
to room temperature. The filter was placed into a glass bottle
along with 10 mls of hybridization solution and the entire
end-labeled product of the second ASO. The hybridization reaction
was placed in a rotisserie oven (Hybaid) and left at 40.degree. C.
for a minimum of 4 hours. After the hybridization, the filter was
washed at various temperatures and images captured on film as
described above.
[0202] The two films that best captured the allele specific assay
with the two ASOs were converted into digital images by scanning
them into Adobe PhotoShop. These images were overlaid against each
other in Graphic Converter and then scored and stored in FileMaker
Pro 4.0.
K. Association Study Analysis
[0203] In order to determine whether mutations in candidate genes
are responsible for the asthma phenotype, association studies are
performed using a case-control study design. To avoid issues of
population admixture which can bias case-control studies, the
unaffected controls were collected in both the US and the UK. A
total of three hundred controls were collected, 200 in the UK and
100 in the US. Inclusion into the study required that the control
individual was negative for asthma, as determined by self report of
never having asthma, has no first degree relatives with asthma, and
was negative for eczema and symptoms indicative of atopy within the
past 12 months. Data from an abbreviated questionnaire similar to
that administered to the affected sib pair families were collected.
Results from skin prick tests to 4 common allergens were also
collected. The results of the skin prick test were used to select a
subset of control that were most likely to be asthma and atopy
negative.
[0204] A subset of unrelated cases are selected from the affected
sib pair families based on the evidence for linkage at the
chromosomal location of interest. One affected sib from families
demonstrating identity-by-decent (IBD) at the appropriate marker
loci is selected. In the selection criteria, preference is given to
families with multiple affected sibs all of whom are concordant at
the marker locus as well as to families where affected and
unaffected sibs are discordant.
[0205] For each polymorphism, the frequency of the alleles in the
control and case populations is compared using a Fisher exact test.
It is expected that a mutation increasing susceptibility to the
disease would be more prevalent in the cases than in the controls,
while a protective mutation should be more prevalent in the control
group. Similarly, the genotype frequencies of the SNPs are compared
between cases and controls. P-values are computed for both the
allele and genotype frequencies. A small p-value is indicative of
an association between the SNPs and the disease phenotype. The
analysis is repeated for the US and UK population separately, to
adjust for the possibility of genetic heterogeneity.
[0206] 1. Association Test with Individual SNPs
[0207] Statistical analyses for the two SNPs in Gene 214 are
presented in Table 8. Column one list the exon containing the SNP
of interest. The control ("CNTL") allele frequency and sample size
("N") are in columns two and three. The affected individuals
("CASE") allele frequency and sample size ("N") are listed in
columns four and five. The sixth column contains the significance
value level of comparison between the control allele frequencies
and the case allele frequencies. The SNP in Exon C had allelic
frequencies significantly different in the cases versus the
controls in the US and combined samples. In the Combined and US
population, this SNP was more frequent in the cases (4.1% and
10.4%, respectively) than in the control population (0.8% and
1.3%), and the differences were statistically significance
(p=0.0099 and p=0.0083). This analysis suggests that Gene 214, is,
at least partially responsible for the asthmatic phenotype in those
families linked to the chromosome 12 region.
TABLE-US-00007 TABLE 8 Frequencies ALLELE EXON CNTL N CASE N
P-VALUE Combined sample B 17.8% 214 20.3% 111 0.4577 C 0.8% 194
4.1% 97 0.0083 US sample B 15.1% 76 16.7% 24 0.8204 C 1.3% 75 10.4%
24 0.0099 UK sample B 19.2% 138 21.3% 87 0.6291 C 0.4% 119 2.1% 73
0.1559
II. Preparation of Nucleic Acids, Vectors, Transformations and Host
Cells
[0208] The nucleic acids of this invention can be produced in large
quantities by replication in a suitable host cell. Natural or
synthetic nucleic acid fragments, comprising at least ten
contiguous bases coding for a desired peptide or polypeptide can be
incorporated into recombinant nucleic acid constructs, usually DNA
constructs, capable of introduction into and replication in a
prokaryotic or eukaryotic cell. Usually the nucleic acid constructs
will be suitable for replication in a unicellular host, such as
yeast or bacteria, but may also be intended for introduction to
(with and without integration within the genome) cultured mammalian
or plant or other eukaryotic cells, cell lines, tissues, or
organisms. The purification of nucleic acids produced by the
methods of the present invention is described, for example, in
Sambrook et al, Molecular Cloning. A Laboratory Manual, 2nd Ed.
(Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989) or
Ausubel et al, Current Protocols in Molecular Biology, J. Wiley and
Sons, NY (1992).
[0209] The nucleic acids of the present invention can also be
produced by chemical synthesis, e.g., by the phosphoramidite method
described by Beaucage et al, Tetra. Letts., 22:1859-1862 (1981) or
the triester method according to Matteucci, et al, J. Am. Chem.
Soc., 103:3185 (1981), and can performed on commercial, automated
oligonucleotide synthesizers. A double-stranded fragment may be
obtained from the single-stranded product of chemical synthesis
either by synthesizing the complementary strand and annealing the
strands together under appropriate conditions or by adding the
complementary strand using DNA polymerase with an appropriate
primer sequence.
[0210] These nucleic acids can encode full-length variant forms of
proteins as well as the naturally-occurring protein. The variant
proteins (which could be especially useful for detection and
treatment of disorders) can have the variant amino acid sequences
encoded by the polymorphisms described in Table 5, when said
polymorphisms are read so as to be in-frame with the full-length
coding sequence of which it is a component.
[0211] Nucleic acid constructs prepared for introduction into a
prokaryotic or eukaryotic host will comprise a replication system
recognized by the host, including the intended nucleic acid
fragment encoding the selected protein or polypeptide, and will
preferably also include transcription and translational initiation
regulatory sequences operably linked to the protein encoding
segment. Expression vectors may include, for example, an origin of
replication or autonomously replicating sequence (ARS) and
expression control sequences, a promoter, an enhancer and necessary
processing information sites, such as ribosome-binding sites, RNA
splice sites, polyadenylation sites, transcriptional terminator
sequences, and mRNA stabilizing sequences. Secretion signals are
also included, where appropriate, whether from a native Gene 214
protein or from other receptors or from secreted proteins of the
same or related species, which allow the protein to cross and/or
lodge in cell membranes, and thus attain its functional topology,
or be secreted from the cell. Such vectors may be prepared by means
of standard recombinant techniques well known in the art and
discussed, for example, in Sambrook et al, Molecular Cloning. A
Laboratory Manual, 2nd Ed. (Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y. (1989) or Ausubel et al, Current Protocols in
Molecular Biology, J. Wiley and Sons, NY (1992).
[0212] An appropriate promoter and other necessary vector sequences
will be selected so as to be functional in the host, and will
include, when appropriate, those naturally associated with Gene 214
gene. Examples of workable combinations of cell lines and
expression vectors are described in Sambrook et al, Molecular
Cloning. A Laboratory Manual, 2nd Ed. (Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y. (1989) or Ausubel et al,
Current Protocols in Molecular Biology, J. Wiley and Sons, NY
(1992). Many useful vectors are known in the art and can be
obtained from such vendors as Stratagene (supra), New England
BioLabs, Beverly, Mass., U.S.A, Promega Biotech, and other
biotechnology product suppliers. Promoters such as the trp, lac and
phage promoters, tRNA promoters and glycolytic enzyme promoters may
be used in prokaryotic hosts. Useful yeast promoters include
promoter regions for metallothionein, 3-phosphoglycerate kinase or
other glycolytic enzymes such as enolase or
glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for
maltose and galactose utilization, and others. Vectors and
promoters suitable for use in yeast expression are further
described in EP 73,675A. Appropriate non-native mammalian promoters
might include the early and late promoters from SV40 (Fiers et al,
Nature, 273:113 (1978)) or promoters derived from murine Moloney
leukemia virus, mouse tumor virus, avian sarcoma viruses,
adenovirus II, bovine papilloma virus or polyoma. In addition, the
construct may be joined to an amplifiable gene (e.g., DHFR) so that
multiple copies of the gene may be made. For appropriate enhancer
and other expression control sequences, see also Enhancers and
Eukaryotic Gene Expression, Cold Spring Harbor Press, Cold Spring
Harbor, NY (1983). While such expression vectors may replicate
autonomously, they may also replicate by being inserted into the
genome of the host cell, by methods well known in the art.
[0213] Expression and cloning vectors will likely contain a
selectable marker, a gene encoding a protein necessary for survival
or growth of a host cell transformed with the vector. The presence
of this gene ensures growth of only those host cells which express
the inserts. Typical selection genes encode proteins that a) confer
resistance to antibiotics or other toxic substances, e.g.
ampicillin, neomycin, methotrexate, etc.; b) complement auxotrophic
deficiencies, or c) supply critical nutrients not available from
complex media, e.g., the gene encoding D-alanine racemase for
Bacilli. The choice of the proper selectable marker will depend on
the host cell, and appropriate markers for different hosts are well
known in the art.
[0214] The vectors containing the nucleic acids of interest can be
transcribed in vitro, and the resulting RNA introduced into the
host cell by well-known methods, e.g., by injection (see, Kubo et
al, FEBS Letts. 241:119 (1988)), or the vectors can be introduced
directly into host cells by methods well known in the art, which
vary depending on the type of cellular host, including
electroporation; transfection employing calcium chloride, rubidium
chloride, calcium phosphate, DEAE-dextran, or other substances;
microprojectile bombardment; lipofection; infection (where the
vector is an infectious agent, such as a retroviral genome); and
other methods. See generally, Sambrook et al., 1989 and Ausubel et
al., 1992. The introduction of the nucleic acids into the host cell
by any method known in the art, including those described above,
will be referred to herein as "transformation." The cells into
which have been introduced nucleic acids described above are meant
to also include the progeny of such cells.
[0215] Large quantities of the nucleic acids and proteins of the
present invention may be prepared by expressing the Gene 214
nucleic acids or portions thereof in vectors or other expression
vehicles in compatible prokaryotic or eukaryotic host cells. The
most commonly used prokaryotic hosts are strains of Escherichia
coli, although other prokaryotes, such as Bacillus subtilis or
Pseudomonas may also be used.
[0216] Mammalian or other eukaryotic host cells, such as those of
yeast, filamentous fungi, plant, insect, or amphibian or avian
species, may also be useful for production of the proteins of the
present invention. Propagation of mammalian cells in culture is per
se well known. See, Jakoby and Pastan (eds.), Cell Culture. Methods
in Enzymology, volume 58, Academic Press, Inc., Harcourt Brace
Jovanovich, NY, (1979)). Examples of commonly used mammalian host
cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO)
cells, and WI38, BHK, and COS cell lines, although it will be
appreciated by the skilled practitioner that other cell lines may
be appropriate, e.g., to provide higher expression desirable
glycosylation patterns, or other features.
[0217] Clones are selected by using markers depending on the mode
of the vector construction. The marker may be on the same or a
different DNA molecule, preferably the same DNA molecule. In
prokaryotic hosts, the transformant may be selected, e.g., by
resistance to ampicillin, tetracycline or other antibiotics.
Production of a particular product based on temperature sensitivity
may also serve as an appropriate marker.
[0218] Prokaryotic or eukaryotic cells transformed with the nucleic
acids of the present invention will be useful not only for the
production of the nucleic acids and proteins of the present
invention, but also, for example, in studying the characteristics
of Gene 214 proteins.
[0219] Antisense nucleic acid sequences arc useful in preventing or
diminishing the expression of Gene 214 gene, as will be appreciated
by one skilled in the art. For example, nucleic acid vectors
containing all or a fragment Gene 214 gene, complementary sequences
of the former, or other sequences from the 12q23-qter region may be
placed under the control of a promoter in an antisense orientation
and introduced into a cell. Such fragments can be 16 or more
nucleotides in length. Expression of such an antisense construct
within a cell will interfere with Gene 214 transcription and/or
translation and/or replication.
[0220] The probes and primers based on the Gene 214 gene sequences
disclosed herein are used to identify homologous Gene 214 gene
sequences and proteins in other species. These Gene 214 gene
sequences and proteins are used in the diagnostic/prognostic,
therapeutic and drug screening methods described herein for the
species from which they have been isolated.
III. Protein Expression and Purification
[0221] Expression and purification of the Gene 214 protein of the
invention can be performed essentially as outlined below. To
facilitate the cloning, expression and purification of membrane and
secreted protein from the 12q23-qter, a gene expression system,
such as the pET System (Novagen), for cloning and expression of
recombinant proteins in E. coli is selected. Also, a DNA sequence
encoding a peptide tag, the His-Tap, is fused to the 3' end of DNA
sequences of interest to facilitate purification of the recombinant
protein products. The 3' end is selected for fusion to avoid
alteration of any 5' terminal signal sequence.
[0222] Nucleic acids chosen, for example, from the nucleic acids
set forth SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, and
SEQ ID NO:10, or SEQ ID NO:1 for cloning the genes are prepared by
polymerase chain reaction (PCR). Synthetic oligonucleotide primers
specific for the 5' and 3' ends of the nucleotide sequences are
designed and purchased from Life Technologies (Gaithersburg, Md.).
All forward primers (specific for the 5' end of the sequence) are
designed to include an NcoI cloning site at the 5' terminus. These
primers are designed to permit initiation of protein translation at
the methionine residue encoded within the NcoI site followed by a
valine residue and the protein encoded by the DNA sequence. All
reverse primers (specific for the 3' end of the sequence) include
an EcoRI site at the 5' terminus to permit cloning of the sequence
into the reading frame of the pET-28b. The pET-28b vector provides
a sequence encoding an additional 20 carboxyl-terminal amino acids
including six histidine residues (at the C-terminus), which
comprise the histidine affinity tag.
[0223] DNA prepared from the 12q23-qter region is used as the
source of template DNA for PCR amplification (Ausubel et al,
Current Protocols in Molecular Biology, John Wilty & Sons
(1994)). To amplify a DNA sequence containing the nucleotide
sequence, c DNA (50 ng) is introduced into a reaction vial
containing 2 mM MgCl.sub.2, 1 micromolar synthetic oligonucleotide
primers (forward and reverse primers) complementary to and flanking
a defined 12q23-qter region, 0.2 mM of each of deoxynucleotide
triphosphate, dATP, dGTP, dCTP, dTTP and 2.5 units of heat stable
DNA polymerase (Amplitaq, Roche Molecular Systems, Inc.,
Branchburg, N.J.) in a final volume of 100 microliters.
[0224] Upon completion of thermal cycling reactions, each sample of
amplified DNA is purified using the Qiaquick Spin PCR purification
kit (Qiagen, Gaithersburg, Md.). All amplified DNA samples are
subjected to digestion with the restriction endonucleases, e.g.,
NcoI and EcoRI (New England BioLabs, Beverly, Mass., U.S.A.)
(Ausubel et al, Current Protocols in Molecular Biology, John Wiley
& Sons, Inc. (1994)). DNA samples are then subjected to
electrophoresis on 1.0% NuSeive (FMC BioProducts, Rockland, Me.)
agarose gels. DNA is visualized by exposure to ethidium bromide and
long wave UV irradiation. DNA contained in slices isolated from the
agarose gel are purified using the Bio 101 GeneClean Kit protocol
(Bio 101, Vista, Calif.).
[0225] The pET-28b vector is prepared for cloning by digestion with
restriction endonucleases, e.g., NcoI and EcoRI (New England
BioLabs, Beverly, Mass.) (Ausubel et al, Current Protocols in
Molecular Biology, John Wiley & Sons, Inc. (1994)). The pET-28a
vector, which encodes the histidine affinity tag that can be fused
to the 5' end of an inserted gene, is prepared by digestion with
appropriate restriction endonucleases.
[0226] Following digestion, DNA inserts are cloned (Ausubel et al,
Current Protocols in Molecular Biology, John Wiley & Sons, Inc.
(1994)) into the previously digested pET-28b expression vector.
Products of the ligation reaction are then used to transform the
BL21 strain of E. coli (Ausubel et al, Current Protocols in
Molecular Biology, John Wiley & Sons, Inc. (1994)) as described
below.
[0227] Competent bacteria, E. coli strain BL21 or E. coli strain
BL21 (DE3), are transformed with recombinant pET expression
plasmids carrying the cloned sequence according to standard methods
(Ausubel et al, Current Protocols in Molecular Biology, John Wiley
& Sons, Inc. (1994)). Briefly, 1 microliter of ligation
reaction is mixed with 50 microliters of electrocompetent cells and
subjected to a high voltage pulse, after which samples were
incubated in 0.45 ml SOC medium (0.5% yeast extract, 2.0% tryptone,
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl.sub.2, 10 mM MgSO.sub.4 and 20
mM glucose) at 37.degree. C. with shaking for 1 hour. Samples are
then spread on LB agar plates containing 25 .mu.g/ml kanamycin
sulfate for growth overnight. Transformed colonies of BL21 are then
picked and analyzed to evaluate cloned inserts, as described
below.
[0228] Individual BL21 clones transformed with recombinant pET-28b
12q23-qter region nucleotide sequences are analyzed by PCR
amplification of the cloned inserts using the same forward and
reverse primers specific for the 12q23-qter region sequences that
are used in the original PCR amplification cloning reactions.
Successful amplification verifies the integration of the sequence
in the expression vector (Ausubel et al, Current Protocols in
Molecular Biology, John Wiley & Sons, Inc. (1994)).
[0229] Individual clones of recombinant pET-28b vectors carrying
properly cloned 12q23-qter region nucleotide sequences are picked
and incubated in 5 ml of LB broth plus 25 .mu.g/ml kanamycin
sulfate overnight. The following day plasmid DNA is isolated and
purified using the Qiagen plasmid purification protocol (Qiagen
Inc., Chatsworth, Calif.).
[0230] The pET vector can be propagated in any E. coli K-12 strain,
e.g., HMS174, HB101, JM109, DH5 and the like, for purposes of
cloning or plasmid preparation. Hosts for expression include E.
coli strains containing a chromosomal copy of the gene for T7 RNA
polymerase. These hosts are lysogens of bacteriophage DE3, a lambda
derivative that carries the lad gene, the lacUV5 promoter and the
gene for T7 RNA polymerase. T7 RNA polymerase is induced by
addition of isopropyl-.beta.-D-thiogalactoside (IPTG), and the T7
RNA polymerase transcribes any target plasmid containing a
functional T7 promoter, such as pET-28b, carrying its gene of
interest. Strains include, for example, BL21(DE3) (Studier et al,
Meth. Enzymol., 185:60-89 (1990)).
[0231] To express the recombinant sequence, 50 ng of plasmid DNA
are isolated as described above to transform competent BL21(DE3)
bacteria as described above (provided by Novagen as part of the pET
expression kit). The lacZ gene (.beta.-galactosidase) is expressed
in the pET-System as described for the 12q23-qter region
recombinant constructions. Transformed cells were cultured in SOC
medium for 1 hour, and the culture is then plated on LB plates
containing 25 .mu.g/ml kanamycin sulfate. The following day, the
bacterial colonies are pooled and grown in LB medium containing
kanamycin sulfate (25 .mu.g/ml) to an optical density at 600 nM of
0.5 to 1.0 O.D. units, at which point 1 mM IPTG was added to the
culture for 3 hours to induce gene expression of the 12q23-qter
region recombinant DNA constructions.
[0232] After induction of gene expression with IPTG, bacteria are
collected by centrifugation in a Sorvall RC-3B centrifuge at
3500.times.g for 15 minutes at 4.degree. C. Pellets are resuspended
in 50 ml of cold mM Tris-HCl, pH 8.0, 0.1 M NaCl and 0.1 mM EDTA
(STE buffer). Cells are then centrifuged at 2000.times.g for 20
minutes at 4.degree. C. Wet pellets are weighed and frozen at
-80.degree. C. until ready for protein purification.
[0233] A variety of methodologies known in the art can be used to
purify the isolated proteins (Coligan et al, Current Protocols in
Protein Science, John Wiley & Sons (1995)). For example, the
frozen cells can be thawed, resuspended in buffer and ruptured by
several passages through a small volume microfluidizer (Model
M-110S, Microfluidics International Corp., Newton, Mass.). The
resultant homogenate is centrifuged to yield a clear supernatant
(crude extract) and, following filtration, the crude extract is
fractioned over columns. Fractions are monitored by absorbance at
OD.sub.280 nm and peak fractions may be analyzed by SDS-PAGE.
[0234] The concentrations of purified protein preparations are
quantified spectrophotometrically using absorbance coefficients
calculated from amino acid content (Perkins, Eur. J. Biochem.,
157:169-180 (1986)). Protein concentrations are also measured by
the method of Bradford, Anal. Biochem., 72:248-254 (1976) and Lowry
et al, J. Biol. Chem., 193:265-275 (1951) using bovine serum
albumin as a standard.
[0235] SDS-polyacrylamide gels of various concentrations are
purchased from BioRad (Hercules, Calif.), and stained with
Coomassie blue. Molecular weight markers may include rabbit
skeletal muscle myosin (200 kDa), E. coli .beta.-galactosidase (116
kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum
albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anyhdrase
(31 kDa), soybean trypsin inhibitor (21.5 kDa), egg white lysozyme
(14.4 kDa) and bovine aprotinin (6.5 kDa).
[0236] Proteins can also be isolated by other conventional means of
protein biochemistry and purification to obtain a substantially
pure product, i.e., 80, 95, or 99% free of cell component
contaminants, as described in Jacoby, Methods in Enzymology, Vol.
104, Academic Press, New York (1984); Scoopes, Protein
Purification, Principles and Practice, 2.sup.nd Ed.,
Springer-Verlag, New York (1987); and Deutscher (ed.), Guide to
Protein Purification, Methods in Enzymology, Vol. 182 (1990). If
the protein is secreted, it can be isolated from the supernatant in
which the host cell is grown; otherwise, it can be isolated from a
lysate of the host cells.
[0237] Once a sufficient quantity of the desired protein has been
obtained, it may be used for various purposes. One use of the
protein or polypeptide is the production of antibodies specific for
binding. These antibodies may be either polyclonal or monoclonal,
and may be produced by in vitro or in vivo techniques well known in
the art. Monoclonal antibodies to epitopes of any of the peptides
identified and isolated as described can be prepared from murine
hybridomas (Kohler, Nature, 256:495 (1975)). In summary, a mouse is
inoculated with a few micrograms of protein over a period of two
weeks. The mouse is then sacrificed. The cells that produce
antibodies are then removed from the mouse's spleen. The spleen
cells are then fused with polyethylene glycol with mouse myeloma
cells. The successfully fused cells are diluted in a microtiter
plate and growth of the culture is continued. The amount of
antibody per well is measured by immunoassay methods such as ELISA
(Engvall, Meth. Enzymol., 70:419 (1980)). Clones producing antibody
can be expanded and further propagated to produce protein
antibodies. Other suitable techniques involve in vitro exposure of
lymphocytes to the antigenic polypeptides, or alternatively, to
selection of libraries of antibodies in phage or similar vectors.
See Huse et al, Science, 246:1275-1281 (1989). For additional
information on antibody production see Davis et al, Basic Methods
in Molecular Biology, Elsevier, NY, Section 21-2 (1989). Such
antibodies are particularly useful in diagnostic assays for
detection of variant protein forms, or as an active ingredient in a
pharmaceutical composition.
III. Transformed Hosts, Development of Pharmaceuticals and Research
Tools
[0238] Cells and animals that carry Gene 214 can be used as model
systems to study and test for substances that have potential as
therapeutic agents. The cells are typically cultured mesenchymal
stem cells. These may be isolated from individuals with somatic or
germline Gene 214. Alternatively, the cell line can be engineered
to carry the Gene 214, as described above. After a test substance
is applied to the cells, the transformed phenotype of the cell is
determined. Any trait of transformed cells can be assessed,
including respiratory diseases including asthma, atopy, and
response to application of putative therapeutic agents.
IV. Diagnostic Applications
[0239] As discussed herein, chromosomal region 12q23-qter has been
genetically linked to a variety of diseases and disorders. This
inventorion provides nucleic acids and SNPs which can be useful in
diagnosing individuals with chromosomal abnormalities linked to
these diseases.
[0240] Antibody-Based Diagnostic Methods:
[0241] The invention provides methods for detecting
disease-associated antigenic components in a biological sample,
which methods comprise the steps of: (i) contacting a sample
suspected to contain a disease-associated antigenic component with
an antibody specific for an disease--associated antigen,
extracellular or intracellular, under conditions in which a stable
antigen-antibody complex can form between the antibody and
disease-associated antigenic components in the sample; and (ii)
detecting any antigen-antibody complex formed in step (i) using any
suitable means known in the art, wherein the detection of a complex
indicates the presence of disease-associated antigenic components
in the sample. It will be understood that assays that utilize
antibodies directed against sequences previously unidentified, or
previously unidentified as being disease-associated, which
sequences are disclosed herein, are within the scope of the
invention.
[0242] Many immunoassay formats are known in the art, and the
particular format used is determined by the desired application. An
immunoassay can use, for example, a monoclonal antibody directed
against a single disease-associated epitope, a combination of
monoclonal antibodies directed against different epitopes of a
single disease--associated antigenic component, monoclonal
antibodies directed towards epitopes of different
disease--associated antigens, polyclonal antibodies directed
towards the same disease--associated antigen, or polyclonal
antibodies directed towards different disease--associated antigens.
Protocols can also, for example, use solid supports, or may involve
immunoprecipitation.
[0243] Typically, immunoassays use either a labeled antibody or a
labeled antigenic component (e.g., that competes with the antigen
in the sample for binding to the antibody). Suitable labels include
without limitation enzyme-based, fluorescent, chemiluminescent,
radioactive, or dye molecules. Assays that amplify the signals from
the probe are also known, such as, for example, those that utilize
biotin and avidin, and enzyme-labeled immunoassays, such as ELISA
assays.
[0244] Kits suitable for antibody-based diagnostic applications
typically include one or more of the following components: [0245]
(i) Antibodies: The antibodies can be pre-labeled; alternatively,
the antibody may be unlabeled and the ingredients for labeling can
be included in the kit in separate containers, or a secondary,
labeled antibody is provided; and [0246] (ii) Reaction components:
The kit can also contain other suitably packaged reagents and
materials needed for the particular immunoassay protocol, including
solid-phase matrices, if applicable, and standards.
[0247] The kits referred to above can include instructions for
conducting the test. Furthermore, in preferred embodiments, the
diagnostic kits are adaptable to high-throughput and/or automated
operation.
[0248] Nucleic-Acid-Based Diagnostic Methods:
[0249] The invention provides methods for detecting
disease--associated nucleic acids in a sample, such as in a
biological sample, which methods comprise the steps of: (i)
contacting a sample suspected to contain adisease--associated
nucleic acid with one or more disease--associated nucleic acid
probes under conditions in which hybrids can form between any of
the probes and disease--associated nucleic acid in the sample; and
(ii) detecting any hybrids formed in step (i) using any suitable
means known in the art, wherein the detection of hybrids indicates
the presence of the disease--associated nucleic acid in the sample.
To detect disease--associated nucleic acids present in low levels
in biological samples, it may be necessary to amplify the
disease--associated sequences or the hybridization signal as part
of the diagnostic assay. Techniques for amplification are known to
those of skill in the art.
[0250] Disease--associated nucleic acids useful as probes in
diagnostic methods include oligonucleotides at least about 15
nucleotides in length, preferably at least about 20 nucleotides in
length, and most preferably at least about 25-55 nucleotides in
length, that hybridize specifically with one or more
disease--associated nucleic acids.
[0251] A sample to be analyzed, such as, for example, a tissue
sample, may be contacted directly with the nucleic acid probes.
Alternatively, the sample may be treated to extract the nucleic
acids contained therein. It will be understood that the particular
method used to extract DNA will depend on the nature of the
biological sample. The resulting nucleic acid from the sample may
be subjected to gel electrophoresis or other size separation
techniques, or, the nucleic acid sample may be immobilized on an
appropriate solid matrix without size separation.
[0252] Kits suitable for nucleic acid-based diagnostic applications
typically include the following components: [0253] (i) Probe DNA:
The probe DNA may be prelabeled; alternatively, the probe DNA may
be unlabeled and the ingredients for labeling may be included in
the kit in separate containers; and [0254] (ii) Hybridization
reagents: The kit may also contain other suitably packaged reagents
and materials necessary or desirable for the particular
hybridization protocol, including solid-phase matrices, if
applicable, and standards.
[0255] In cases where a disease condition is suspected to involve
an alteration of the disease gene, specific oligonucleotides may be
constructed and used to assess the level of disease mRNA in cells
affected or other tissue affected by the disease.
[0256] For example, to test whether a person has a disease gene,
polymerase chain reaction can be used. In order to identify an
individual who possesses the disease gene or the wild type copy,
two oligonucleotides are synthesized by standard methods or are
obtained from a commercial supplier of custom-made
oligonucleotides. The length and base composition are determined by
standard criteria using the Oligo 4.0 primer Picking program
(Wojchich Rychlik, 1992). One of the oligonucleotides is designed
so that it will hybridize only to the disease gene DNA under the
PCR conditions used. The other oligonucleotide is designed to
hybridize to a segment of genomic DNA, wild type or non disease
gene such that amplification of DNA using these oligonucleotide
primers produces a conveniently identified DNA fragment. Tissue
samples may be obtained from hair follicles, whole blood, or the
buccal cavity. The DNA fragment generated by this procedure is
sequenced by standard techniques.
[0257] Other amplification techniques besides PCR may be used as
alternatives, such as ligation-mediated PCR or techniques involving
Q-beta replicase (Cahill et al, Clin. Chem., 37(9):1482-5 (1991)).
Products of amplification can be detected by agarose gel
electrophoresis, quantitative hybridization, or equivalent
techniques for nucleic acid detection known to one skilled in the
art of molecular biology (Sambrook et al, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring, NY
(1989)). Other alterations in the disease gene may be diagnosed by
the same type of amplification-detection procedures, by using
oligonucleotides designed to identify those alterations.
V. Genomic Screening
[0258] The use of polymorphic genetic markers linked to the Gene
214 gene is very useful in predicting susceptibility to the
diseases genetical linked to 12q23-qter. Similarly, as provided in
Table 5 the identification of polymorphic genetic markers within
the Gene 214 gene will allow the identification of specific allelic
variants that are in linkage disequilibrium with other genetic
lesions that affect one of the disease states discussed herein
including respiratory disorders and obesity. SSCP allows the
identification of polymorphisms within the genomic and coding
region of the disclosed gene. Table 3 provides primers which one
skilled in the art could identify exons which contain SNP's. Table
4 provides primers to identify the sequence change. This
information can assist one skilled in the art to identify
additional SNP's for use in genomic screening.
[0259] This method has been used successfully by others skilled in
the art (e.g., Sheffield et al, Genet., 4:1837-1844 (1995);
LeBlanc-Straceski et al, Genomics, 19:341-9 (1994); Chen et al,
Genomics, 25:1-8 (1995)). Use of these reagents with populations or
individuals will predict their risk for diseases or disorders
described herein, especially respiratory disorders and obesity.
VI. Treatment of Disorders
[0260] Thus, the present invention provides methods of screening
for drugs comprising contacting such an agent with a novel protein
of this invention or fragment thereof and assaying (i) for the
presence of a complex between the agent and the protein or
fragment, or (ii) for the presence of a complex between the protein
or fragment and a ligand, by methods well known in the art. In such
competitive binding assays the novel protein or fragment is
typically labeled. Free protein or fragment is separated from that
present in a protein:protein complex, and the amount of free (i.e.,
uncomplexed) label is a measure of the binding of the agent being
tested to the novel protein or its interference with protein ligand
binding, respectively.
[0261] This invention also contemplates the use of competitive drug
screening assays in which neutralizing antibodies capable of
specifically binding the Gene 214 proteincompete with a test
compound for binding to the Gene 214 protein or fragments thereof.
In this manner, the antibodies can be used to detect the presence
of any peptide which shares one or more antigenic determinants of a
Gene 214 protein.
[0262] The goal of rational drug design is to produce structural
analogs of biologically active proteins of interest or of small
molecules with which they interact (e.g., agonists, antagonists,
inhibitors) in order to fashion drugs which are, for example, more
active or stable forms of the protein, or which, e.g., enhance or
interfere with the function of a protein in vivo. See, e.g.,
Hodgson, Bio/Technology, 9:19-21 (1991). In one approach, one first
determines the three-dimensional structure of a protein of interest
or, for example, of the Gene 214 receptor or ligand complex, by
x-ray crystallography, by computer modeling or most typically, by a
combination of approaches. Less often, useful information regarding
the structure of a protein may be gained by modeling based on the
structure of homologous proteins. An example of rational drug
design is the development of HIV protease inhibitors (Erickson et
al, Science, 249:527-533 (1990)). In addition, peptides (e.g., Gene
214 protein) are analyzed by an alanine scan (Wells, Methods in
Enzymol., 202:390-411 (1991)). In this technique, an amino acid
residue is replaced by Ala, and its effect on the peptide's
activity is determined. Each of the amino acid residues of the
peptide is analyzed in this manner to determine the important
regions of the peptide.
[0263] It is also possible to isolate a target-specific antibody,
selected by a functional assay, and then to solve its crystal
structure. In principle, this approach yields a pharmacore upon
which subsequent drug design can be based. It is possible to bypass
protein crystallography altogether by generating anti-idiotypic
antibodies (anti-ids) to a functional, pharmacologically active
antibody. As a mirror image of a mirror image, the binding site of
the anti-ids would be expected to be an analog of the original
receptor. The anti-id could then be used to identify and isolate
peptides from banks of chemically or biologically produced banks of
peptides. Selected peptides would then act as the pharmacore.
[0264] Thus, one may design drugs which have, e.g., improved Gene
214 proteinactivity or stability or which act as inhibitors,
agonists, antagonists, etc. of Gene 214 proteinactivity. By virtue
of the availability of cloned Gene 214 gene sequences, sufficient
amounts of the Gene 214 protein may be made available to perform
such analytical studies as x-ray crystallography. In addition, the
knowledge of the Gene 214 protein sequence will guide those
employing computer modeling techniques in place of, or in addition
to x-ray crystallography.
[0265] Cells and animals that carry the Gene 214 gene or an analog
thereof can be used as model systems to study and test for
substances that have potential as therapeutic agents. After a test
substance is applied to the cells, the transformed phenotype of the
cell is determined.
[0266] The therapeutic agents and compositions of the present
invention are useful for preventing or treating respiratory
disease. Pharmaceutical formulations suitable for therapy comprise
the active agent in conjunction with one or more biologically
acceptable carriers. Suitable biologically acceptable carriers
include, but are not limited to, phosphate-buffered saline, saline,
deionized water, or the like. Preferred biologically acceptable
carriers are physiologically or pharmaceutically acceptable
carriers.
[0267] The compositions include an effective amount of active
agent. Effective amounts are those quantities of the active agents
of the present invention that afford prophyladic protection against
a respiratory disease, or which result in amelioration or cure of
an existing respiratory disease. Prophylactic methods incorporate a
prophylactically effective amount of an active agent or
composition. A prophylactically effective amount is an amount
effective to prevent disease. Treatment methods incorporate a
therapeutically effective amount of an active agent or composition.
A therapeutically effective amount is an amount sufficient to
ameliorate or eliminate the symptoms of disease. The effective
amount will depend upon the agent, the severity of disease and the
nature of the disease, and the particular host. The amount can be
determined by experimentation known in the art, such as by
establishing a matrix of dosage amounts and frequencies of dosage
administration and comparing a group of experimental units or
subjects to each point in the matrix. The prophylactically and/or
therapeutically effective amounts can be administered in one
administration or over repeated administrations. Therapeutic
administration can be followed by prophylactic administration, once
initial clinical symptoms of disease have been resolved.
[0268] The agents and compositions can be administered topically or
systemically. Systemic administration includes both oral and
parental routes. Parental routes include, without limitation,
subcutaneous, intramuscular, intraperitoneal, intravenous,
transdermal, and intranasal administration.
VII. Gene Therapy
[0269] In recent years, significant technological advances have
been made in the area of gene therapy for both genetic and acquired
diseases. (Kay et al, Proc. Natl. Acad. Sci. USA, 94:12744-12746
(1997)) Gene therapy can be defined as the deliberate transfer of
DNA for therapeutic purposes. Improvement in gene transfer methods
has allowed for development of gene therapy protocols for the
treatment of diverse types of diseases. Gene therapy has also taken
advantage of recent advances in the identification of new
therapeutic genes, improvement in both viral and nonviral gene
delivery systems, better understanding of gene regulation, and
improvement in cell isolation and transplantation. Gene therapy
would be carried out according to generally accepted methods as
described by, for example, Friedman, Therapy for Genetic Diseases,
Friedman, Ed., Oxford University Press, pages 105-121 (1991).
[0270] Vectors for introduction of genes both for recombination and
for extrachromosomal maintenance are known in the art, and any
suitable vector may be used. Methods for introducing DNA into cells
such as electroporation, calcium phosphate co-precipitation, and
viral transduction are known in the art, and the choice of method
is within the competence of one skilled in the art (Robbins, Ed.,
Gene Therapy Protocols, Human Press, N.J. (1997)). Cells
transformed with a Gene 214 gene can be used as model systems to
study chromosome 12 disorders and to identify drug treatments for
the treatment of such disorders.
[0271] Gene transfer systems known in the art may be useful in the
practice of the gene therapy methods of the present invention.
These include viral and nonviral transfer methods. A number of
viruses have been used as gene transfer vectors, including polyoma,
i.e., SV40 (Madzak et al, J. Gen. Virol., 73:1533-1536 (1992)),
adenovirus (Berkner, Curr. Top. Microbiol. Immunol., 158:39-61
(1992); Berkner et al, Bio Techniques, 6:616-629 (1988); Gorziglia
et al, J. Virol., 66:4407-4412 (1992); Quantin et al, Proc. Natl.
Acad. Sci. USA, 89:2581-2584 (1992); Rosenfeld et al, Cell,
68:143-155 (1992); Wilkinson et al, Nucl. Acids Res., 20:2233-2239
(1992); Stratford-Perricaudet et al, Hum. Gene Ther., 1:241-256
(1990)), vaccinia virus (Mackett et al, Biotechnology, 24:495-499
(1992)), adeno-associated virus (Muzyczka, Curr. Top. Microbiol.
Immunol., 158:91-123 (1992); Ohi et al, Gene, 89:279-282 (1990)),
herpes viruses including HSV and EBV (Margolskee, Curr. Top.
Microbiol. Immunol., 158:67-90 (1992); Johnson et al, J. Virol.,
66:2952-2965 (1992); Fink et al, Hum. Gene Ther., 3:11-19 (1992);
Breakfield et al, Mol. Neurobiol., 1:337-371 (1987); Fresse et al,
Biochem. Pharmacol., 40:2189-2199 (1990)), and retroviruses of
avian (Brandyopadhyay et al, Mol. Cell Biol., 4:749-754 (1984);
Petropouplos et al, J. Virol., 66:3391-3397 (1992)), murine
(Miller, Curr. Top. Microbiol. Immunol., 158:1-24 (1992); Miller et
al, Mol. Cell Biol., 5:431-437 (1985); Sorge et al, Mol. Cell
Biol., 4:1730-1737 (1984); Mann et al, J. Virol., 54:401-407
(1985)), and human origin (Page et al, J. Virol., 64:5370-5276
(1990); Buchschalcher et al, J. Virol., 66:2731-2739 (1992)). Most
human gene therapy protocols have been based on disabled murine
retroviruses.
[0272] Nonviral gene transfer methods known in the art include
chemical techniques such as calcium phosphate coprecipitation
(Graham et al, Virology, 52:456-467 (1973); Pellicer et al,
Science, 209:1414-1422 (1980)), mechanical techniques, for example
microinjection (Anderson et al, Proc. Natl. Acad. Sci. USA,
77:5399-5403 (1980); Gordon et al, Proc. Natl. Acad. Sci. USA,
77:7380-7384 (1980); Brinster et al, Cell, 27:223-231 (1981);
Constantini et al, Nature, 294:92-94 (1981)), membrane
fusion-mediated transfer via liposomes (Feigner et al, Proc. Natl.
Acad. Sci. USA, 84:7413-7417 (1987); Wang et al, Biochemistry,
28:9508-9514 (1989); Kaneda et al, J. Biol. Chem., 264:12126-12129
(1989); Stewart et al, Hum. Gene Ther., 3:267-275 (1992); Nabel et
al, Science, 249:1285-1288 (1990); Lim et al, Circulation,
83:2007-2011 (1992)), and direct DNA uptake and receptor-mediated
DNA transfer (Wolff et al, Science, 247:1465-1468 (1990); Wu et al,
BioTechniques, 11:474-485 (1991); Zenke et al, Proc. Natl. Acad.
Sci. USA, 87:3655-3659 (1990); Wu et al, J. Biol. Chem.,
264:16985-16987 (1989); Wolff et al, BioTechniques, 11:474-485
(1991); Wagner et al, 1990; Wagner et al, Proc. Natl. Acad. Sci.
USA, 88:4255-4259 (1991); Cotten et al, Proc. Natl. Acad. Sci. USA,
87:4033-4037 (1990); Curiel et al, Proc. Natl. Acad. Sci. USA,
88:8850-8854 (1991); Curiel et al, Hum. Gene Ther., 3:147-154
(1991)).
[0273] In an approach which combines biological and physical gene
transfer methods, plasmid DNA of any size is combined with a
polylysine-conjugated antibody specific to the adenovirus hexon
protein, and the resulting complex is bound to an adenovirus
vector. The trimolecular complex is then used to infect cells. The
adenovirus vector permits efficient binding, internalization, and
degradation of the endosome before the coupled DNA is damaged.
[0274] Liposome/DNA complexes have been shown to be capable of
mediating direct in vivo gene transfer. While in standard liposome
preparations the gene transfer process is non-specific, localized
in vivo uptake and expression have been reported in tumor deposits,
for example, following direct in situ administration (Nabel, Hum.
Gene Ther., 3:399-410 (1992)).
VIII. Transgenic Animals
[0275] This invention further relates to nonhuman transgenic
animals capable of expressing an exogenous or non-naturally
occurring variant Gene 214 gene. Such a transgenic animal can also
have one or more endogenous genes inactivated or can, instead of
expressing an exogenous variant gene, have one or more endogenous
analogs inactivated. Any nonhuman animal can be used; however
typical animals are rodents, such as mice, rats, or guinea
pigs.
[0276] Animals for testing therapeutic agents can be selected after
treatment of germline cells or zygotes. Thus, expression of an
exogenous Gene 214 gene or a variant can be achieved by operably
linking the gene to a promoter and optionally an enhancer, and then
microinjecting the construct into a zygote. See, e.g., Hogan, et
al., Manipulating the Mouse Embryo, A Laboratory Manual, Cold
Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Such treatments
include insertion of the exogenous gene and disrupted homologous
genes. Alternatively, the gene(s) of the animals may be disrupted
by insertion or deletion mutation of other genetic alterations
using conventional techniques, such as those described by, for
example, Capecchi, Science, 244:1288 (1989); Valancuis et al, Mol.
Cell Biol., 11:1402 (1991); Hasty et al, Nature, 350:243 (1991);
Shinkai et al, Cell, 68:855 (1992); Mombaerts et al, Cell, 68:869
(1992); Philpott et al, Science, 256:1448 (1992); Snouwaert et al,
Science, 257:1083 (1992); Donehower et al, Nature, 356:215 (1992).
After test substances have been administered to the animals,
modulation of the disorder must be assessed. If the test substance
reduces the incidence of the disorder, then the test substance is a
candidate therapeutic agent. These animal models provide an
extremely important vehicle for potential therapeutic products.
[0277] The disclosure of each of the patents, patent applications
and publications cited in the specification is hereby incorporated
by reference herein in its entirety.
[0278] Although the invention has been set forth in detail, one
skilled in the art will recognize that numerous changes and
modifications can be made, and that such changes and modifications
may be made without departing from the spirit and scope of the
invention.
Sequence CWU 1
1
51110304DNAHomo sapiensmisc_feature(267)..(267)n is a, c, g, or t
1cgggcgtgta tatctcttca tagagagcgc tcagacagcg tgcgttaatc tgcgtcgata
60tatagagatc tttatcactg agtagataga acgtacatga atgtacgaac agtccagacg
120agtaacttga ctaggataag atagacagta ccaactaatg agacaagaag
agggaatcat 180atagaatcat gtagtctgag tctagcgagt gtcgacatga
tcacaagcga aatacagact 240atgagaagag gtagaaataa taagtanact
gagaagagag gtcatatgta catacaaatc 300agtaaagcaa tagaaattga
atacattata agccacagtt acagaattag cctaatttaa 360caaccatggc
aagcgagtta tatcaaacat agaagagtaa actctatcga ccatgggtag
420gaacgaataa aggcgtcgag aagacaataa gaatgcgtgt taaacagcaa
tacaagagaa 480tagcaccact gaagcagacc aaaggcgtca ccggggaagt
agggaagagg cacctcacaa 540ggagaggaaa gggcagtcct gattttgaaa
atttcagtga aaagacagtg ttgttcccgg 600aggcagctta gtgatcccgc
atcgactctg aagaggaccc tgagggtagg ggatttttgg 660gcctgaccgg
cctatgctga acgcccaccg ggaattcagg gagaaacacg gggccccggc
720ttccaggaga gcagccaggc cacagccctg aggacgggca aaccccaccc
aggcacggtg 780agagggaggc cgcccaggcc tggggcctgg cggcagggga
tgaagtggac cagagccccg 840caaatcctaa cgtgggtgag cagtgagcct
gtgtggctgc gagtggctcc gttttggggc 900tgtttgttcc tgcagcaaat
gatgccagcc ctgacggaac cagtgcacgt ccaccacgag 960ctgcccacgt
cctctccagg aagggacccg ggtccacgag ctgcccacgt cctctccagg
1020aagggaccga agaccacgag ctgcccacgc cctctccagg aggggacacc
gggttcacga 1080gctgcccacg tcctctccag gaggggacac cgggttcatg
agctgcccac gccctttcca 1140ggaagggacc ccgggttcac gagctgccca
cgtcctctcc aggaggggac accgggttca 1200cgagctgccc acgtcctctc
caggaaggga cccaggtcca cgaactgccc acgccctctc 1260caggagggga
cccgggtcca cgagctgccc acgtcgtctc caggaaggga cccgggtcca
1320cgagctgccc acgtcctctc caggaaggga cccgggtcca cgagctgccc
acgtcctctc 1380caggaaggga ccccgggttc acgagctgcc cacgtcctct
ccaggaaggg accccgggtt 1440cacgagctgc ccacgtcctc tccaggaggg
gaccccgggt tcacgagctg cccacgtcct 1500ctccaggaag ggaccccggg
ttcacgagct gcccacgtcg tctccaggaa gggacccggg 1560tccacgagct
gcccacgtcc tctccaggaa aggacccggg tccacgagct ggccacgtcc
1620tctgcaggaa gggaccccgg gtccacgagc tgcccacgtc ctctccagga
agggaccccg 1680ggttcacgag ctgcccacgt cctctccagg aagggacccc
gggtccacga gctgcccacg 1740tcctctccag gaagggaccc cgggtccacg
aactgcccac gtcctctcca ggaagggacc 1800ccgggttcac gagctgccca
cgtcctctcc aggaggggac accgggttca cgagctgccc 1860acgccctctc
caggaaggga ccccgggttc atgagctgcc cacgtcctct ccaggaaggg
1920acccgggtcc acgaactgcc cacgccctct ccaggagggg acccgggtcc
acgagctgcc 1980cacgtcgtca acgggaaggg acccgggtcc acgagctgcc
cacgtcctct ccaggaaggg 2040acccgggtcc acgaactgcc cacgcgctct
ccaggagggg acaccgggtt cacgagctgc 2100ccacgccctc tccaggaagg
gaccccgggt tcacgagctg cccacgtcct ctccaggagg 2160ggacaccggg
ttcacgagct gcccacgtcc tctccaggag gggacaccgg gttcacgagc
2220tgcccacgcc ctctccagga ggggacaccg ggttcacgag ctgcccacgt
cctctccagg 2280aagggacccg ggtccacgag ctgcccacgt cctctccagg
aggggacacc gggttcacga 2340gctgcccacg cactttccag gaagggaccc
cgggttcagg tctcctgccg gcccacatcg 2400tgcctttgtg taaatcagaa
gaaagatgag gaacaggccc tcctctctct ccaggcaggc 2460tttggtggag
gggctggatc tcctgccgca ccttccctgg cagggcaccc tgtgcttgag
2520ccccagaact gcaggcggcc ggcagagaag gggtccatga tggcgcctcg
gtgcgcagcc 2580ttggacctgc ccccatggac ctgggtgagg acttcccagc
ccttccccgg ctccagctgc 2640tctccctaag ccgcctcacc ccttcctcgg
gcagggggca gtggacgagg gttccgtccc 2700tccaggggat gctcccaaac
ccctgccagg acttggcaga tccggcctct catcttggca 2760gctagatggt
gggacgggat catcgtggtg gctttaattt gcatttctct gatgactgat
2820gatttcgagc atctcttcat atgtttgctg gctttgggga tagagatatt
tcttcctaaa 2880gcaaaacttg attatgtcat ttctgcttca agatgccagt
gatgcctgag gtctgcaggg 2940cagtgcatac gctcaccgcc tggccgctca
ggagcctgtg cttgaccccc aaatccgccc 3000cccaactccc tgttaccggc
tcactccttc catgaggggc cttccccagg gacagccgat 3060gctctcctga
tggctcctgc ccttgcagag tgctgccccc gcctgcccac ctggcctgga
3120ccctcgcctg agccccctca gggctctgcg ccacctcaac ccaggcgttt
gttccgcagg 3180aacctcccgg ctcttcccac tcgggaaagg aaggctctgg
gcatggaggt cggccaggcc 3240ccatccccgt accctggccc ttcttcctgc
ttcctgtttg tcactgcccc ggggcctttg 3300cacctgcatt ccctctctct
gtgagtgtcc tggggcccgt tacccacgtc accgtcccag 3360gatacctttt
cttttctttc tctctctcca gctttattga ggtatagttg acaattcagg
3420acggtgtgca ctcaaggtat gcagcatcac aacctgacac acgtaggcat
tgtgaaatga 3480gtcccacaat tgggctaatt aacacaccca tcaccttaca
tggttacttc tttctgtggt 3540gagaacacta aattttaaat agaggacaca
cagcctgggc aacatagtga gaccctgtct 3600ctacaaatat aaaaaaatta
tctggacgtg gtggtgcaca cctgtggtcc cagctacttg 3660ggaagctgag
gctggagaat cacttgagcc tgggaggcgg aggttgcggt gcactccagc
3720ctgggcgaca gagggaggcc ctatctcaaa ataaataaat aaaggacaca
ttcttatcag 3780ctgtagtcac cacgttcatt acatcttaga acccgctaat
ctcataactg cacctttgtt 3840ccctgtgacc ctcaactccc ggtcccctcc
agccctgaca gccactgttc actctgcttc 3900tgtgagttcc gctttttcac
acgtcactcg agtgaggcca tgtgctgttt gtctttctgt 3960gcctggctta
tctcacttac cacaaatgcc cttcaggttc atcgtgtcct cacaaatggc
4020gggcttgccc tgccctgccc tgccctgccc tcccttccct tcccttctct
ctctctcctt 4080tctctctctc tggctctctc tctctcccac ccttcccttt
ccctcctgtg gaataacact 4140cctgtgtgtg tgtgcatgca tgtgtgtgta
tatttctcac atattttcat tcatgcatcc 4200gttgatggac acttgggttg
attccgtgtc ctggctgctg ggacagtgct gcgatgaaca 4260cgagggtaca
gacgcctctc ctacacgcta atttcaactc tttggatata cacccagcag
4320tgggattgct ggatcaggtg ggagctctat ttccacattt ttgaggaacc
tccctgccgt 4380ctcccatggt ggctgtgcca acgacgttcc cagggacaga
gtgcaacggg cccctttcct 4440ccatgtcctc gccaacactc gctatctttt
gcgttttgat gacagtcatc ccaataggtg 4500ccagttggta cctcctgtgg
tttttatttg attttcctga tgattagtga tgctggacgt 4560tatttcgtct
acacttcggc cacttacatg ttttccttcg agacacgcag attcaggtcc
4620tttgcacgtt ttaaaatttt ttttgtttgt ttttgttatt gagttgaatt
ccttctacaa 4680tttgcaaatt aactcctcat catatacatg gattgcaaat
acccccgcct ccccctgggg 4740ttttgccttt tcactgcaaa tactcccgcc
tccccatggg ggttgccttt tccctgccaa 4800tacccccacc tccccatggg
ggttgccttt tccctgcaaa tacccccacc tccccgtggg 4860ttctgccttt
tccctgccaa tacccccgcc tccccctggg ggttgccttt tcactctgtt
4920ggtttccttt gcggaagctt tctggtttgt tgcactctca ctgtctattt
ttgcttctgt 4980tgcctgtgct tgtggggcca tattttaaaa aaatcattgc
ccggaccagc ctcaagaagt 5040tttcctccta cgttttcttc taagagtttt
atggtgtcgg gtcttaggtt tgaatcttta 5100atccgtgttg agttgatttt
cgtaggtggt gtcggatgag gccctttcat cctcctccac 5160ttttcccagc
accacctatt gaggatgccc ctttccccgt cgtgtgtcct tggcgccttt
5220gctgaaggtc agttggccgt aactgtgcat ggggaccctt cctggccccc
ctggtgccct 5280gtgccccata tgtcccaccc cctcccttac tttttctcca
tggcatgaat caccccagac 5340ctactataca aaatttatcc tatttatttt
tatttattta tttatttttg agatggagtc 5400tcactctgtc acccaggctg
gagtgcagtg gcacgatctc ggctcactgc aagctccgcc 5460tcccaggttc
acgccattct cctgcctcag cctcccaagt agctgggatt acgggcgccc
5520gccaccatgc ccggctaaat tttttgtttt tttcgtagag acagagtttc
cctatgttgc 5580ccccaggttg gtctcgaact cctgggctca agtaatcctt
ccacttcggc ctcccaaagt 5640gctgggatta caggcatgag ccattcggcc
cggcctattt tttttttttc agacagagtt 5700tcactcttgt cacccaggct
gaaatgcatt gcaatgatct tggctcactg caacttccac 5760ctcccaggtt
caaaggattt ttctggcctc agcctcccga ggagctggga ttacagtgtg
5820caaccaccac accgggctaa aatttttgga attttttttt tttactagag
acagggttca 5880acaatgctgg tcaggctggt ctcgaattcc tgacctcaag
tgatcctccc acctcggcct 5940cccaaagtgc tgggattaca ggcgtgagcc
gccatgcctg gccatggata ttgtaaatgt 6000tcttgtttgt tgtatgtttt
cctcactggg ctgtgcactc ctgagggcgg ggcatctgtc 6060ccattcttca
gtgctgggtc ccctgtgtct gggacagtgt atacatacag caggtgcata
6120atcagtcttg actggaaggg tgagggagtc aacgcacatg gcagtcattg
gactatgtgt 6180ctgagaagca taactcactt aatcttgaag ttcacttatg
gattgaagtg tgcggttcag 6240tgacttttaa tatatttacc gagttgtgta
accatcacca ccatctaatt ttaaatcatt 6300ttcatcatcc ctaaaagaaa
cttcagaccc actagctgtc cctcccccta ttcctcccac 6360cccagccctg
gtcctggccg caggctgctc acctgcatct ctctgtggat ctgccggttg
6420tggacatttc acacacctgc gtgcagtctt ctgtgcctgc ctctttcact
cgctgtgatg 6480tttaagttca cccatgttgt catctatatc ggtacttact
tccttttttt ttttggagat 6540gaagtcttgc tcttgtcacc caggctggag
tgcagtggcg tgatctcggc tcacagcaac 6600ttctgcctct ggggttcaag
tgattctcct gccttagcct cccaagtagc tgggactaca 6660ggtttgcacc
accatgtcct gctaattttt ttttttttgt atttttaata gagacagggt
6720ttctcctcat tggccaggct ggtctcgaac tcctgacctc agacgatcca
cctgcctcag 6780cctcccgaag tgttgggatt acaggcacga gccactgtgc
ccggccatca ttccttttta 6840ctgctgacta atagtctgct gtgtgaatcc
accgctagaa acccactcat cagttgatgg 6900tcatgtgggt tgcttctgct
attcgcttat tatgaacagt gctggaataa acgttcctgt 6960gcactcttgg
gcatacgcct aggagtggaa ctgctgggtc aaatggtgac tttacgttta
7020acgttctgag gagccgccag gcgttttaac acagtgactg caccatttca
cattcctgcc 7080aacaatgtgt gagaattcca atttctctac atccccaaca
ttttccttta aaaaaaagaa 7140aaaagaaaca tagccatcta agtggatgtg
gagcagactg tccctctggt ttgggtttgc 7200gttgctttta tggctcatga
tgtctgagtc tctctccatg tgctcatggg gattcgtata 7260tctactttgg
gaaatgctta ttcaagtcct ttgtccacat ttgactgggt tgcttgtctt
7320tttatttcat ttactacgat gacagcccct acatggaagg attttgtttt
tgtaatccca 7380ttaccccgag gtgagaatga attgccagtt gctcaaggcc
ttcagctctt agggaggagc 7440ctggacctgg agctgctccg ggctctggca
aagctccaat cccggcctca gtccttgagg 7500cctggtcctc acccagcttt
ctccttccac cgtgccatgg aggaagcccg acctccctgc 7560acggctggcc
tggggttgtt cacgactgag tccaggtgtc cccagaacgg atgtcactgg
7620tcacagtgtt cctggtaata ggtgacccca ggcacagggt gttcctgatc
ataggtaacc 7680caggcacagg tgtcccagtc acaggtgtct ccaggcacag
gtgtccccag tcacaggtgt 7740cccaggtcac aggcgtcccc aggcacaggt
gtccctggtc acagatgtcc ccaggcacag 7800gtgtcccagg cacaggtgtc
tccaggcaca ggcgtcccag gtcacaggtg tccccggtca 7860caggtgtccc
tggtcacagg tgtctccagg cacaggtgtc cctggtcaca ggtgtccccg
7920gtcacaggtg tcccaggtca caggtgtccc caggcacagg tgtccccggt
cacaggtgtc 7980tccggtcaca ggtgtcccca ggcataggtg tccctggtca
caggcaccca tggtcacagg 8040tgtccccagg cacaggtgtc ctggtcacag
gtgtcccagt cacagctgtc cccggtcaca 8100ggtgtctcca ggcacaggtg
ttcccggtca caggtgtccc caggcacagg tgtcccggtc 8160acaggtgtcc
ccaggcacag gagttcctgg tcacaggtgt ccccaggcac aggcagccac
8220aggaagccga tgcatggaac agagagaaac agagacacaa agaaaagaga
gtgagagaca 8280gaagaaatgg gaaacagaaa tggttggaga aaagcatcca
gtagacatga atagagagga 8340agaggaggag ggggacgggc agcagagacc
cagggaggct gcagtgcctg gacccctcac 8400cacactttcc attctgccct
tcctggggaa gacttccaga aaagtgggcc aggctgaggg 8460gacgatgagg
acacagaggc cccaggggag ggagggagga gcgggccacc cggaggggct
8520gtggtcagct caaagcctct ggagtcaagg ataaatcctc tgacctttga
cctccgacct 8580ccctctcctt ggctccaggc tccccacaca gctttccatg
accaaatctt acaggaagct 8640gaagggcagt ccggtgaggg tctgtaagtc
accgccaggg cacagaacgg aggttggcag 8700gggaggagag acccctgggc
tgccgtctgc cttcaccctg cacatcaggc ctgtgtgggg 8760gtgtcaccat
ccttcactcc ctggcatctg atccaagatt acgcctggca gggcctctcc
8820tctgggatta gctccgggaa agctcccatc agtgaaggga ggggctcagg
ctctgtgcac 8880acaggggtgc ccccttccag ggagggagca gctctcccac
atggcagaac actcatttcc 8940tgtcagtgct ctcctgagca cacaaggatt
aaactgagca gcaagcactc caggtggccg 9000agaggccctg ggggatgggc
cccttgccct ggcctcccct gcaaggcagc tcccgccccg 9060gggccctgcc
tctgagagcg aggtgtgcag gctcttccta tgggctacct ggcccatccc
9120cagaacggcc tgcactgtcc ctccccgacc tgcacccaga catggacact
caccctcccc 9180aacccctgag acattcaggt ccacactggg gcctgggccc
cctcaagttg catggggact 9240ggggtgcctt ggcgcctctt ctgtgagtat
tcctacacac agagcctgct tcctctccaa 9300cctgcaccta aacatggaca
ctcaccatcc ccaacccccg agactttcag gtccacactg 9360gggcctgggc
cccctcaagt tgcatgggga ctgggctgcc tcggcgcctc ttctgtgagt
9420gttcctacac acagagcctg cctcctgtcc gggtgatgtt gggtcgtcct
ccgcctctgg 9480gagcacctgc aggggctgtt gctctgggct ccctggagat
gcaagccccc gggcctgcct 9540gcttgttatg tgtgtattca ttaagcccat
gccagcgggg gtctccgcaa gaaacaggca 9600cagtgctgtg agggggctaa
tgaggcctga tttctccagg ggcaggcagg acgggagccc 9660atgagggttg
ctgaggaccc agggatgtgc actgtgggaa gccaccacca cccagaagcc
9720ggcaagggca agggagaagt tagtggtgcc agaacatggc taaacgaggc
agccatggaa 9780aggggatgca gacaggaagt ggagaggaag gcggttctcc
aggagcccta ggacctgctc 9840tggggctgct gctgctgagc ccaactggga
accagagcac aggataatgg tgacactggt 9900gatgatggcg atggagatga
ttatgatggt gatgatgatg gtgatggtgg tgatgatggt 9960gatgatgatg
gtgacggtgg tgatggtgat ggtgatgatg gtgatgatgg tgacggtggt
10020gatggtgctg atgatgatgg tgatgctgat ggtgatggtg acggtgatga
tgatggtgac 10080ggtgatgatg gtgatgatgg tgatggtgat gctgatggtg
gtggtggtga tgatggtggt 10140gatgatgatg atgatgatgg tgatgatggt
gatgctgatg gtgatgatgg tgatggtgat 10200catggtgatg atgatggtga
tggtgatgat gatgatggtg atggtggtga tgatggtgat 10260ggtgatgatg
atgatggtga tggtgatgtc ttcaccacgg ggcg 1030421581DNAHomo
sapiensCDS(3)..(1307) 2tc acg agc tgc cca cgt cct ctc cag gaa ggg
acc ccg ggt tca cga 47 Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr
Pro Gly Ser Arg 1 5 10 15 gct gcc cac gtc gtc tcc agg aag gga ccc
ggg tcc acg agc tgc cca 95Ala Ala His Val Val Ser Arg Lys Gly Pro
Gly Ser Thr Ser Cys Pro 20 25 30 cgt cct ctc cag gaa agg acc cgg
gtc cac gag ctg gcc acg tcc tct 143Arg Pro Leu Gln Glu Arg Thr Arg
Val His Glu Leu Ala Thr Ser Ser 35 40 45 gca gga agg gac ccc ggg
tcc acg agc tgc cca cgt cct ctc cag gaa 191Ala Gly Arg Asp Pro Gly
Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu 50 55 60 ggg acc ccg ggt
tca cga gct gcc cac gtc ctc tcc agg aag gga ccc 239Gly Thr Pro Gly
Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro 65 70 75 cgg gtc
cac gag ctg ccc acg tcc tct cca gga agg gac ccc ggg tcc 287Arg Val
His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser 80 85 90 95
acg aac tgc cca cgt cct ctc cag gaa ggg acc ccg ggt tca cga gct
335Thr Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
100 105 110 gcc cac gtc ctc tcc agg agg gga cac cgg gtt cac gag ctg
ccc acg 383Ala His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr 115 120 125 ccc tct cca gga agg gac ccc ggg ttc atg agc tgc
cca cgt cct ctc 431Pro Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu 130 135 140 cag gaa ggg acc cgg gtc cac gaa ctg ccc
acg ccc tct cca gga ggg 479Gln Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly 145 150 155 gac ccg ggt cca cga gct gcc cac
gtc gtc aac ggg aag gga ccc ggg 527Asp Pro Gly Pro Arg Ala Ala His
Val Val Asn Gly Lys Gly Pro Gly 160 165 170 175 tcc acg agc tgc cca
cgt cct ctc cag gaa ggg acc cgg gtc cac gaa 575Ser Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu 180 185 190 ctg ccc acg
cgc tct cca gga ggg gac acc ggg ttc acg agc tgc cca 623Leu Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro 195 200 205 cgc
cct ctc cag gaa ggg acc ccg ggt tca cga gct gcc cac gtc ctc 671Arg
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu 210 215
220 tcc agg agg gga cac cgg gtt cac gag ctg ccc acg tcc tct cca gga
719Ser Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
225 230 235 ggg gac acc ggg ttc acg agc tgc cca cgc cct ctc cag gag
ggg aca 767Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr 240 245 250 255 ccg ggt tca cga gct gcc cac gtc ctc tcc agg
aag gga ccc ggg tcc 815Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser 260 265 270 acg agc tgc cca cgt cct ctc cag gag
ggg aca ccg ggt tca cga gct 863Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala 275 280 285 gcc cac gca ctt tcc agg aag
gga ccc cgg gtt cag gtc tcc tgc cgg 911Ala His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg 290 295 300 ccc aca tcg tgc ctt
tgt gta aat cag aag aaa gat gag gaa cag gcc 959Pro Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala 305 310 315 ctc ctc tct
ctc cag gca ggc ttt ggt gga ggg gct gga tct cct gcc 1007Leu Leu Ser
Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala 320 325 330 335
gca cct tcc ctg gca ggg cac cct gtg ctt gag ccc cag aac tgc agg
1055Ala Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln Asn Cys Arg
340 345 350 cgg ccg gca gag aag ggg tcc atg atg gcg cct cgg tgc gca
gcc ttg 1103Arg Pro Ala Glu Lys Gly Ser Met Met Ala Pro Arg Cys Ala
Ala Leu 355 360 365 gac ctg ccc cca tgg acc tgg gaa cct ccc ggc tct
tcc cac tcg gga 1151Asp Leu Pro Pro Trp Thr Trp Glu Pro Pro Gly Ser
Ser His Ser Gly 370 375 380 aag gaa ggc tct ggg cat gga ggt cgg cca
ggc ccc atc ccc gta ccc 1199Lys Glu Gly Ser Gly His Gly Gly Arg Pro
Gly Pro Ile Pro Val Pro 385 390 395 tgg ccc ttc ttc ctg ctt cct gtt
tgt cac tgc ccc ggg gcc ttt gca 1247Trp Pro Phe Phe Leu Leu Pro Val
Cys His Cys Pro Gly Ala Phe Ala 400 405 410 415
cct gca ttc cct ctc tct aga cag ggt ttc tcc tca ttg gcc agg ctg
1295Pro Ala Phe Pro Leu Ser Arg Gln Gly Phe Ser Ser Leu Ala Arg Leu
420 425 430 gtc tcg aac tcc tgacctcaga cgatccacct gcctcagcct
cccgaagtgt 1347Val Ser Asn Ser 435 tgggattaca ggcacgagcc actgtgcccg
gccatcattc ctttttactg ctgactaata 1407gtctgctgtg tgaatccacc
gctagaaacc cactcatcag ttgatggtca tgtgggttgc 1467ttctgctatt
cgcttattat gaacagtgct ggaataaacg ttcctgtgca ctcttgggca
1527tacgcctagg agtggaactg ctgggtcaaa aaaaaaaaaa aaaaaaaaaa aaaa
15813435PRTHomo sapiens 3Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly
Thr Pro Gly Ser Arg Ala 1 5 10 15 Ala His Val Val Ser Arg Lys Gly
Pro Gly Ser Thr Ser Cys Pro Arg 20 25 30 Pro Leu Gln Glu Arg Thr
Arg Val His Glu Leu Ala Thr Ser Ser Ala 35 40 45 Gly Arg Asp Pro
Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly 50 55 60 Thr Pro
Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro Arg 65 70 75 80
Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser Thr 85
90 95 Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
Ala 100 105 110 His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr Pro 115 120 125 Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu Gln 130 135 140 Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly Asp 145 150 155 160 Pro Gly Pro Arg Ala Ala
His Val Val Asn Gly Lys Gly Pro Gly Ser 165 170 175 Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu Leu 180 185 190 Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg 195 200 205
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser 210
215 220 Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
Gly 225 230 235 240 Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln
Glu Gly Thr Pro 245 250 255 Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser Thr 260 265 270 Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala Ala 275 280 285 His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg Pro 290 295 300 Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala Leu 305 310 315 320 Leu
Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala Ala 325 330
335 Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln Asn Cys Arg Arg
340 345 350 Pro Ala Glu Lys Gly Ser Met Met Ala Pro Arg Cys Ala Ala
Leu Asp 355 360 365 Leu Pro Pro Trp Thr Trp Glu Pro Pro Gly Ser Ser
His Ser Gly Lys 370 375 380 Glu Gly Ser Gly His Gly Gly Arg Pro Gly
Pro Ile Pro Val Pro Trp 385 390 395 400 Pro Phe Phe Leu Leu Pro Val
Cys His Cys Pro Gly Ala Phe Ala Pro 405 410 415 Ala Phe Pro Leu Ser
Arg Gln Gly Phe Ser Ser Leu Ala Arg Leu Val 420 425 430 Ser Asn Ser
435 41441DNAHomo sapiensCDS(3)..(1166) 4tc acg agc tgc cca cgt cct
ctc cag gaa ggg acc ccg ggt tca cga 47 Thr Ser Cys Pro Arg Pro Leu
Gln Glu Gly Thr Pro Gly Ser Arg 1 5 10 15 gct gcc cac gtc gtc tcc
agg aag gga ccc ggg tcc acg agc tgc cca 95Ala Ala His Val Val Ser
Arg Lys Gly Pro Gly Ser Thr Ser Cys Pro 20 25 30 cgt cct ctc cag
gaa agg acc cgg gtc cac gag ctg gcc acg tcc tct 143Arg Pro Leu Gln
Glu Arg Thr Arg Val His Glu Leu Ala Thr Ser Ser 35 40 45 gca gga
agg gac ccc ggg tcc acg agc tgc cca cgt cct ctc cag gaa 191Ala Gly
Arg Asp Pro Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu 50 55 60
ggg acc ccg ggt tca cga gct gcc cac gtc ctc tcc agg aag gga ccc
239Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro
65 70 75 cgg gtc cac gag ctg ccc acg tcc tct cca gga agg gac ccc
ggg tcc 287Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro
Gly Ser 80 85 90 95 acg aac tgc cca cgt cct ctc cag gaa ggg acc ccg
ggt tca cga gct 335Thr Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro
Gly Ser Arg Ala 100 105 110 gcc cac gtc ctc tcc agg agg gga cac cgg
gtt cac gag ctg ccc acg 383Ala His Val Leu Ser Arg Arg Gly His Arg
Val His Glu Leu Pro Thr 115 120 125 ccc tct cca gga agg gac ccc ggg
ttc atg agc tgc cca cgt cct ctc 431Pro Ser Pro Gly Arg Asp Pro Gly
Phe Met Ser Cys Pro Arg Pro Leu 130 135 140 cag gaa ggg acc cgg gtc
cac gaa ctg ccc acg ccc tct cca gga ggg 479Gln Glu Gly Thr Arg Val
His Glu Leu Pro Thr Pro Ser Pro Gly Gly 145 150 155 gac ccg ggt cca
cga gct gcc cac gtc gtc aac ggg aag gga ccc ggg 527Asp Pro Gly Pro
Arg Ala Ala His Val Val Asn Gly Lys Gly Pro Gly 160 165 170 175 tcc
acg agc tgc cca cgt cct ctc cag gaa ggg acc cgg gtc cac gaa 575Ser
Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu 180 185
190 ctg ccc acg cgc tct cca gga ggg gac acc ggg ttc acg agc tgc cca
623Leu Pro Thr Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro
195 200 205 cgc cct ctc cag gaa ggg acc ccg ggt tca cga gct gcc cac
gtc ctc 671Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His
Val Leu 210 215 220 tcc agg agg gga cac cgg gtt cac gag ctg ccc acg
tcc tct cca gga 719Ser Arg Arg Gly His Arg Val His Glu Leu Pro Thr
Ser Ser Pro Gly 225 230 235 ggg gac acc ggg ttc acg agc tgc cca cgc
cct ctc cag gag ggg aca 767Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg
Pro Leu Gln Glu Gly Thr 240 245 250 255 ccg ggt tca cga gct gcc cac
gtc ctc tcc agg aag gga ccc ggg tcc 815Pro Gly Ser Arg Ala Ala His
Val Leu Ser Arg Lys Gly Pro Gly Ser 260 265 270 acg agc tgc cca cgt
cct ctc cag gag ggg aca ccg ggt tca cga gct 863Thr Ser Cys Pro Arg
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala 275 280 285 gcc cac gca
ctt tcc agg aag gga ccc cgg gtt cag gtc tcc tgc cgg 911Ala His Ala
Leu Ser Arg Lys Gly Pro Arg Val Gln Val Ser Cys Arg 290 295 300 ccc
aca tcg tgc ctt tgt gta aat cag aag aaa gat gag gaa cag gcc 959Pro
Thr Ser Cys Leu Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala 305 310
315 ctc ctc tct ctc cag gca ggc ttt ggt gga ggg gct gga tct cct gcc
1007Leu Leu Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala
320 325 330 335 gca cct tcc ctg gca ggg cac cct gtg ctt gag ccc cag
aac tgc agg 1055Ala Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln
Asn Cys Arg 340 345 350 cgg ccg gca gag aag ggg tcc atg atg gcg cct
cgg tgc gca gcc ttg 1103Arg Pro Ala Glu Lys Gly Ser Met Met Ala Pro
Arg Cys Ala Ala Leu 355 360 365 gac ctg ccc cca tgg acc tgg aga cag
ggt ttc tcc tca ttg gcc agg 1151Asp Leu Pro Pro Trp Thr Trp Arg Gln
Gly Phe Ser Ser Leu Ala Arg 370 375 380 ctg gtc tcg aac tcc
tgacctcaga cgatccacct gcctcagcct cccgaagtgt 1206Leu Val Ser Asn Ser
385 tgggattaca ggcacgagcc actgtgcccg gccatcattc ctttttactg
ctgactaata 1266gtctgctgtg tgaatccacc gctagaaacc cactcatcag
ttgatggtca tgtgggttgc 1326ttctgctatt cgcttattat gaacagtgct
ggaataaacg ttcctgtgca ctcttgggca 1386tacgcctagg agtggaactg
ctgggtcaaa aaaaaaaaaa aaaaaaaaaa aaaaa 14415388PRTHomo sapiens 5Thr
Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala 1 5 10
15 Ala His Val Val Ser Arg Lys Gly Pro Gly Ser Thr Ser Cys Pro Arg
20 25 30 Pro Leu Gln Glu Arg Thr Arg Val His Glu Leu Ala Thr Ser
Ser Ala 35 40 45 Gly Arg Asp Pro Gly Ser Thr Ser Cys Pro Arg Pro
Leu Gln Glu Gly 50 55 60 Thr Pro Gly Ser Arg Ala Ala His Val Leu
Ser Arg Lys Gly Pro Arg 65 70 75 80 Val His Glu Leu Pro Thr Ser Ser
Pro Gly Arg Asp Pro Gly Ser Thr 85 90 95 Asn Cys Pro Arg Pro Leu
Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala 100 105 110 His Val Leu Ser
Arg Arg Gly His Arg Val His Glu Leu Pro Thr Pro 115 120 125 Ser Pro
Gly Arg Asp Pro Gly Phe Met Ser Cys Pro Arg Pro Leu Gln 130 135 140
Glu Gly Thr Arg Val His Glu Leu Pro Thr Pro Ser Pro Gly Gly Asp 145
150 155 160 Pro Gly Pro Arg Ala Ala His Val Val Asn Gly Lys Gly Pro
Gly Ser 165 170 175 Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Arg
Val His Glu Leu 180 185 190 Pro Thr Arg Ser Pro Gly Gly Asp Thr Gly
Phe Thr Ser Cys Pro Arg 195 200 205 Pro Leu Gln Glu Gly Thr Pro Gly
Ser Arg Ala Ala His Val Leu Ser 210 215 220 Arg Arg Gly His Arg Val
His Glu Leu Pro Thr Ser Ser Pro Gly Gly 225 230 235 240 Asp Thr Gly
Phe Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro 245 250 255 Gly
Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro Gly Ser Thr 260 265
270 Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala
275 280 285 His Ala Leu Ser Arg Lys Gly Pro Arg Val Gln Val Ser Cys
Arg Pro 290 295 300 Thr Ser Cys Leu Cys Val Asn Gln Lys Lys Asp Glu
Glu Gln Ala Leu 305 310 315 320 Leu Ser Leu Gln Ala Gly Phe Gly Gly
Gly Ala Gly Ser Pro Ala Ala 325 330 335 Pro Ser Leu Ala Gly His Pro
Val Leu Glu Pro Gln Asn Cys Arg Arg 340 345 350 Pro Ala Glu Lys Gly
Ser Met Met Ala Pro Arg Cys Ala Ala Leu Asp 355 360 365 Leu Pro Pro
Trp Thr Trp Arg Gln Gly Phe Ser Ser Leu Ala Arg Leu 370 375 380 Val
Ser Asn Ser 385 61576DNAHomo sapiensCDS(3)..(1190) 6tc acg agc tgc
cca cgt cct ctc cag gaa ggg acc ccg ggt tca cga 47 Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg 1 5 10 15 gct gcc cac
gtc gtc tcc agg aag gga ccc ggg tcc acg agc tgc cca 95Ala Ala His
Val Val Ser Arg Lys Gly Pro Gly Ser Thr Ser Cys Pro 20 25 30 cgt
cct ctc cag gaa agg acc cgg gtc cac gag ctg gcc acg tcc tct 143Arg
Pro Leu Gln Glu Arg Thr Arg Val His Glu Leu Ala Thr Ser Ser 35 40
45 gca gga agg gac ccc ggg tcc acg agc tgc cca cgt cct ctc cag gaa
191Ala Gly Arg Asp Pro Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu
50 55 60 ggg acc ccg ggt tca cga gct gcc cac gtc ctc tcc agg aag
gga ccc 239Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys
Gly Pro 65 70 75 cgg gtc cac gag ctg ccc acg tcc tct cca gga agg
gac ccc ggg tcc 287Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg
Asp Pro Gly Ser 80 85 90 95 acg aac tgc cca cgt cct ctc cag gaa ggg
acc ccg ggt tca cga gct 335Thr Asn Cys Pro Arg Pro Leu Gln Glu Gly
Thr Pro Gly Ser Arg Ala 100 105 110 gcc cac gtc ctc tcc agg agg gga
cac cgg gtt cac gag ctg ccc acg 383Ala His Val Leu Ser Arg Arg Gly
His Arg Val His Glu Leu Pro Thr 115 120 125 ccc tct cca gga agg gac
ccc ggg ttc atg agc tgc cca cgt cct ctc 431Pro Ser Pro Gly Arg Asp
Pro Gly Phe Met Ser Cys Pro Arg Pro Leu 130 135 140 cag gaa ggg acc
cgg gtc cac gaa ctg ccc acg ccc tct cca gga ggg 479Gln Glu Gly Thr
Arg Val His Glu Leu Pro Thr Pro Ser Pro Gly Gly 145 150 155 gac ccg
ggt cca cga gct gcc cac gtc gtc aac ggg aag gga ccc ggg 527Asp Pro
Gly Pro Arg Ala Ala His Val Val Asn Gly Lys Gly Pro Gly 160 165 170
175 tcc acg agc tgc cca cgt cct ctc cag gaa ggg acc cgg gtc cac gaa
575Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu
180 185 190 ctg ccc acg cgc tct cca gga ggg gac acc ggg ttc acg agc
tgc cca 623Leu Pro Thr Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser
Cys Pro 195 200 205 cgc cct ctc cag gaa ggg acc ccg ggt tca cga gct
gcc cac gtc ctc 671Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
Ala His Val Leu 210 215 220 tcc agg agg gga cac cgg gtt cac gag ctg
ccc acg tcc tct cca gga 719Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr Ser Ser Pro Gly 225 230 235 ggg gac acc ggg ttc acg agc tgc
cca cgc cct ctc cag gag ggg aca 767Gly Asp Thr Gly Phe Thr Ser Cys
Pro Arg Pro Leu Gln Glu Gly Thr 240 245 250 255 ccg ggt tca cga gct
gcc cac gtc ctc tcc agg aag gga ccc ggg tcc 815Pro Gly Ser Arg Ala
Ala His Val Leu Ser Arg Lys Gly Pro Gly Ser 260 265 270 acg agc tgc
cca cgt cct ctc cag gag ggg aca ccg ggt tca cga gct 863Thr Ser Cys
Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala 275 280 285 gcc
cac gca ctt tcc agg aag gga ccc cgg gtt cag gtc tcc tgc cgg 911Ala
His Ala Leu Ser Arg Lys Gly Pro Arg Val Gln Val Ser Cys Arg 290 295
300 ccc aca tcg tgc ctt tgt gta aat cag aag aaa gat gag gaa cag gcc
959Pro Thr Ser Cys Leu Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala
305 310 315 ctc ctc tct ctc cag gca ggc ttt ggt gga ggg gct gga tct
cct gcc 1007Leu Leu Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser
Pro Ala 320 325 330 335 gca cct tcc ctg gca ggg cac cct gtg ctt gag
ccc cag aac tgc agg 1055Ala Pro Ser Leu Ala Gly His Pro Val Leu Glu
Pro Gln Asn Cys Arg 340 345 350 cgg ccg gca gag aag ggg tcc atg atg
gcg cct cgg tgc gca gcc ttg 1103Arg Pro Ala Glu Lys Gly Ser Met Met
Ala Pro Arg Cys Ala Ala Leu 355 360 365 gac ctg ccc cca tgg acc tgg
gaa cct ccc ggc tct tcc cac tcg gga 1151Asp Leu Pro Pro Trp Thr Trp
Glu Pro Pro Gly Ser Ser His Ser Gly 370 375 380
aag gaa ggc tct ggg cat gga gct tta ttg agg tat agt tgacaattca
1200Lys Glu Gly Ser Gly His Gly Ala Leu Leu Arg Tyr Ser 385 390 395
ggacggtgtg cactcaaggt atgcagcatc acaacctgac acacgtaggc attgtgaaat
1260gagtcccaca attgggctaa ttaacacacc catcacctta catggttact
tctttctgtg 1320gtgagaacac taaattttaa atagaggaca cacagcctgg
gcaacatagt gagaccctgt 1380ctctacaaat ataaaaaaat tatctggacg
tggtggtgca cacctgtggt cccagctact 1440tgggaagctg aggctggaga
atcacttgag cctgggaggc ggaggttgcg gtgcactcca 1500gcctgggcga
cagagggagg ccctatctca aaataaataa ataaaggaca cattcttatc
1560aaaaaaaaaa aaaaaa 15767396PRTHomo sapiens 7Thr Ser Cys Pro Arg
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala 1 5 10 15 Ala His Val
Val Ser Arg Lys Gly Pro Gly Ser Thr Ser Cys Pro Arg 20 25 30 Pro
Leu Gln Glu Arg Thr Arg Val His Glu Leu Ala Thr Ser Ser Ala 35 40
45 Gly Arg Asp Pro Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly
50 55 60 Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly
Pro Arg 65 70 75 80 Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp
Pro Gly Ser Thr 85 90 95 Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr
Pro Gly Ser Arg Ala Ala 100 105 110 His Val Leu Ser Arg Arg Gly His
Arg Val His Glu Leu Pro Thr Pro 115 120 125 Ser Pro Gly Arg Asp Pro
Gly Phe Met Ser Cys Pro Arg Pro Leu Gln 130 135 140 Glu Gly Thr Arg
Val His Glu Leu Pro Thr Pro Ser Pro Gly Gly Asp 145 150 155 160 Pro
Gly Pro Arg Ala Ala His Val Val Asn Gly Lys Gly Pro Gly Ser 165 170
175 Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu Leu
180 185 190 Pro Thr Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys
Pro Arg 195 200 205 Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala
His Val Leu Ser 210 215 220 Arg Arg Gly His Arg Val His Glu Leu Pro
Thr Ser Ser Pro Gly Gly 225 230 235 240 Asp Thr Gly Phe Thr Ser Cys
Pro Arg Pro Leu Gln Glu Gly Thr Pro 245 250 255 Gly Ser Arg Ala Ala
His Val Leu Ser Arg Lys Gly Pro Gly Ser Thr 260 265 270 Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala 275 280 285 His
Ala Leu Ser Arg Lys Gly Pro Arg Val Gln Val Ser Cys Arg Pro 290 295
300 Thr Ser Cys Leu Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala Leu
305 310 315 320 Leu Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser
Pro Ala Ala 325 330 335 Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro
Gln Asn Cys Arg Arg 340 345 350 Pro Ala Glu Lys Gly Ser Met Met Ala
Pro Arg Cys Ala Ala Leu Asp 355 360 365 Leu Pro Pro Trp Thr Trp Glu
Pro Pro Gly Ser Ser His Ser Gly Lys 370 375 380 Glu Gly Ser Gly His
Gly Ala Leu Leu Arg Tyr Ser 385 390 395 82010DNAHomo
sapiensCDS(3)..(1244) 8tc acg agc tgc cca cgt cct ctc cag gaa ggg
acc ccg ggt tca cga 47 Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr
Pro Gly Ser Arg 1 5 10 15 gct gcc cac gtc gtc tcc agg aag gga ccc
ggg tcc acg agc tgc cca 95Ala Ala His Val Val Ser Arg Lys Gly Pro
Gly Ser Thr Ser Cys Pro 20 25 30 cgt cct ctc cag gaa agg acc cgg
gtc cac gag ctg gcc acg tcc tct 143Arg Pro Leu Gln Glu Arg Thr Arg
Val His Glu Leu Ala Thr Ser Ser 35 40 45 gca gga agg gac ccc ggg
tcc acg agc tgc cca cgt cct ctc cag gaa 191Ala Gly Arg Asp Pro Gly
Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu 50 55 60 ggg acc ccg ggt
tca cga gct gcc cac gtc ctc tcc agg aag gga ccc 239Gly Thr Pro Gly
Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro 65 70 75 cgg gtc
cac gag ctg ccc acg tcc tct cca gga agg gac ccc ggg tcc 287Arg Val
His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser 80 85 90 95
acg aac tgc cca cgt cct ctc cag gaa ggg acc ccg ggt tca cga gct
335Thr Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
100 105 110 gcc cac gtc ctc tcc agg agg gga cac cgg gtt cac gag ctg
ccc acg 383Ala His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr 115 120 125 ccc tct cca gga agg gac ccc ggg ttc atg agc tgc
cca cgt cct ctc 431Pro Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu 130 135 140 cag gaa ggg acc cgg gtc cac gaa ctg ccc
acg ccc tct cca gga ggg 479Gln Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly 145 150 155 gac ccg ggt cca cga gct gcc cac
gtc gtc aac ggg aag gga ccc ggg 527Asp Pro Gly Pro Arg Ala Ala His
Val Val Asn Gly Lys Gly Pro Gly 160 165 170 175 tcc acg agc tgc cca
cgt cct ctc cag gaa ggg acc cgg gtc cac gaa 575Ser Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu 180 185 190 ctg ccc acg
cgc tct cca gga ggg gac acc ggg ttc acg agc tgc cca 623Leu Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro 195 200 205 cgc
cct ctc cag gaa ggg acc ccg ggt tca cga gct gcc cac gtc ctc 671Arg
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu 210 215
220 tcc agg agg gga cac cgg gtt cac gag ctg ccc acg tcc tct cca gga
719Ser Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
225 230 235 ggg gac acc ggg ttc acg agc tgc cca cgc cct ctc cag gag
ggg aca 767Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr 240 245 250 255 ccg ggt tca cga gct gcc cac gtc ctc tcc agg
aag gga ccc ggg tcc 815Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser 260 265 270 acg agc tgc cca cgt cct ctc cag gag
ggg aca ccg ggt tca cga gct 863Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala 275 280 285 gcc cac gca ctt tcc agg aag
gga ccc cgg gtt cag gtc tcc tgc cgg 911Ala His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg 290 295 300 ccc aca tcg tgc ctt
tgt gta aat cag aag aaa gat gag gaa cag gcc 959Pro Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala 305 310 315 ctc ctc tct
ctc cag gca ggc ttt ggt gga ggg gct gga tct cct gcc 1007Leu Leu Ser
Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala 320 325 330 335
gca cct tcc ctg gca ggg cac cct gtg ctt gag ccc cag aac tgc agg
1055Ala Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln Asn Cys Arg
340 345 350 cgg ccg gca gag aag ggg tcc atg atg gcg cct cgg tgc gca
gcc ttg 1103Arg Pro Ala Glu Lys Gly Ser Met Met Ala Pro Arg Cys Ala
Ala Leu 355 360 365 gac ctg ccc cca tgg acc tgg atg cca gtg atg cct
gag gtc tgc agg 1151Asp Leu Pro Pro Trp Thr Trp Met Pro Val Met Pro
Glu Val Cys Arg 370 375 380 gca gtg cat acg ctc acc gcc tgg ccg ctc
agg agc ctg tgc ttg acc 1199Ala Val His Thr Leu Thr Ala Trp Pro Leu
Arg Ser Leu Cys Leu Thr 385 390 395 ccc aaa tcc gcc ccc caa ctc cct
gtt acc ggc tca ctc ctt cca 1244Pro Lys Ser Ala Pro Gln Leu Pro Val
Thr Gly Ser Leu Leu Pro 400 405 410 tgaggggcct tccccaggga
cagccgatgc tctcctgatg gctcctgccc ttgcagagtg 1304ctgcccccgc
ctgcccacct ggcctggacc ctcgcctgag ccccctcagg gctctgcgcc
1364acctcaaccc aggcgtttgt tccgcaggaa cctcccggct cttcccactc
gggaaaggaa 1424ggctctgggc atggaggtcg gccaggcccc atccccgtac
cctggccctt cttcctgctt 1484cctgtttgtc actgccccgg ggcctttgca
cctgcattcc ctctctctgt gagtgtcctg 1544gggcccgtta cccacgtcac
cgtcccagga taccttttct tttctttctc tctctccagc 1604tttattgagg
tatagttgac aattcaggac ggtgtgcact caaggtatgc agcatcacaa
1664cctgacacac gtaggcattg tgaaatgagt cccacaattg ggctaattaa
cacacccatc 1724accttacatg gttacttctt tctgtggtga gaacactaaa
ttttaaatag aggacacaca 1784gcctgggcaa catagtgaga ccctgtctct
acaaatataa aaaaattatc tggacgtggt 1844ggtgcacacc tgtggtccca
gctacttggg aagctgaggc tggagaatca cttgagcctg 1904ggaggcggag
gttgcggtgc actccagcct gggcgacaga gggaggccct atctcaaaat
1964aaataaataa aggacacatt cttatcaaaa aaaaaaaaaa aaaaaa
20109414PRTHomo sapiens 9Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly
Thr Pro Gly Ser Arg Ala 1 5 10 15 Ala His Val Val Ser Arg Lys Gly
Pro Gly Ser Thr Ser Cys Pro Arg 20 25 30 Pro Leu Gln Glu Arg Thr
Arg Val His Glu Leu Ala Thr Ser Ser Ala 35 40 45 Gly Arg Asp Pro
Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly 50 55 60 Thr Pro
Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro Arg 65 70 75 80
Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser Thr 85
90 95 Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
Ala 100 105 110 His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr Pro 115 120 125 Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu Gln 130 135 140 Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly Asp 145 150 155 160 Pro Gly Pro Arg Ala Ala
His Val Val Asn Gly Lys Gly Pro Gly Ser 165 170 175 Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu Leu 180 185 190 Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg 195 200 205
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser 210
215 220 Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
Gly 225 230 235 240 Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln
Glu Gly Thr Pro 245 250 255 Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser Thr 260 265 270 Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala Ala 275 280 285 His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg Pro 290 295 300 Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala Leu 305 310 315 320 Leu
Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala Ala 325 330
335 Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln Asn Cys Arg Arg
340 345 350 Pro Ala Glu Lys Gly Ser Met Met Ala Pro Arg Cys Ala Ala
Leu Asp 355 360 365 Leu Pro Pro Trp Thr Trp Met Pro Val Met Pro Glu
Val Cys Arg Ala 370 375 380 Val His Thr Leu Thr Ala Trp Pro Leu Arg
Ser Leu Cys Leu Thr Pro 385 390 395 400 Lys Ser Ala Pro Gln Leu Pro
Val Thr Gly Ser Leu Leu Pro 405 410 101744DNAHomo
sapiensCDS(3)..(1349) 10tc acg agc tgc cca cgt cct ctc cag gaa ggg
acc ccg ggt tca cga 47 Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly Thr
Pro Gly Ser Arg 1 5 10 15 gct gcc cac gtc gtc tcc agg aag gga ccc
ggg tcc acg agc tgc cca 95Ala Ala His Val Val Ser Arg Lys Gly Pro
Gly Ser Thr Ser Cys Pro 20 25 30 cgt cct ctc cag gaa agg acc cgg
gtc cac gag ctg gcc acg tcc tct 143Arg Pro Leu Gln Glu Arg Thr Arg
Val His Glu Leu Ala Thr Ser Ser 35 40 45 gca gga agg gac ccc ggg
tcc acg agc tgc cca cgt cct ctc cag gaa 191Ala Gly Arg Asp Pro Gly
Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu 50 55 60 ggg acc ccg ggt
tca cga gct gcc cac gtc ctc tcc agg aag gga ccc 239Gly Thr Pro Gly
Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro 65 70 75 cgg gtc
cac gag ctg ccc acg tcc tct cca gga agg gac ccc ggg tcc 287Arg Val
His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser 80 85 90 95
acg aac tgc cca cgt cct ctc cag gaa ggg acc ccg ggt tca cga gct
335Thr Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
100 105 110 gcc cac gtc ctc tcc agg agg gga cac cgg gtt cac gag ctg
ccc acg 383Ala His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr 115 120 125 ccc tct cca gga agg gac ccc ggg ttc atg agc tgc
cca cgt cct ctc 431Pro Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu 130 135 140 cag gaa ggg acc cgg gtc cac gaa ctg ccc
acg ccc tct cca gga ggg 479Gln Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly 145 150 155 gac ccg ggt cca cga gct gcc cac
gtc gtc aac ggg aag gga ccc ggg 527Asp Pro Gly Pro Arg Ala Ala His
Val Val Asn Gly Lys Gly Pro Gly 160 165 170 175 tcc acg agc tgc cca
cgt cct ctc cag gaa ggg acc cgg gtc cac gaa 575Ser Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu 180 185 190 ctg ccc acg
cgc tct cca gga ggg gac acc ggg ttc acg agc tgc cca 623Leu Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro 195 200 205 cgc
cct ctc cag gaa ggg acc ccg ggt tca cga gct gcc cac gtc ctc 671Arg
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu 210 215
220 tcc agg agg gga cac cgg gtt cac gag ctg ccc acg tcc tct cca gga
719Ser Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
225 230 235 ggg gac acc ggg ttc acg agc tgc cca cgc cct ctc cag gag
ggg aca 767Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr 240 245 250 255 ccg ggt tca cga gct gcc cac gtc ctc tcc agg
aag gga ccc ggg tcc 815Pro Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser 260 265 270 acg agc tgc cca cgt cct ctc cag gag
ggg aca ccg ggt tca cga gct 863Thr Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala 275 280 285 gcc cac gca ctt tcc agg aag
gga ccc cgg gtt cag gtc tcc tgc cgg 911Ala His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg 290 295 300 ccc aca tcg tgc ctt
tgt gta aat cag aag aaa gat gag gaa cag gcc 959Pro Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala 305 310 315 ctc ctc tct
ctc cag gca ggc ttt ggt gga ggg gct gga tct cct gcc 1007Leu Leu Ser
Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala
320 325 330 335 gca cct tcc ctg gca ggg cac cct gtg ctt gag ccc cag
aac tgc agg 1055Ala Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln
Asn Cys Arg 340 345 350 cgg ccg gca gag aag ggg tcc atg atg gcg cct
cgg tgc gca gcc ttg 1103Arg Pro Ala Glu Lys Gly Ser Met Met Ala Pro
Arg Cys Ala Ala Leu 355 360 365 gac ctg ccc cca tgg acc tgg gaa cct
ccc ggc tct tcc cac tcg gga 1151Asp Leu Pro Pro Trp Thr Trp Glu Pro
Pro Gly Ser Ser His Ser Gly 370 375 380 aag gaa ggc tct ggg cat gga
ggt cgg cca ggc ccc atc ccc gta ccc 1199Lys Glu Gly Ser Gly His Gly
Gly Arg Pro Gly Pro Ile Pro Val Pro 385 390 395 tgg ccc ttc ttc ctg
ctt cct gtt tgt cac tgc ccc ggg gcc ttt gca 1247Trp Pro Phe Phe Leu
Leu Pro Val Cys His Cys Pro Gly Ala Phe Ala 400 405 410 415 cct gca
ttc cct ctc tct gtg agt gtc ctg ggg ccc gtt acc cac gtc 1295Pro Ala
Phe Pro Leu Ser Val Ser Val Leu Gly Pro Val Thr His Val 420 425 430
acc gtc cca gga tac ctt ttc ttt tct ttc tct ctc tcc agc ttt att
1343Thr Val Pro Gly Tyr Leu Phe Phe Ser Phe Ser Leu Ser Ser Phe Ile
435 440 445 gag gta tagttgacaa ttcaggacgg tgtgcactca aggtatgcag
catcacaacc 1399Glu Val tgacacacgt aggcattgtg aaatgagtcc cacaattggg
ctaattaaca cacccatcac 1459cttacatggt tacttctttc tgtggtgaga
acactaaatt ttaaatagag gacacacagc 1519ctgggcaaca tagtgagacc
ctgtctctac aaatataaaa aaattatctg gacgtggtgg 1579tgcacacctg
tggtcccagc tacttgggaa gctgaggctg gagaatcact tgagcctggg
1639aggcggaggt tgcggtgcac tccagcctgg gcgacagagg gaggccctat
ctcaaaataa 1699ataaataaag gacacattct tatcaaaaaa aaaaaaaaaa aaaaa
174411449PRTHomo sapiens 11Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly
Thr Pro Gly Ser Arg Ala 1 5 10 15 Ala His Val Val Ser Arg Lys Gly
Pro Gly Ser Thr Ser Cys Pro Arg 20 25 30 Pro Leu Gln Glu Arg Thr
Arg Val His Glu Leu Ala Thr Ser Ser Ala 35 40 45 Gly Arg Asp Pro
Gly Ser Thr Ser Cys Pro Arg Pro Leu Gln Glu Gly 50 55 60 Thr Pro
Gly Ser Arg Ala Ala His Val Leu Ser Arg Lys Gly Pro Arg 65 70 75 80
Val His Glu Leu Pro Thr Ser Ser Pro Gly Arg Asp Pro Gly Ser Thr 85
90 95 Asn Cys Pro Arg Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala
Ala 100 105 110 His Val Leu Ser Arg Arg Gly His Arg Val His Glu Leu
Pro Thr Pro 115 120 125 Ser Pro Gly Arg Asp Pro Gly Phe Met Ser Cys
Pro Arg Pro Leu Gln 130 135 140 Glu Gly Thr Arg Val His Glu Leu Pro
Thr Pro Ser Pro Gly Gly Asp 145 150 155 160 Pro Gly Pro Arg Ala Ala
His Val Val Asn Gly Lys Gly Pro Gly Ser 165 170 175 Thr Ser Cys Pro
Arg Pro Leu Gln Glu Gly Thr Arg Val His Glu Leu 180 185 190 Pro Thr
Arg Ser Pro Gly Gly Asp Thr Gly Phe Thr Ser Cys Pro Arg 195 200 205
Pro Leu Gln Glu Gly Thr Pro Gly Ser Arg Ala Ala His Val Leu Ser 210
215 220 Arg Arg Gly His Arg Val His Glu Leu Pro Thr Ser Ser Pro Gly
Gly 225 230 235 240 Asp Thr Gly Phe Thr Ser Cys Pro Arg Pro Leu Gln
Glu Gly Thr Pro 245 250 255 Gly Ser Arg Ala Ala His Val Leu Ser Arg
Lys Gly Pro Gly Ser Thr 260 265 270 Ser Cys Pro Arg Pro Leu Gln Glu
Gly Thr Pro Gly Ser Arg Ala Ala 275 280 285 His Ala Leu Ser Arg Lys
Gly Pro Arg Val Gln Val Ser Cys Arg Pro 290 295 300 Thr Ser Cys Leu
Cys Val Asn Gln Lys Lys Asp Glu Glu Gln Ala Leu 305 310 315 320 Leu
Ser Leu Gln Ala Gly Phe Gly Gly Gly Ala Gly Ser Pro Ala Ala 325 330
335 Pro Ser Leu Ala Gly His Pro Val Leu Glu Pro Gln Asn Cys Arg Arg
340 345 350 Pro Ala Glu Lys Gly Ser Met Met Ala Pro Arg Cys Ala Ala
Leu Asp 355 360 365 Leu Pro Pro Trp Thr Trp Glu Pro Pro Gly Ser Ser
His Ser Gly Lys 370 375 380 Glu Gly Ser Gly His Gly Gly Arg Pro Gly
Pro Ile Pro Val Pro Trp 385 390 395 400 Pro Phe Phe Leu Leu Pro Val
Cys His Cys Pro Gly Ala Phe Ala Pro 405 410 415 Ala Phe Pro Leu Ser
Val Ser Val Leu Gly Pro Val Thr His Val Thr 420 425 430 Val Pro Gly
Tyr Leu Phe Phe Ser Phe Ser Leu Ser Ser Phe Ile Glu 435 440 445 Val
1222DNAArtificial SequencePrimer 12gtagtaacag aatggacttt ga
221322DNAArtificial SequencePrimer 13agagaggaac agcatcaaag tc
221422DNAArtificial SequencePrimer 14caaacagggt ccaccgtgga aa
221522DNAArtificial SequencePrimer 15gtgtttcagc cacatttcca cg
221622DNAArtificial SequencePrimer 16atccaccgct agaaacccac tc
221722DNAArtificial SequencePrimer 17gaccatcaac tgatgagtgg gt
221822DNAArtificial SequencePrimer 18tcatgggggt gctttgacct tg
221922DNAArtificial SequencePrimer 19tggcctcaaa ggctcaaggt ca
222018DNAArtificial SequencePrimer 20tgtaggacta tattgctc
182118DNAArtificial SequencePrimer 21cgacatttag gtgacact
182215DNAArtificial SequenceSynthetic adapter oligonucleotide
22gtcttcacca cgggg 152311DNAArtificial SequenceSynthetic adapter
oligonucleotide 23gtggtgaaga c 112418DNAArtificial SequencePrimer
24gcccttaggg agagcagc 182520DNAArtificial SequencePrimer
25ccacatcgtg cctttgtgta 202620DNAArtificial SequencePrimer
26cactgtgtta aaacgcctgg 202720DNAArtificial SequencePrimer
27gttgggatta caggcacgag 202820DNAArtificial SequencePrimer
28cagaagcaac ccacatgacc 202920DNAArtificial SequencePrimer
29actacaggtt tgcaccacca 203020DNAArtificial SequencePrimer
30atgctctcct gatggctcct 203119DNAArtificial SequencePrimer
31agggaatgca ggtgcaaag 193220DNAArtificial SequencePrimer
32actcgggaaa ggaaggctct 203320DNAArtificial SequencePrimer
33cataccttga gtgcacaccg 203420DNAArtificial SequencePrimer
34gacagtctgc tccacatcca 203522DNAArtificial SequencePrimer
35tggagatgaa gtcttgctct tg 223620DNAArtificial SequencePrimer
36atatgtttgc tggctttggg 203720DNAArtificial SequencePrimer
37cccaggctgt gtgtcctcta 20381124DNAHomo sapiens 38tcacgagctg
cccacgtcct ctccaggaag ggaccccggg ttcacgagct gcccacgtcg 60tctccaggaa
gggacccggg tccacgagct gcccacgtcc tctccaggaa aggacccggg
120tccacgagct ggccacgtcc tctgcaggaa gggaccccgg gtccacgagc
tgcccacgtc 180ctctccagga agggaccccg ggttcacgag ctgcccacgt
cctctccagg aagggacccc 240gggtccacga gctgcccacg tcctctccag
gaagggaccc cgggtccacg aactgcccac 300gtcctctcca ggaagggacc
ccgggttcac gagctgccca cgtcctctcc aggaggggac 360accgggttca
cgagctgccc acgccctctc caggaaggga ccccgggttc atgagctgcc
420cacgtcctct ccaggaaggg acccgggtcc acgaactgcc cacgccctct
ccaggagggg 480acccgggtcc acgagctgcc cacgtcgtca acgggaaggg
acccgggtcc acgagctgcc 540cacgtcctct ccaggaaggg acccgggtcc
acgaactgcc cacgcgctct ccaggagggg 600acaccgggtt cacgagctgc
ccacgccctc tccaggaagg gaccccgggt tcacgagctg 660cccacgtcct
ctccaggagg ggacaccggg ttcacgagct gcccacgtcc tctccaggag
720gggacaccgg gttcacgagc tgcccacgcc ctctccagga ggggacaccg
ggttcacgag 780ctgcccacgt cctctccagg aagggacccg ggtccacgag
ctgcccacgt cctctccagg 840aggggacacc gggttcacga gctgcccacg
cactttccag gaagggaccc cgggttcagg 900tctcctgccg gcccacatcg
tgcctttgtg taaatcagaa gaaagatgag gaacaggccc 960tcctctctct
ccaggcaggc tttggtggag gggctggatc tcctgccgca ccttccctgg
1020cagggcaccc tgtgcttgag ccccagaact gcaggcggcc ggcagagaag
gggtccatga 1080tggcgcctcg gtgcgcagcc ttggacctgc ccccatggac ctgg
112439289DNAHomo sapiens 39agacagggtt tctcctcatt ggccaggctg
gtctcgaact cctgacctca gacgatccac 60ctgcctcagc ctcccgaagt gttgggatta
caggcacgag ccactgtgcc cggccatcat 120tcctttttac tgctgactaa
tagtctgctg tgtgaatcca ccgctagaaa cccactcatc 180agttgatggt
catgtgggtt gcttctgcta ttcgcttatt atgaacagtg ctggaataaa
240cgttcctgtg cactcttggg catacgccta ggagtggaac tgctgggtc
28940139DNAHomo sapiens 40gaacctcccg gctcttccca ctcgggaaag
gaaggctctg ggcatggagg tcggccaggc 60cccatccccg taccctggcc cttcttcctg
cttcctgttt gtcactgccc cggggccttt 120gcacctgcat tccctctct
1394149DNAHomo sapiens 41gaacctcccg gctcttccca ctcgggaaag
gaaggctctg ggcatggag 4942866DNAHomo sapiens 42atgccagtga tgcctgaggt
ctgcagggca gtgcatacgc tcaccgcctg gccgctcagg 60agcctgtgct tgacccccaa
atccgccccc caactccctg ttaccggctc actccttcca 120tgaggggcct
tccccaggga cagccgatgc tctcctgatg gctcctgccc ttgcagagtg
180ctgcccccgc ctgcccacct ggcctggacc ctcgcctgag ccccctcagg
gctctgcgcc 240acctcaaccc aggcgtttgt tccgcaggaa cctcccggct
cttcccactc gggaaaggaa 300ggctctgggc atggaggtcg gccaggcccc
atccccgtac cctggccctt cttcctgctt 360cctgtttgtc actgccccgg
ggcctttgca cctgcattcc ctctctctgt gagtgtcctg 420gggcccgtta
cccacgtcac cgtcccagga taccttttct tttctttctc tctctccagc
480tttattgagg tatagttgac aattcaggac ggtgtgcact caaggtatgc
agcatcacaa 540cctgacacac gtaggcattg tgaaatgagt cccacaattg
ggctaattaa cacacccatc 600accttacatg gttacttctt tctgtggtga
gaacactaaa ttttaaatag aggacacaca 660gcctgggcaa catagtgaga
ccctgtctct acaaatataa aaaaattatc tggacgtggt 720ggtgcacacc
tgtggtccca gctacttggg aagctgaggc tggagaatca cttgagcctg
780ggaggcggag gttgcggtgc actccagcct gggcgacaga gggaggccct
atctcaaaat 840aaataaataa aggacacatt cttatc 86643387DNAHomo sapiens
43ctttattgag gtatagttga caattcagga cggtgtgcac tcaaggtatg cagcatcaca
60acctgacaca cgtaggcatt gtgaaatgag tcccacaatt gggctaatta acacacccat
120caccttacat ggttacttct ttctgtggtg agaacactaa attttaaata
gaggacacac 180agcctgggca acatagtgag accctgtctc tacaaatata
aaaaaattat ctggacgtgg 240tggtgcacac ctgtggtccc agctacttgg
gaagctgagg ctggagaatc acttgagcct 300gggaggcgga ggttgcggtg
cactccagcc tgggcgacag agggaggccc tatctcaaaa 360taaataaata
aaggacacat tcttatc 38744599DNAHomo sapiens 44gaacctcccg gctcttccca
ctcgggaaag gaaggctctg ggcatggagg tcggccaggc 60cccatccccg taccctggcc
cttcttcctg cttcctgttt gtcactgccc cggggccttt 120gcacctgcat
tccctctctc tgtgagtgtc ctggggcccg ttacccacgt caccgtccca
180ggataccttt tcttttcttt ctctctctcc agctttattg aggtatagtt
gacaattcag 240gacggtgtgc actcaaggta tgcagcatca caacctgaca
cacgtaggca ttgtgaaatg 300agtcccacaa ttgggctaat taacacaccc
atcaccttac atggttactt ctttctgtgg 360tgagaacact aaattttaaa
tagaggacac acagcctggg caacatagtg agaccctgtc 420tctacaaata
taaaaaaatt atctggacgt ggtggtgcac acctgtggtc ccagctactt
480gggaagctga ggctggagaa tcacttgagc ctgggaggcg gaggttgcgg
tgcactccag 540cctgggcgac agagggaggc cctatctcaa aataaataaa
taaaggacac attcttatc 599451028DNAHomo
sapiensmisc_feature(267)..(267)n is a, c, g, or t 45cgggcgtgta
tatctcttca tagagagcgc tcagacagcg tgcgttaatc tgcgtcgata 60tatagagatc
tttatcactg agtagataga acgtacatga atgtacgaac agtccagacg
120agtaacttga ctaggataag atagacagta ccaactaatg agacaagaag
agggaatcat 180atagaatcat gtagtctgag tctagcgagt gtcgacatga
tcacaagcga aatacagact 240atgagaagag gtagaaataa taagtanact
gagaagagag gtcatatgta catacaaatc 300agtaaagcaa tagaaattga
atacattata agccacagtt acagaattag cctaatttaa 360caaccatggc
aagcgagtta tatcaaacat agaagagtaa actctatcga ccatgggtag
420gaacgaataa aggcgtcgag aagacaataa gaatgcgtgt taaacagcaa
tacaagagaa 480tagcaccact gaagcagacc aaaggcgtca ccggggaagt
agggaagagg cacctcacaa 540ggagaggaaa gggcagtcct gattttgaaa
atttcagtga aaagacagtg ttgttcccgg 600aggcagctta gtgatcccgc
atcgactctg aagaggaccc tgagggtagg ggatttttgg 660gcctgaccgg
cctatgctga acgcccaccg ggaattcagg gagaaacacg gggccccggc
720ttccaggaga gcagccaggc cacagccctg aggacgggca aaccccaccc
aggcacggtg 780agagggaggc cgcccaggcc tggggcctgg cggcagggga
tgaagtggac cagagccccg 840caaatcctaa cgtgggtgag cagtgagcct
gtgtggctgc gagtggctcc gttttggggc 900tgtttgttcc tgcagcaaat
gatgccagcc ctgacggaac cagtgcacgt ccaccacgag 960ctgcccacgt
cctctccagg aagggacccg ggtccacgag ctgcccacgt cctctccagg 1020aagggacc
10284640DNAHomo sapiens 46actacaggtt tgcaccacca tgtcctgcta
attttttttt 404740DNAHomo sapiens 47actacaggtt tgcaccaccg tgtcctgcta
attttttttt 404839DNAHomo sapiens 48tgtgcactct tgggcatacg cctaggagtg
gaactgctg 394939DNAHomo sapiens 49tgtgcactct tgggcatatg cctaggagtg
gaactgctg 395039DNAHomo sapiens 50gggctctgcg ccacctcaac ccaggcgttt
gttccgcag 395139DNAHomo sapiens 51gggctctgcg ccacctcaac tcaggcgttt
gttccgcag 39
* * * * *
References